_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
503223620,7/15/2014 10:26:42,,1323486934,7/15/2014 10:26:29,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,bilateral groin ADENOPATHY,19-29-35,94-102-114,"CHRONIC LYMPHOCYTIC LEUKEMIA,","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223620,7/15/2014 11:01:51,,1323510537,7/15/2014 11:01:38,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,bilateral groin ADENOPATHY,19-29-35,94-102-114,"CHRONIC LYMPHOCYTIC LEUKEMIA,","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223620,7/15/2014 11:34:48,,1323532261,7/15/2014 11:34:20,prodege,1,6316959,GBR,,,46.208.145.114,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,bilateral groin ADENOPATHY,19-29-35,94-102-114,"CHRONIC LYMPHOCYTIC LEUKEMIA,","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223620,7/15/2014 11:36:09,,1323533065,7/15/2014 11:35:45,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,bilateral groin ADENOPATHY,19-35-29,94-102-114,"CHRONIC LYMPHOCYTIC LEUKEMIA,","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223620,7/15/2014 11:37:35,,1323533850,7/15/2014 11:37:18,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,bilateral groin ADENOPATHY biopsy proven lymphocytic,19-29-35-50-57-102,70-81-94-102-114-172-164,"metastatic melanoma CHRONIC LYMPHOCYTIC LEUKEMIA, radical vulvectomy.","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223620,7/15/2014 11:46:43,,1323539181,7/15/2014 11:46:24,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,bilateral groin ADENOPATHY,19-29-35,70-81-90-94-102-114,"metastatic melanoma and CHRONIC LYMPHOCYTIC LEUKEMIA,","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223620,7/15/2014 11:52:12,,1323542702,7/15/2014 11:51:37,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,groin ADENOPATHY,29-35,94-102-114,"CHRONIC LYMPHOCYTIC LEUKEMIA,","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223620,7/15/2014 11:54:48,,1323544187,7/15/2014 11:54:10,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,bilateral groin ADENOPATHY,19-29-35,94-102-114,"CHRONIC LYMPHOCYTIC LEUKEMIA,","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223620,7/15/2014 11:58:11,,1323545957,7/15/2014 11:57:46,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,bilateral groin ADENOPATHY,19-29-35,94-102-114,"CHRONIC LYMPHOCYTIC LEUKEMIA,","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223620,7/15/2014 11:58:59,,1323546362,7/15/2014 11:58:38,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,35,94,,,45,122,ADENOPATHY,CHRONIC LYMPHOCYTIC LEUKEMIA,bilateral groin ADENOPATHY,19-29-35,94-102-114,"CHRONIC LYMPHOCYTIC LEUKEMIA,","Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy.",35,94 102 114,35,94,45,122,-1,RO-disease_may_have_finding,902567,"Five months later, bilateral groin adenopathy was biopsy proven to be metastatic melanoma and chronic lymphocytic leukemia, and the patient died 8 months after the radical vulvectomy",adenopathy,chronic lymphocytic leukemia
503223621,7/15/2014 10:18:27,,1323481703,7/15/2014 10:18:02,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,PATHOLOGICAL FRACTURE,61-74,121-128,SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223621,7/15/2014 10:21:18,,1323483736,7/15/2014 10:21:05,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,PATHOLOGICAL FRACTURE,61-74,121-128,SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223621,7/15/2014 10:32:15,,1323490686,7/15/2014 10:32:01,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,PATHOLOGICAL FRACTURE,61-74,121-128,SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223621,7/15/2014 11:01:10,,1323510101,7/15/2014 11:00:39,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,PATHOLOGICAL FRACTURE,61-74,121-128,SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223621,7/15/2014 11:05:30,,1323513239,7/15/2014 11:05:15,instagc,1,23149109,USA,NC,Durham,75.189.206.205,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,PATHOLOGICAL FRACTURE,61-74,105-118-121-128,complication of SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223621,7/15/2014 11:20:38,,1323524252,7/15/2014 11:20:16,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,PATHOLOGICAL FRACTURE,61-74,121-128,SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223621,7/15/2014 11:39:44,,1323535074,7/15/2014 11:39:17,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,radiotherapy PATHOLOGICAL FRACTURE,61-74-9,9-121-128,radiotherapy SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223621,7/15/2014 12:02:51,,1323547946,7/15/2014 12:02:34,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,radiotherapy alone could not resolve the problem of PATHOLOGICAL FRACTURE,9-22-28-34-46-50-58-61-74-38,95-105-118-121-128,important complication of SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223621,7/15/2014 12:03:52,,1323548276,7/15/2014 12:03:33,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,PATHOLOGICAL FRACTURE,61-74,121-128,SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223621,7/15/2014 12:06:21,,1323549130,7/15/2014 12:06:07,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,61,121,,,82,138,PATHOLOGICAL FRACTURE,SPINAL METASTASES,PATHOLOGICAL FRACTURE,61-74,121-128,SPINAL METASTASES.,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases.",61 74,121 128,61,121,82,138,1,RO-disease_may_have_finding,902720,"However, radiotherapy alone could not resolve the problem of pathological fracture which is an important complication of spinal metastases",pathological fracture,spinal metastases
503223622,7/15/2014 10:57:19,,1323507770,7/15/2014 10:57:07,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,FOLLICULAR LYMPHOMAS,230-241,207-211-213,BCL 2 GENE,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223622,7/15/2014 11:09:50,,1323517202,7/15/2014 11:09:41,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,FOLLICULAR LYMPHOMAS,230-241,207-211-213,BCL 2 GENE,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223622,7/15/2014 11:12:12,,1323518936,7/15/2014 11:11:58,instagc,1,13763729,USA,,,75.182.89.225,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,FOLLICULAR LYMPHOMAS,230-241,207-211-213,BCL 2 GENE,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223622,7/15/2014 11:25:05,,1323526742,7/15/2014 11:24:47,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,FOLLICULAR LYMPHOMAS,230-241,207-211-213,BCL 2 GENE,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223622,7/15/2014 11:26:25,,1323527344,7/15/2014 11:25:32,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,BCL - gene immunoglobulin FOLLICULAR LYMPHOMAS,68-71-74-119-230-241,207-211-213-230-241-119,immunoglobulin BCL 2 GENE follicular lymphomas,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223622,7/15/2014 11:42:28,,1323536810,7/15/2014 11:42:12,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,FOLLICULAR LYMPHOMAS,230-241,195-200-203-207-211-213-218-227-230-241,form of the BCL 2 GENE observed in follicular lymphomas,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223622,7/15/2014 12:03:04,,1323548013,7/15/2014 12:02:51,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,gene observed in FOLLICULAR LYMPHOMAS,213-218-227-230-241,195-200-203-207-211-213,form of the BCL 2 GENE,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223622,7/15/2014 12:03:06,,1323548014,7/15/2014 12:02:51,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,FOLLICULAR LYMPHOMAS,230-241,207-211-213,BCL 2 GENE,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223622,7/15/2014 12:06:05,,1323549057,7/15/2014 12:05:33,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,FOLLICULAR LYMPHOMAS,230-241,207-211-213,BCL 2 GENE,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223622,7/15/2014 12:06:57,,1323549349,7/15/2014 12:06:05,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,230,207,,,250,217,FOLLICULAR LYMPHOMAS,BCL-2 GENE,FOLLICULAR LYMPHOMAS,230-241,182-195-200-203-207-211-213,translocated form of the BCL 2 GENE,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation.",230 241,207 211 213,230,207,250,217,-1,RO-has_manifestation,906095,"This growth enhancement was also seen in cells transfected with the BCL-2 gene with its own promoter juxtaposed to the immunoglobulin heavy chain gene enhancer, which represents the translocated form of the BCL-2 gene observed in follicular lymphomas with the t(14;18) translocation",follicular lymphomas,BCL-2 gene
503223623,7/15/2014 10:23:31,,1323485036,7/15/2014 10:23:02,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,35,69,,,39,79,SKIN,DERMATITIS,Dermatologic Reactions Serious SKIN reactions,3-16-27-35-40,69-57,"exfoliative DERMATITIS,","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223623,7/15/2014 10:23:38,,1323485130,7/15/2014 10:23:21,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,35,69,,,39,79,SKIN,DERMATITIS,Dermatologic Reactions Serious SKIN reactions,3-16-27-35-40,57-69,"exfoliative DERMATITIS,","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223623,7/15/2014 10:26:29,,1323486795,7/15/2014 10:26:06,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,35,69,,,39,79,SKIN,DERMATITIS,Serious SKIN reactions,27-35-40,57-69,"exfoliative DERMATITIS,","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223623,7/15/2014 10:34:53,,1323492413,7/15/2014 10:34:37,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,35,69,,,39,79,SKIN,DERMATITIS,SKIN reactions,35-40,57-69,"exfoliative DERMATITIS,","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223623,7/15/2014 11:10:04,,1323517388,7/15/2014 11:09:47,instagc,1,23149109,USA,NC,Durham,75.189.206.205,35,69,,,39,79,SKIN,DERMATITIS,Dermatologic Reactions Serious SKIN reactions,3-16-27-35-40,57-69,"exfoliative DERMATITIS,","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223623,7/15/2014 11:13:16,,1323519597,7/15/2014 11:12:51,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,35,69,,,39,79,SKIN,DERMATITIS,"Dermatologic Reactions Serious SKIN reactions exfoliative dermatitis,",3-16-27-35-40-57-69,57-69-81-89-97,"exfoliative DERMATITIS, Stevens Johnson syndrome,","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223623,7/15/2014 11:23:40,,1323525884,7/15/2014 11:23:12,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,35,69,,,39,79,SKIN,DERMATITIS,"Dermatologic Reactions Serious SKIN reactions exfoliative dermatitis, Stevens Johnson syndrome, toxic epidermal necrolysis)",3-16-27-35-40-57-69-81-89-97-107-113-123,3-16-27-35-40-50-57-69-81-89-97-107-123-113,"Dermatologic Reactions Serious skin reactions (e.g., exfoliative DERMATITIS, Stevens Johnson syndrome, toxic epidermal necrolysis)","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223623,7/15/2014 11:40:07,,1323535326,7/15/2014 11:39:48,prodege,1,23999031,AUS,8,Perth,203.59.238.194,35,69,,,39,79,SKIN,DERMATITIS,"SKIN exfoliative dermatitis, Stevens Johnson syndrome, toxic epidermal necrolysis)",35-57-69-81-89-97-107-113-123,57-69-81-89-97-107-113-123,"exfoliative DERMATITIS, Stevens Johnson syndrome, toxic epidermal necrolysis)","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223623,7/15/2014 11:47:02,,1323539347,7/15/2014 11:46:44,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,35,69,,,39,79,SKIN,DERMATITIS,Dermatologic Reactions Serious SKIN reactions,3-16-27-35-40,35-40-50-57-69-81-89-97-107-113-123,"skin reactions (e.g., exfoliative DERMATITIS, Stevens Johnson syndrome, toxic epidermal necrolysis)","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223623,7/15/2014 11:56:52,,1323545278,7/15/2014 11:56:40,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,35,69,,,39,79,SKIN,DERMATITIS,SKIN,35,69,"DERMATITIS,","1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.",35,69,35,69,39,79,1,RO-disease_has_primary_anatomic_site,902185,"1  Dermatologic Reactions  Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning",skin,dermatitis
503223624,7/15/2014 10:16:38,,1323480504,7/15/2014 10:16:27,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,PROSTATES,124,80-90,PROSTATIC CARCINOMAS,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223624,7/15/2014 10:19:58,,1323482855,7/15/2014 10:19:54,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,in surgically resected PROSTATES by PCR technique,101-104-115-124-134-137-141,71-75-78-80-90-101-104-115,and in 5 PROSTATIC CARCINOMAS in surgically resected,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223624,7/15/2014 10:26:10,,1323486598,7/15/2014 10:25:40,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,PROSTATES,124,80-90,PROSTATIC CARCINOMAS,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223624,7/15/2014 10:29:14,,1323488691,7/15/2014 10:29:00,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,PROSTATES,124,80-90,PROSTATIC CARCINOMAS,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223624,7/15/2014 10:42:49,,1323497675,7/15/2014 10:41:58,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,prostatic benign hyperplasias prostatic carcinomas PROSTATES,41-51-58-80-90-124,51-58-80-90-124-41,prostatic benign hyperplasias PROSTATIC CARCINOMAS prostates,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223624,7/15/2014 11:19:38,,1323523704,7/15/2014 11:19:23,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,HPV PROSTATES,31-124,31-80-90,HPV PROSTATIC CARCINOMAS,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223624,7/15/2014 11:37:08,,1323533592,7/15/2014 11:36:45,prodege,1,23999031,AUS,8,Perth,203.59.238.194,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,prostatic benign hyperplasias prostatic carcinomas PROSTATES,41-51-58-80-90-124,41-51-58-80-90,prostatic benign hyperplasias PROSTATIC CARCINOMAS,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223624,7/15/2014 11:40:48,,1323535687,7/15/2014 11:40:11,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,HPV prostatic benign hyperplasias prostatic carcinomas resected PROSTATES PCR,31-41-51-58-80-90-115-124-137,31-41-51-71-80-90-115-124-137,HPV prostatic benign and PROSTATIC CARCINOMAS resected prostates PCR,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223624,7/15/2014 11:46:12,,1323538838,7/15/2014 11:45:42,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,surgically resected PROSTATES by PCR technique,104-115-124-134-137-141,80-90-101-104-115-124-134-137-141,PROSTATIC CARCINOMAS in surgically resected prostates by PCR technique,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223624,7/15/2014 12:00:19,,1323546936,7/15/2014 12:00:03,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,124,80,,,133,100,PROSTATES,PROSTATIC CARCINOMAS,PROSTATES,124,80-90,PROSTATIC CARCINOMAS,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers.,124,80 90,124,80,133,100,1,RO-disease_has_primary_anatomic_site,902355,We investigate the presence of HPV in 60 prostatic benign hyperplasias and in 5 prostatic carcinomas in surgically resected prostates by PCR technique using consensus and type specific primers,prostates,prostatic carcinomas
503223625,7/15/2014 10:18:26,,1323481689,7/15/2014 10:18:06,vivatic,1,25451531,GBR,,,83.67.28.193,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,Ventricular TACHYCARDIA,591-603,552-565-577,Nonsustained VENTRICULAR TACHYCARDIA,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223625,7/15/2014 10:19:09,,1323482272,7/15/2014 10:18:09,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,603,565-577,VENTRICULAR TACHYCARDIA,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223625,7/15/2014 10:20:06,,1323482899,7/15/2014 10:20:02,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,tachycardia ? Ventricular TACHYCARDIA Ventricular fibrillation Sinus,577-589-591-603-617-629-644,538-550-552-565-577-591-603-617,tachycardia ? Nonsustained VENTRICULAR TACHYCARDIA Ventricular tachycardia Ventricular,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223625,7/15/2014 10:27:25,,1323487393,7/15/2014 10:27:06,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,Ventricular TACHYCARDIA,591-603,552-565-577,Nonsustained VENTRICULAR TACHYCARDIA,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223625,7/15/2014 10:32:16,,1323490719,7/15/2014 10:32:02,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,603,565-577,VENTRICULAR TACHYCARDIA,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223625,7/15/2014 10:48:15,,1323501670,7/15/2014 10:48:00,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,603,565-577,VENTRICULAR TACHYCARDIA,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223625,7/15/2014 11:09:40,,1323517074,7/15/2014 11:09:12,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,tachycardia ? Ventricular TACHYCARDIA Ventricular fibrillation Sinus node dysfunction,577-589-591-603-617-629-644-650-655,523-531-538-550-552-565-577-591-603-617-629,Ectopic atrial tachycardia ? Nonsustained VENTRICULAR TACHYCARDIA Ventricular tachycardia Ventricular fibrillation,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223625,7/15/2014 11:24:26,,1323526349,7/15/2014 11:22:55,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,Arrhythmia Tachyarrhythmia Bradyarrhythmia Automatic implantable defibrillator Pacemaker Hypokalemia Congestive heart failure Bundle branch block Atrial appendage Coronary artery bypass surgery Valvular surgery Interscalene block anesthesia Atrial premature contractions Ventricular premature contractions Sinus tachycardia fibrillation Amiodarone Antiarrhythmic drugs flutter Paroxysmal SVT Multifocal atrial tachycardia Ectopic atrial tachycardia Nonsustained ventricular tachycardia ? Ventricular TACHYCARDIA Ventricular fibrillation Sinus node dysfunction Wenckebach rhythm Junctional rhythm,35-48-66-84-94-106-122-134-158-169-175-185-192-207-214-226-235-242-249-259-268-278-291-297-310-317-327-342-354-364-379-385-406-421-434-449-464-474-485-491-502-509-523-531-538-552-565-577-589-591-603-617-629-644-650-655-669-680-689-700-199,35-48-66-84-94-106-122-134-158-169-175-185-192-199-207-214-226-235-242-249-259-268-278-291-297-310-317-327-342-354-364-379-385-397-406-421-434-449-457-464-474-485-491-502-509-523-531-550-552-565-577-591-603-617-629-644-650-655-669-680-689-700-399,Arrhythmia Tachyarrhythmia Bradyarrhythmia Automatic implantable defibrillator Pacemaker Hypokalemia Congestive heart failure Bundle branch block Atrial appendage Coronary artery bypass surgery Valvular surgery Interscalene block anesthesia Atrial premature contractions Ventricular premature contractions Sinus tachycardia ? Atrial fibrillation Amiodarone Antiarrhythmic drugs Atrial flutter Paroxysmal SVT Multifocal atrial tachycardia Ectopic atrial ? Nonsustained VENTRICULAR TACHYCARDIA Ventricular tachycardia Ventricular fibrillation Sinus node dysfunction Wenckebach rhythm Junctional rhythm,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223625,7/15/2014 11:43:37,,1323537510,7/15/2014 11:43:13,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,Arrhythmia Tachyarrhythmia Bradyarrhythmia Amiodarone Antiarrhythmic tachycardia ? TACHYCARDIA fibrillation Sinus,35-48-421-434-577-589-603-629-644-66,35-48-66-550-552-565-577-603,Arrhythmia Tachyarrhythmia Bradyarrhythmia ? Nonsustained VENTRICULAR TACHYCARDIA tachycardia,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223625,7/15/2014 11:57:27,,1323545597,7/15/2014 11:56:49,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,603,565,,,614,588,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,603,565-577,VENTRICULAR TACHYCARDIA,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?.,603,565 577,603,565,614,588,-1,RO-has_definitional_manifestation,904789,ALERT TRIGGERS  Clinical Alerts: ? Arrhythmia ? Tachyarrhythmia ? Bradyarrhythmia ? Automatic implantable defibrillator ? Pacemaker ? Hypokalemia ? Age &gt;60 ? Congestive heart failure ? Bundle-branch block ? Atrial appendage ? Coronary artery bypass surgery ? Valvular surgery ? Interscalene block anesthesia ? Atrial premature contractions ? Ventricular premature contractions ? Sinus tachycardia ? Atrial fibrillation ? Amiodarone ? Antiarrhythmic drugs ? Atrial flutter ? Paroxysmal SVT ? Multifocal atrial tachycardia ? Ectopic atrial tachycardia ? Nonsustained ventricular tachycardia ? Ventricular tachycardia ? Ventricular fibrillation ? Sinus node dysfunction ? Wenckebach rhythm ? Junctional rhythm ?,tachycardia,ventricular tachycardia
503223626,7/15/2014 10:22:22,,1323484437,7/15/2014 10:22:12,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,479,534,,,483,542,SKIN,VITILIGO,SKIN,479,534,VITILIGO,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223626,7/15/2014 10:27:01,,1323487139,7/15/2014 10:26:45,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,479,534,,,483,542,SKIN,VITILIGO,pigmented SKIN,469-479,534-543,VITILIGO patches,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223626,7/15/2014 10:30:21,,1323489365,7/15/2014 10:30:06,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,479,534,,,483,542,SKIN,VITILIGO,SKIN,479,534-543,VITILIGO patches,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223626,7/15/2014 10:34:27,,1323492069,7/15/2014 10:33:47,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,479,534,,,483,542,SKIN,VITILIGO,SKIN,479,534,VITILIGO,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223626,7/15/2014 10:47:59,,1323501440,7/15/2014 10:47:47,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,479,534,,,483,542,SKIN,VITILIGO,SKIN,479,534,VITILIGO,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223626,7/15/2014 11:05:56,,1323513610,7/15/2014 11:05:17,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,479,534,,,483,542,SKIN,VITILIGO,dihydroxyacetone pigmented SKIN the vitiligo patches,47-469-479-488-534-543,469-479-534-543-47,dihydroxyacetone pigmented skin VITILIGO patches,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223626,7/15/2014 11:10:37,,1323517712,7/15/2014 11:10:24,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,479,534,,,483,542,SKIN,VITILIGO,normally pigmented SKIN,460-469-479,534-543,VITILIGO patches,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223626,7/15/2014 11:23:52,,1323526023,7/15/2014 11:23:33,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,479,534,,,483,542,SKIN,VITILIGO,SKIN,479,534,VITILIGO,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223626,7/15/2014 11:36:01,,1323533019,7/15/2014 11:35:41,prodege,1,6316959,GBR,,,46.208.145.114,479,534,,,483,542,SKIN,VITILIGO,normally pigmented SKIN,460-469-479,534-543,VITILIGO patches,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223626,7/15/2014 11:39:07,,1323534764,7/15/2014 11:38:46,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,479,534,,,483,542,SKIN,VITILIGO,normally pigmented SKIN,469-479-460,534-543-551-555-562,VITILIGO patches and normal skin.,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin.",479,534,479,534,483,542,1,RO-disease_has_primary_anatomic_site,902476,"? An artificial tanning preparation containing dihydroxyacetone (DHA) to help mask the extent of vitiligo for several days (most appropriate for skin with a yellow hue) ? Cosmetic tattooing in darker-skinned patients with localized, stable vitiligo in whom repigmentation is unlikely (most effective for involvement of the lips) ? Recommend regular sunscreen use in all vitiligo patients, both to prevent burning of depigmented areas and to prevent tanning of normally pigmented skin and the resulting enhancement of contrast between vitiligo patches and normal skin",skin,vitiligo
503223627,7/15/2014 10:19:39,,1323482650,7/15/2014 10:19:29,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,CARDIAC ARRHYTHMIAS,14-22,78-83,FISH OIL,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223627,7/15/2014 10:23:02,,1323484795,7/15/2014 10:22:47,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,CARDIAC ARRHYTHMIAS,14-22,78-83,FISH OIL,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223627,7/15/2014 10:26:26,,1323486772,7/15/2014 10:26:11,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,CARDIAC ARRHYTHMIAS,14-22,78-83,FISH OIL,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223627,7/15/2014 10:32:58,,1323491167,7/15/2014 10:32:46,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,CARDIAC ARRHYTHMIAS,14-22,78-83,FISH OIL,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223627,7/15/2014 11:01:33,,1323510366,7/15/2014 11:01:10,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,CARDIAC ARRHYTHMIAS,14-22,70-78-83-87,fish FISH OIL intakes,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223627,7/15/2014 11:15:42,,1323521080,7/15/2014 11:15:19,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,CARDIAC ARRHYTHMIAS,14-22,78-83-87,FISH OIL intakes,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223627,7/15/2014 11:28:46,,1323528779,7/15/2014 11:28:14,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,CARDIAC ARRHYTHMIAS blood pressure plasma lipids.,14-22-128-134-146-153,14-22-78-83-128-134-153-146,cardiac arrhythmias FISH OIL blood pressure plasma lipids.,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223627,7/15/2014 11:38:54,,1323534692,7/15/2014 11:38:22,prodege,1,23999031,AUS,8,Perth,203.59.238.194,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,CARDIAC ARRHYTHMIAS,14-22,14-22-78-83,cardiac arrhythmias FISH OIL,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223627,7/15/2014 11:55:16,,1323544392,7/15/2014 11:55:00,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,CARDIAC ARRHYTHMIAS,14-22,78-83-87,FISH OIL intakes,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223627,7/15/2014 12:04:06,,1323548333,7/15/2014 12:03:53,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,14,78,,,33,86,CARDIAC ARRHYTHMIAS,FISH OIL,Prevention of CARDIAC ARRHYTHMIAS and sudden death,0-11-14-22-34-38-45,78-83-87-95-100-105-118,FISH OIL intakes that have little effect,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids.,14 22,78 83,14,78,33,86,1,RO-may_prevent,907011,Prevention of cardiac arrhythmias and sudden death is demonstrable at fish or fish oil intakes that have little or no effect on blood pressure or plasma lipids,cardiac arrhythmias,fish oil
503223628,7/15/2014 10:19:36,,1323482634,7/15/2014 10:19:32,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,80,0,,,84,11,PAIN,PARACETAMOL,analgesic for minor PAIN.,60-70-74-80,0-28-32,PARACETAMOL was the,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223628,7/15/2014 10:26:54,,1323487030,7/15/2014 10:26:46,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,80,0,,,84,11,PAIN,PARACETAMOL,minor PAIN.,74-80,0,PARACETAMOL,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223628,7/15/2014 10:45:03,,1323499352,7/15/2014 10:44:55,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,80,0,,,84,11,PAIN,PARACETAMOL,PAIN.,80,0,PARACETAMOL,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223628,7/15/2014 11:02:15,,1323510765,7/15/2014 11:01:50,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,80,0,,,84,11,PAIN,PARACETAMOL,PAIN.,80,0,PARACETAMOL,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223628,7/15/2014 11:03:47,,1323511773,7/15/2014 11:03:38,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,80,0,,,84,11,PAIN,PARACETAMOL,minor PAIN.,74-80,0-12,PARACETAMOL (acetaminophen),Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223628,7/15/2014 11:05:43,,1323513346,7/15/2014 11:05:31,instagc,1,23149109,USA,NC,Durham,75.189.206.205,80,0,,,84,11,PAIN,PARACETAMOL,analgesic for minor PAIN.,60-74-80-70,0-12,PARACETAMOL (acetaminophen),Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223628,7/15/2014 11:11:05,,1323518061,7/15/2014 11:10:59,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,80,0,,,84,11,PAIN,PARACETAMOL,minor PAIN.,74-80,0,PARACETAMOL,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223628,7/15/2014 11:24:46,,1323526578,7/15/2014 11:24:27,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,80,0,,,84,11,PAIN,PARACETAMOL,Paracetamol (acetaminophen) analgesic PAIN.,0-12-60-80,0-28-32-60-12,PARACETAMOL (acetaminophen) was the analgesic,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223628,7/15/2014 11:41:24,,1323536111,7/15/2014 11:41:05,prodege,1,6316959,GBR,,,46.208.145.114,80,0,,,84,11,PAIN,PARACETAMOL,minor PAIN.,74-80,0-12,PARACETAMOL (acetaminophen),Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223628,7/15/2014 11:42:26,,1323536777,7/15/2014 11:42:05,prodege,1,23999031,AUS,8,Perth,203.59.238.194,80,0,,,84,11,PAIN,PARACETAMOL,PAIN.,80,0-80-74,PARACETAMOL minor pain.,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain.,80,0,80,0,84,11,1,RO-may_treat,908294,Paracetamol (acetaminophen) was the most common alternative analgesic for minor pain,pain,Paracetamol
503223629,7/15/2014 10:23:54,,1323485255,7/15/2014 10:23:41,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,156,113,,,160,123,SKIN,DERMATOSES,SKIN,156,100-113,inflammatory DERMATOSES,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223629,7/15/2014 10:24:26,,1323485507,7/15/2014 10:24:09,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,156,113,,,160,123,SKIN,DERMATOSES,SKIN,156,100-113,inflammatory DERMATOSES,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223629,7/15/2014 10:29:30,,1323488840,7/15/2014 10:29:16,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,156,113,,,160,123,SKIN,DERMATOSES,SKIN,156,113,DERMATOSES,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223629,7/15/2014 10:51:26,,1323504114,7/15/2014 10:50:57,clixsense,1,6416850,USA,VA,Midlothian,108.4.51.140,156,113,,,160,123,SKIN,DERMATOSES,SKIN,156,100-113,inflammatory DERMATOSES,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223629,7/15/2014 11:00:42,,1323509775,7/15/2014 11:00:30,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,156,113,,,160,123,SKIN,DERMATOSES,human SKIN,150-156,100-113,inflammatory DERMATOSES,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223629,7/15/2014 11:09:40,,1323517071,7/15/2014 11:09:27,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,156,113,,,160,123,SKIN,DERMATOSES,human SKIN,150-156,100-113,inflammatory DERMATOSES,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223629,7/15/2014 11:18:26,,1323522935,7/15/2014 11:18:01,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,156,113,,,160,123,SKIN,DERMATOSES,normal human SKIN by immunohistochemical and morphometric methods.,143-150-156-161-164-184-188-201,100-113,inflammatory DERMATOSES,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223629,7/15/2014 11:28:20,,1323528594,7/15/2014 11:27:23,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,156,113,,,160,123,SKIN,DERMATOSES,OKM 5 positive dendritic cells epidermis inflammatory dermatoses SKIN immunohistochemical morphometric methods.,20-24-26-35-45-58-100-113-156-164-188-201,20-24-26-35-45-58-100-113-156-164-188-201,OKM 5 positive dendritic cells epidermis inflammatory DERMATOSES skin immunohistochemical morphometric methods.,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223629,7/15/2014 11:31:27,,1323530287,7/15/2014 11:31:10,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,156,113,,,160,123,SKIN,DERMATOSES,SKIN,156,100-113,inflammatory DERMATOSES,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223629,7/15/2014 11:36:53,,1323533441,7/15/2014 11:36:34,prodege,1,6316959,GBR,,,46.208.145.114,156,113,,,160,123,SKIN,DERMATOSES,SKIN,156,100-113,inflammatory DERMATOSES,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods.,156,113,156,113,160,123,1,RO-disease_has_primary_anatomic_site,902112,The distribution of OKM 5-positive dendritic cells in the epidermis was investigated in 75 cases of inflammatory dermatoses and in 14 cases of normal human skin by immunohistochemical and morphometric methods,skin,dermatoses
503223630,7/15/2014 10:16:11,,1323480163,7/15/2014 10:15:24,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,MOTION SICKNESS,45-52,12,SCOPOLAMINE,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223630,7/15/2014 10:28:34,,1323488263,7/15/2014 10:28:21,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,significant MOTION SICKNESS,33-45-52,0-12,Transdermal SCOPOLAMINE,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223630,7/15/2014 10:48:48,,1323502181,7/15/2014 10:48:38,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,MOTION SICKNESS,45-52,12,SCOPOLAMINE,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223630,7/15/2014 11:11:25,,1323518350,7/15/2014 11:11:15,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,MOTION SICKNESS,45-52,0-12,Transdermal SCOPOLAMINE,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223630,7/15/2014 11:15:49,,1323521132,7/15/2014 11:15:34,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,MOTION SICKNESS,45-52,12-45-52,SCOPOLAMINE motion sickness,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223630,7/15/2014 11:20:39,,1323524254,7/15/2014 11:20:06,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,MOTION SICKNESS,45-52,12,SCOPOLAMINE,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223630,7/15/2014 11:43:56,,1323537707,7/15/2014 11:43:39,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,scopolamine MOTION SICKNESS scopolamine dimenhydrinate.,12-45-52-131-116,12-116-131,SCOPOLAMINE scopolamine dimenhydrinate.,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223630,7/15/2014 11:54:32,,1323544087,7/15/2014 11:53:43,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,MOTION SICKNESS,45-52,0-12,Transdermal SCOPOLAMINE,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223630,7/15/2014 11:58:40,,1323546232,7/15/2014 11:58:23,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,MOTION SICKNESS,45-52,0-12,Transdermal SCOPOLAMINE,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223630,7/15/2014 12:02:50,,1323547939,7/15/2014 12:02:28,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,45,12,,,60,23,MOTION SICKNESS,SCOPOLAMINE,MOTION SICKNESS,45-52,12,SCOPOLAMINE,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate.",45 52,12,45,12,60,23,1,RO-may_prevent,907382,"Transdermal scopolamine provides significant motion sickness protection, similar in extent to that provided by oral scopolamine or dimenhydrinate",motion sickness,scopolamine
503223631,7/15/2014 10:18:49,,1323481987,7/15/2014 10:18:44,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,0,42,,,6,51,LENSES,CATARACTS,LENSES were examined with,0-7-12-21,28-33-38-42-52-57-64,slit lamp and CATARACTS were graded on,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223631,7/15/2014 10:19:48,,1323482744,7/15/2014 10:19:26,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,0,42,,,6,51,LENSES,CATARACTS,LENSES,0,42,CATARACTS,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223631,7/15/2014 10:23:54,,1323485259,7/15/2014 10:23:40,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,0,42,,,6,51,LENSES,CATARACTS,LENSES,0,42,CATARACTS,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223631,7/15/2014 10:29:49,,1323489021,7/15/2014 10:29:37,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,0,42,,,6,51,LENSES,CATARACTS,LENSES,0,42,CATARACTS,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223631,7/15/2014 11:08:50,,1323516300,7/15/2014 11:08:26,instagc,1,23149109,USA,NC,Durham,75.189.206.205,0,42,,,6,51,LENSES,CATARACTS,LENSES,0,42,CATARACTS,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223631,7/15/2014 11:16:25,,1323521533,7/15/2014 11:16:14,instagc,1,13763729,USA,,,75.182.89.225,0,42,,,6,51,LENSES,CATARACTS,LENSES,0,42,CATARACTS,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223631,7/15/2014 11:22:24,,1323525142,7/15/2014 11:22:08,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,0,42,,,6,51,LENSES,CATARACTS,LENSES,0,42,CATARACTS,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223631,7/15/2014 11:36:30,,1323533256,7/15/2014 11:36:13,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,0,42,,,6,51,LENSES,CATARACTS,LENSES slit lamp,0-28-33,28-33-42,slit lamp CATARACTS,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223631,7/15/2014 11:41:57,,1323536519,7/15/2014 11:41:35,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,0,42,,,6,51,LENSES,CATARACTS,LENSES,0,42-52-57-64-67-69,CATARACTS were graded on a scale,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223631,7/15/2014 11:42:22,,1323536752,7/15/2014 11:42:04,prodege,1,6316959,GBR,,,46.208.145.114,0,42,,,6,51,LENSES,CATARACTS,LENSES,0,42,CATARACTS,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+.,0,42,0,42,6,51,1,RO-has_finding_site,905124,Lenses were examined with a slit lamp and cataracts were graded on a scale of 1+ to 4+,Lenses,cataracts
503223632,7/15/2014 10:50:28,,1323503370,7/15/2014 10:49:37,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,110,132,,,114,144,GVHD,CYCLOSPORINE,"myeloablation body irradiation, cyclophosphamide, etoposide GVHD prophylaxis cyclosporine methotrexate.",18-56-61-74-96-110-115-132-149,18-56-61-74-96-110-115-132-149,"myeloablation body irradiation, cyclophosphamide, etoposide GVHD prophylaxis CYCLOSPORINE methotrexate.","Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223632,7/15/2014 10:53:01,,1323505119,7/15/2014 10:52:10,clixsense,1,6416850,USA,VA,Midlothian,108.4.51.140,110,132,,,114,144,GVHD,CYCLOSPORINE,GVHD,110,110-115-132-145-149,GVHD prophylaxis CYCLOSPORINE and methotrexate.,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223632,7/15/2014 10:54:31,,1323506146,7/15/2014 10:53:31,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,110,132,,,114,144,GVHD,CYCLOSPORINE,GVHD prophylaxis,110-115,132,CYCLOSPORINE,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223632,7/15/2014 10:56:11,,1323507109,7/15/2014 10:55:58,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,110,132,,,114,144,GVHD,CYCLOSPORINE,GVHD prophylaxis,110-115,132,CYCLOSPORINE,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223632,7/15/2014 11:09:14,,1323516719,7/15/2014 11:08:50,instagc,1,13763729,USA,,,75.182.89.225,110,132,,,114,144,GVHD,CYCLOSPORINE,GVHD,110,132,CYCLOSPORINE,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223632,7/15/2014 11:31:33,,1323530366,7/15/2014 11:30:39,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,110,132,,,114,144,GVHD,CYCLOSPORINE,"myeloablation total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",18-50-56-61-74-92-96-110-115-127-132-145-149-106,18-50-56-61-74-92-96-110-115-127-132-145-149-106,"myeloablation total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with CYCLOSPORINE and methotrexate.","Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223632,7/15/2014 11:40:06,,1323535316,7/15/2014 11:39:46,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,110,132,,,114,144,GVHD,CYCLOSPORINE,"myeloablation irradiation, cyclophosphamide, etoposide GVHD prophylaxis cyclosporine",18-61-74-96-110-115-132,18-61-74-96-110-115-132-149,"myeloablation irradiation, cyclophosphamide, etoposide GVHD prophylaxis CYCLOSPORINE methotrexate.","Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223632,7/15/2014 11:50:31,,1323541451,7/15/2014 11:50:15,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,110,132,,,114,144,GVHD,CYCLOSPORINE,GVHD prophylaxis,110-115,132,CYCLOSPORINE,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223632,7/15/2014 11:57:08,,1323545446,7/15/2014 11:56:53,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,110,132,,,114,144,GVHD,CYCLOSPORINE,GVHD,110,132,CYCLOSPORINE,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223632,7/15/2014 12:04:20,,1323548442,7/15/2014 12:04:06,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,110,132,,,114,144,GVHD,CYCLOSPORINE,etoposide GVHD prophylaxis with cyclosporine,96-110-115-127-132,110-115-127-132,GVHD prophylaxis with CYCLOSPORINE,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate.",110,132,110,132,114,144,1,RO-may_prevent,907139,"Patients received myeloablation with fractionated total body irradiation, cyclophosphamide, and etoposide and GVHD prophylaxis with cyclosporine and methotrexate",GVHD,cyclosporine
503223633,7/15/2014 10:25:59,,1323486508,7/15/2014 10:25:44,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"(basal cell DYSPLASIA,",164-171-176,212-222-233,bronchial EPITHELIAL DYSPLASIA,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223633,7/15/2014 10:27:26,,1323487395,7/15/2014 10:27:13,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"(basal cell DYSPLASIA,",164-171-176,212-222-233,bronchial EPITHELIAL DYSPLASIA,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223633,7/15/2014 10:38:19,,1323494530,7/15/2014 10:38:07,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"(basal cell DYSPLASIA,",164-171-176,222-233,EPITHELIAL DYSPLASIA,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223633,7/15/2014 10:40:16,,1323495980,7/15/2014 10:38:41,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"bronchial epithelial dysplasia morphological features DYSPLASIA, bronchial epithelial dysplasia squamous dysplasia.",101-111-122-141-155-176-212-222-233-282-291,101-111-141-155-176-196-201-212-222-233-282-291-122,"bronchial epithelial dysplasia morphological features dysplasia, cell dysplasia, bronchial EPITHELIAL DYSPLASIA squamous dysplasia.","By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223633,7/15/2014 10:47:03,,1323500823,7/15/2014 10:46:25,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"features (basal cell DYSPLASIA, columnar cell dysplasia, bronchial epithelial dysplasia",155-164-171-176-187-196-201-212-222-233,196-201-212-222-233-243-248-261-282-291,"cell dysplasia, bronchial EPITHELIAL DYSPLASIA with transitional differentiation, squamous dysplasia.","By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223633,7/15/2014 10:52:10,,1323504608,7/15/2014 10:51:51,clixsense,1,6416850,USA,VA,Midlothian,108.4.51.140,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"(basal cell DYSPLASIA, columnar cell dysplasia,",164-171-176-187-196-201,196-201-212-222-233-282-291,"cell dysplasia, bronchial EPITHELIAL DYSPLASIA squamous dysplasia.","By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223633,7/15/2014 10:56:49,,1323507506,7/15/2014 10:56:08,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"(basal cell DYSPLASIA,",164-176-171,222-233-212,bronchial EPITHELIAL DYSPLASIA,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223633,7/15/2014 11:09:21,,1323516806,7/15/2014 11:09:09,instagc,1,23149109,USA,NC,Durham,75.189.206.205,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"(basal cell DYSPLASIA,",164-171-176,212-222-233-243-248-261,"bronchial EPITHELIAL DYSPLASIA with transitional differentiation,","By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223633,7/15/2014 11:25:44,,1323527031,7/15/2014 11:25:27,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"DYSPLASIA,",176,222-233,EPITHELIAL DYSPLASIA,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223633,7/15/2014 11:27:21,,1323527960,7/15/2014 11:26:29,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,176,222,,,185,242,DYSPLASIA,EPITHELIAL DYSPLASIA,"lung (basal cell DYSPLASIA, columnar cell dysplasia, bronchial epithelial dysplasia squamous dysplasia.",27-164-171-176-187-196-201-212-222-233-282-291,27-164-171-176-187-196-201-212-222-233-282-291,"lung (basal cell dysplasia, columnar cell dysplasia, bronchial EPITHELIAL DYSPLASIA squamous dysplasia.","By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia.",176,222 233,176,222,185,242,-1,RO-disease_has_finding,901507,"By examining 114 resection lung specimens, we concluded that there are four histological patterns of bronchial epithelial dysplasia based on morphological features (basal cell dysplasia, columnar cell dysplasia, bronchial epithelial dysplasia with transitional differentiation, and squamous dysplasia",dysplasia,epithelial dysplasia
503223634,7/15/2014 10:19:31,,1323482568,7/15/2014 10:19:06,vivatic,1,25451531,GBR,,,83.67.28.193,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",45-50-64-67-78-90-100-108-118-130-134,134,PREECLAMPSIA.,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223634,7/15/2014 10:19:45,,1323482710,7/15/2014 10:19:41,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"risk of four COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm",37-42-45-50-64-67-78-90-100,108-118-130-134,"delivery, stillbirth, and PREECLAMPSIA.","This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223634,7/15/2014 10:23:21,,1323484940,7/15/2014 10:22:59,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50-64-67-78-90-100-108-118-130-134,134,PREECLAMPSIA.,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223634,7/15/2014 10:27:38,,1323487558,7/15/2014 10:27:26,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,COMPLICATIONS OF PREGNANCY:,50-64-67,134,PREECLAMPSIA.,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223634,7/15/2014 10:27:46,,1323487704,7/15/2014 10:27:34,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,COMPLICATIONS OF PREGNANCY:,50-64-67,134,PREECLAMPSIA.,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223634,7/15/2014 10:29:29,,1323488808,7/15/2014 10:28:31,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,COMPLICATIONS OF PREGNANCY:,50-64-67,134,PREECLAMPSIA.,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223634,7/15/2014 10:59:48,,1323509314,7/15/2014 10:59:31,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,COMPLICATIONS OF PREGNANCY:,50-64-67,134,PREECLAMPSIA.,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223634,7/15/2014 11:04:59,,1323512800,7/15/2014 11:04:44,instagc,1,23149109,USA,NC,Durham,75.189.206.205,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,COMPLICATIONS OF PREGNANCY:,50-64-67,134,PREECLAMPSIA.,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223634,7/15/2014 11:08:08,,1323515719,7/15/2014 11:06:03,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,"COMPLICATIONS OF PREGNANCY: gestational diabetes, preterm delivery, stillbirth, preeclampsia.",50-64-67-78-90-100-108-118-134,64-67-78-90-100-108-118-130-134-50,"complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and PREECLAMPSIA.","This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223634,7/15/2014 11:10:42,,1323517812,7/15/2014 11:10:29,instagc,1,13763729,USA,,,75.182.89.225,50,134,,,76,146,COMPLICATIONS OF PREGNANCY,PREECLAMPSIA,COMPLICATIONS OF PREGNANCY:,50-64-67,134,PREECLAMPSIA.,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia.",50 64 67,134,50,134,76,146,-1,RO-disease_has_finding,901860,"This article examines the recurrence risk of four complications of pregnancy: gestational diabetes, preterm delivery, stillbirth, and preeclampsia",complications of pregnancy,preeclampsia
503223635,7/15/2014 10:17:49,,1323481261,7/15/2014 10:17:30,vivatic,1,25451531,GBR,,,83.67.28.193,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"BORDETELLA PERTUSSIS,",47-58,92-101,WHOOPING COUGH.,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223635,7/15/2014 10:25:58,,1323486472,7/15/2014 10:25:45,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"BORDETELLA PERTUSSIS,",47-58,92-101,WHOOPING COUGH.,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223635,7/15/2014 10:33:37,,1323491541,7/15/2014 10:33:26,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"BORDETELLA PERTUSSIS,",47-58,92-101,WHOOPING COUGH.,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223635,7/15/2014 10:47:11,,1323500924,7/15/2014 10:47:02,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"BORDETELLA PERTUSSIS,",47-58,92-101,WHOOPING COUGH.,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223635,7/15/2014 10:54:58,,1323506417,7/15/2014 10:54:33,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"BORDETELLA PERTUSSIS,",47-58,92-101,WHOOPING COUGH.,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223635,7/15/2014 11:02:44,,1323511033,7/15/2014 11:02:34,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"BORDETELLA PERTUSSIS,",47-58,92-101,WHOOPING COUGH.,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223635,7/15/2014 11:08:03,,1323515639,7/15/2014 11:07:53,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"BORDETELLA PERTUSSIS,",47-58,92-101,WHOOPING COUGH.,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223635,7/15/2014 11:21:50,,1323524894,7/15/2014 11:21:34,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"BORDETELLA PERTUSSIS, whooping cough.",47-58-92-101,92-101,WHOOPING COUGH.,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223635,7/15/2014 11:22:31,,1323525203,7/15/2014 11:21:49,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"Pertussis toxin virulence factor BORDETELLA PERTUSSIS, whooping cough.",0-10-27-37-47-58-92-101,0-27-37-47-58-92-101-10,"Pertussis toxin virulence factor Bordetella pertussis, WHOOPING COUGH.","Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223635,7/15/2014 11:43:22,,1323537324,7/15/2014 11:43:01,prodege,1,6316959,GBR,,,46.208.145.114,47,92,,,67,106,BORDETELLA PERTUSSIS,WHOOPING COUGH,"BORDETELLA PERTUSSIS,",47-58,92-101,WHOOPING COUGH.,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough.",47 58,92 101,47,92,67,106,1,RO-has_causative_agent,903889,"Pertussis toxin is a major virulence factor of Bordetella pertussis, the causative agent of whooping cough",Bordetella pertussis,whooping cough
503223636,7/15/2014 10:22:46,,1323484690,7/15/2014 10:22:28,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,FOLLICULAR LYMPHOMA,91-102,63-67-69,BCL 2 GENE,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223636,7/15/2014 10:33:19,,1323491340,7/15/2014 10:33:04,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,FOLLICULAR LYMPHOMA,91-102,63-67-69,BCL 2 GENE,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223636,7/15/2014 10:38:35,,1323494726,7/15/2014 10:38:20,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,FOLLICULAR LYMPHOMA,91-102,63-67-69,BCL 2 GENE,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223636,7/15/2014 10:56:45,,1323507476,7/15/2014 10:56:32,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,FOLLICULAR LYMPHOMA,91-102,63-67-69,BCL 2 GENE,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223636,7/15/2014 11:00:54,,1323509895,7/15/2014 11:00:35,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,FOLLICULAR LYMPHOMA,91-102,63-67-69,BCL 2 GENE,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223636,7/15/2014 11:19:50,,1323523859,7/15/2014 11:19:22,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,bcl 2 gene rearrangement in FOLLICULAR LYMPHOMA,63-69-74-88-91-102-67,63-67-69-74-88-91-102,BCL 2 GENE rearrangement in follicular lymphoma,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223636,7/15/2014 11:40:21,,1323535496,7/15/2014 11:39:50,prodege,1,6316959,GBR,,,46.208.145.114,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,FOLLICULAR LYMPHOMA,91-102,63-67-69-74,BCL 2 GENE rearrangement,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223636,7/15/2014 12:01:06,,1323547284,7/15/2014 12:00:52,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,gene rearrangement in FOLLICULAR LYMPHOMA patients,69-74-88-91-102-111,63-67-69-74,BCL 2 GENE rearrangement,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223636,7/15/2014 12:04:01,,1323548311,7/15/2014 12:02:49,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,gene rearrangement in FOLLICULAR LYMPHOMA,69-74-88-91-102,47-60-63-67-69-74,distribution of BCL 2 GENE rearrangement,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223636,7/15/2014 12:07:07,,1323549382,7/15/2014 12:06:50,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,91,63,,,110,73,FOLLICULAR LYMPHOMA,BCL-2 GENE,FOLLICULAR LYMPHOMA,91-102,63-67-69,BCL 2 GENE,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region.,91 102,63 67 69,91,63,110,73,-1,RO-has_manifestation,906133,This study expands the geographical map of the distribution of bcl-2 gene rearrangement in follicular lymphoma patients in the Middle East region,follicular lymphoma,bcl-2 gene
503223637,7/15/2014 10:18:31,,1323481783,7/15/2014 10:18:27,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"rate rhythm composite, TACHYCARDIA, and Torsades de",193-198-205-216-229-233-242,205-216-229-233-242-245-255-259-261,"composite, tachycardia, and TORSADES DE POINTES), and 5 clusters","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223637,7/15/2014 10:18:32,,1323481800,7/15/2014 10:18:16,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"TACHYCARDIA,",216,233-242-245,"TORSADES DE POINTES),","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223637,7/15/2014 10:22:39,,1323484641,7/15/2014 10:22:23,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"TACHYCARDIA,",216,233-242-245,"TORSADES DE POINTES),","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223637,7/15/2014 10:25:34,,1323486263,7/15/2014 10:25:20,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"TACHYCARDIA,",216,233-242-245,"TORSADES DE POINTES),","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223637,7/15/2014 10:53:30,,1323505477,7/15/2014 10:52:51,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"TACHYCARDIA, Torsades de pointes),",216-233-242-245,216-233-242-245,"tachycardia, TORSADES DE POINTES),","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223637,7/15/2014 10:58:02,,1323508252,7/15/2014 10:57:48,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"TACHYCARDIA,",216,233-242-245,"TORSADES DE POINTES),","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223637,7/15/2014 11:02:35,,1323510944,7/15/2014 11:02:15,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"prolongation, rate TACHYCARDIA,",193-216-179,233-242-245,"TORSADES DE POINTES),","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223637,7/15/2014 11:12:00,,1323518773,7/15/2014 11:11:49,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"TACHYCARDIA,",216,233-242-245,"TORSADES DE POINTES),","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223637,7/15/2014 11:28:48,,1323528814,7/15/2014 11:28:31,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"TACHYCARDIA,",216,233-242-245,"TORSADES DE POINTES),","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223637,7/15/2014 11:57:27,,1323545589,7/15/2014 11:57:08,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,216,233,,,227,252,TACHYCARDIA,TORSADES DE POINTES,"TACHYCARDIA,",216,233-242-245,"TORSADES DE POINTES),","Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders.",216,233 242 245,216,233,227,252,-1,RO-has_definitional_manifestation,904648,"Results revealed that significant cardiac AEs formed 9 clusters affecting Purkinje nerve fibers (arrhythmia, bradycardia, conduction disorder, electrocardiogram, palpitations, QT prolongation, rate rhythm composite, tachycardia, and Torsades de pointes), and 5 clusters affecting the heart muscle (coronary artery disorders, heart failure, myocardial disorders, myocardial infarction, and valve disorders",tachycardia,Torsades de pointes
503223638,7/15/2014 10:18:26,,1323481697,7/15/2014 10:18:11,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,and to the IMMUNODEFICIENCY associated with transplantation,162-166-169-173-190-201-206,226-230-242-245,the development of GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223638,7/15/2014 10:24:52,,1323485787,7/15/2014 10:24:41,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,IMMUNODEFICIENCY,173,245,GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223638,7/15/2014 10:30:10,,1323489213,7/15/2014 10:29:47,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,IMMUNODEFICIENCY,173,245,GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223638,7/15/2014 10:36:13,,1323493309,7/15/2014 10:36:03,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,IMMUNODEFICIENCY,173,245,GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223638,7/15/2014 10:37:53,,1323494319,7/15/2014 10:37:41,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,IMMUNODEFICIENCY,173,245,GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223638,7/15/2014 10:48:26,,1323501829,7/15/2014 10:48:16,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,IMMUNODEFICIENCY,173,245,GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223638,7/15/2014 10:57:44,,1323508072,7/15/2014 10:56:50,clixsense,1,27969116,NLD,,,91.213.37.165,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,IMMUNODEFICIENCY,173,230-242-245,development of GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223638,7/15/2014 11:02:33,,1323510935,7/15/2014 11:02:17,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,IMMUNODEFICIENCY,173,245,GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223638,7/15/2014 11:04:44,,1323512618,7/15/2014 11:04:31,instagc,1,23149109,USA,NC,Durham,75.189.206.205,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,IMMUNODEFICIENCY associated with transplantation,173-190-201-206,230-242-245,development of GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223638,7/15/2014 11:16:40,,1323521639,7/15/2014 11:16:26,instagc,1,13763729,USA,,,75.182.89.225,173,245,,,189,249,IMMUNODEFICIENCY,GVHD,IMMUNODEFICIENCY,173,245,GVHD.,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD.",173,245,173,245,189,249,1,RO-disease_has_finding,901989,"These complications may be related to chemo- or radiotherapy used in conditioning for transplantation, to immunosuppressive treatment given after transplantation and to the immunodeficiency associated with transplantation and the development of GVHD",immunodeficiency,GVHD
503223639,7/15/2014 10:18:43,,1323481919,7/15/2014 10:18:39,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,dermatitis (AD) and ALLERGIC RHINITIS and compared with,121-132-137-141-150-159-163-172,97-100-109-114-121-137-141,in patients with ATOPIC DERMATITIS and allergic,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223639,7/15/2014 10:21:04,,1323483603,7/15/2014 10:20:50,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,ALLERGIC RHINITIS,141-150,114-121-132,ATOPIC DERMATITIS (AD),The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223639,7/15/2014 10:21:42,,1323484029,7/15/2014 10:21:25,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,ALLERGIC RHINITIS,141-150,114-121,ATOPIC DERMATITIS,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223639,7/15/2014 10:27:07,,1323487199,7/15/2014 10:26:56,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,ALLERGIC RHINITIS,141-150,114-121,ATOPIC DERMATITIS,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223639,7/15/2014 10:29:39,,1323488936,7/15/2014 10:28:22,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,ALLERGIC RHINITIS,141-150,114-121,ATOPIC DERMATITIS,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223639,7/15/2014 10:31:40,,1323490317,7/15/2014 10:31:01,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,ALLERGIC RHINITIS,141-150,114-121-132,ATOPIC DERMATITIS (AD),The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223639,7/15/2014 10:52:51,,1323504990,7/15/2014 10:52:20,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,atopic dermatitis (AD) ALLERGIC RHINITIS,114-121-132-141-150,114-121-132,ATOPIC DERMATITIS (AD),The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223639,7/15/2014 11:01:36,,1323510373,7/15/2014 11:01:26,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,ALLERGIC RHINITIS,141-150,114-121-132,ATOPIC DERMATITIS (AD),The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223639,7/15/2014 11:03:21,,1323511477,7/15/2014 11:03:03,clixsense,1,27969116,NLD,,,91.213.37.165,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,dermatitis (AD) ALLERGIC RHINITIS and,121-132-141-150-159,114-121-132-137-141-150,ATOPIC DERMATITIS (AD) and allergic rhinitis,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223639,7/15/2014 11:07:04,,1323514724,7/15/2014 11:06:21,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,141,114,,,158,131,ALLERGIC RHINITIS,ATOPIC DERMATITIS,ALLERGIC RHINITIS,141-150,114-121,ATOPIC DERMATITIS,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls.,141 150,114 121,141,114,158,131,-1,RO-has_manifestation,906239,The effect of recombinant human and murine interleukin-5 (IL-5) on granulocytes was investigated in patients with atopic dermatitis (AD) and allergic rhinitis and compared with those from patients with plaque psoriasis and normal non-atopic controls,allergic rhinitis,atopic dermatitis
503223640,7/15/2014 10:14:03,,1323478847,7/15/2014 10:13:54,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,272,269,,,283,271,TACHYCARDIA,VT,TACHYCARDIA,272,269,VT,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223640,7/15/2014 10:16:20,,1323480236,7/15/2014 10:15:47,vivatic,1,25451531,GBR,,,83.67.28.193,272,269,,,283,271,TACHYCARDIA,VT,VT TACHYCARDIA,269-272,269-272,VT tachycardia,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223640,7/15/2014 10:25:44,,1323486343,7/15/2014 10:25:23,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,272,269,,,283,271,TACHYCARDIA,VT,VT TACHYCARDIA,269-272,254-269,fibrillation VT,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223640,7/15/2014 10:25:49,,1323486376,7/15/2014 10:25:35,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,272,269,,,283,271,TACHYCARDIA,VT,TACHYCARDIA Table 8,272-286-292,269-272-286-292,VT tachycardia Table 8,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223640,7/15/2014 10:27:49,,1323487731,7/15/2014 10:26:43,bitcoinget,1,24792414,USA,,,166.181.81.37,272,269,,,283,271,TACHYCARDIA,VT,VT TACHYCARDIA,269-272,269-272,VT tachycardia,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223640,7/15/2014 10:36:26,,1323493474,7/15/2014 10:36:11,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,272,269,,,283,271,TACHYCARDIA,VT,VT TACHYCARDIA,269-272,269,VT,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223640,7/15/2014 10:59:30,,1323509097,7/15/2014 10:58:21,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,272,269,,,283,271,TACHYCARDIA,VT,TACHYCARDIA,272,269,VT,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223640,7/15/2014 11:11:11,,1323518175,7/15/2014 11:10:47,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,272,269,,,283,271,TACHYCARDIA,VT,VF fibrillation VT TACHYCARDIA,251-254-269-272,237-251-254-269-272,ventricular VF fibrillation VT tachycardia,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223640,7/15/2014 11:29:06,,1323528965,7/15/2014 11:28:50,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,272,269,,,283,271,TACHYCARDIA,VT,TACHYCARDIA,272,269,VT,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223640,7/15/2014 11:39:47,,1323535101,7/15/2014 11:38:56,prodege,1,23999031,AUS,8,Perth,203.59.238.194,272,269,,,283,271,TACHYCARDIA,VT,sinus node dysfunction sinus node disease sinus node disease TACHYCARDIA,81-87-92-107-113-118-197-203-208-272,81-87-92-107-113-118-197-203-208-269,sinus node dysfunction sinus node disease sinus node disease VT,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol.,272,269,272,269,283,271,-1,RO-has_definitional_manifestation,904774,is present High-grade AV block  Class IA and class IC drugs  Rare Aggravation of sinus node dysfunction in sinus node disease  Potentially all antiarrhythmic drugs  Varies with drug and underlying sinus node disease AF fibrillation   LV ventricular   VF fibrillation   VT tachycardia   Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation  Normal;                Section 1 / Chapter IV - Atrial Fibrillation Table 8 - Drugs for Ventricular Rate Control in Atrial Fibrillation Drug  I.V. Loading Dose  I.V. Onset  I.V. Maintenance Dose  Oral Loading Dose  Oral Onset  Oral Maintenance Dose  Drug Interactions and Precautions Esmolol,tachycardia,VT
503223641,7/15/2014 10:20:28,,1323483160,7/15/2014 10:20:22,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,"heart racing, pounding HEADACHE Pheochromocytoma Physical: pallor;",180-186-194-203-212-230-240,118-126-135-143-161-170-180,"blood), elevated glucose PHEOCHROMOCYTOMA History: sweating, heart","obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223641,7/15/2014 10:21:24,,1323483828,7/15/2014 10:20:46,vivatic,1,25451531,GBR,,,83.67.28.193,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,pounding HEADACHE Pheochromocytoma,194-203-212,126-135-143,elevated glucose PHEOCHROMOCYTOMA,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223641,7/15/2014 10:23:24,,1323484976,7/15/2014 10:23:05,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,HEADACHE Pheochromocytoma Physical:,203-212-230,143,PHEOCHROMOCYTOMA,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223641,7/15/2014 10:24:05,,1323485334,7/15/2014 10:23:40,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,HEADACHE,203,143,PHEOCHROMOCYTOMA,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223641,7/15/2014 10:24:45,,1323485706,7/15/2014 10:24:22,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,pounding HEADACHE,194-203,126-135-143,elevated glucose PHEOCHROMOCYTOMA,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223641,7/15/2014 10:33:12,,1323491274,7/15/2014 10:32:45,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,HEADACHE,203,143,PHEOCHROMOCYTOMA,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223641,7/15/2014 10:44:38,,1323499074,7/15/2014 10:44:20,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,HEADACHE,203,143,PHEOCHROMOCYTOMA,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223641,7/15/2014 10:50:33,,1323503444,7/15/2014 10:49:58,clixsense,1,6416850,USA,VA,Midlothian,108.4.51.140,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,HEADACHE Pheochromocytoma pallor;,203-212-240,143,PHEOCHROMOCYTOMA,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223641,7/15/2014 10:51:57,,1323504509,7/15/2014 10:51:16,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,HEADACHE,203,143,PHEOCHROMOCYTOMA,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223641,7/15/2014 10:59:05,,1323508794,7/15/2014 10:58:07,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,203,143,,,211,159,HEADACHE,PHEOCHROMOCYTOMA,HEADACHE Pheochromocytoma Physical: pallor;,203-212-230-240,135-143,glucose PHEOCHROMOCYTOMA,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP.",203,143,203,143,211,159,1,RO-disease_may_have_finding,902983,"obesity, abdominal striae Cushing syndrome  Lab: reduced potassium, metabolic alkalosis, increased cortisol (urine or blood), elevated glucose Pheochromocytoma  History: sweating, heart racing, pounding headache Pheochromocytoma  Physical: pallor; tachycardia; hypertension may be worsened during secretion, or episodic with intervals of normal BP Pheochromocytoma  Lab: increased urine or plasma catecholamines or metanephrine Sleep-disordered breathing  Loud snoring, noctural awakenings with breathlessness, seeming not to be breathing by bed partner, or daytime somnolence  BP improvements of about 3 mm Hg (both SBP",headache,Pheochromocytoma
503223642,7/15/2014 10:17:35,,1323481188,7/15/2014 10:16:51,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,116,69,,,125,73,DYSPLASIA,LSIL,DYSPLASIA,116,69,LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223642,7/15/2014 10:20:05,,1323482886,7/15/2014 10:19:49,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,116,69,,,125,73,DYSPLASIA,LSIL,cervical DYSPLASIA,107-116,69,LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223642,7/15/2014 10:20:54,,1323483514,7/15/2014 10:19:51,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,116,69,,,125,73,DYSPLASIA,LSIL,cervical DYSPLASIA,107-116,69,LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223642,7/15/2014 10:27:14,,1323487243,7/15/2014 10:26:58,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,116,69,,,125,73,DYSPLASIA,LSIL,high grade cervical DYSPLASIA,96-101-107-116,59-63-66-69,ASC US or LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223642,7/15/2014 10:34:23,,1323492058,7/15/2014 10:34:10,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,116,69,,,125,73,DYSPLASIA,LSIL,cervical DYSPLASIA -,107-116-132,59-63-66-69,ASC US or LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223642,7/15/2014 10:43:49,,1323498559,7/15/2014 10:43:28,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,116,69,,,125,73,DYSPLASIA,LSIL,DYSPLASIA,116,69,LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223642,7/15/2014 10:58:06,,1323508272,7/15/2014 10:57:25,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,116,69,,,125,73,DYSPLASIA,LSIL,cervical DYSPLASIA,107-116,59-63-69,ASC US LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223642,7/15/2014 11:08:36,,1323516048,7/15/2014 11:08:26,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,116,69,,,125,73,DYSPLASIA,LSIL,high grade cervical DYSPLASIA,96-101-107-116,69,LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223642,7/15/2014 11:37:28,,1323533756,7/15/2014 11:37:06,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,116,69,,,125,73,DYSPLASIA,LSIL,cervical DYSPLASIA,107-116,69,LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223642,7/15/2014 11:41:04,,1323535911,7/15/2014 11:40:40,prodege,1,6316959,GBR,,,46.208.145.114,116,69,,,125,73,DYSPLASIA,LSIL,high grade cervical DYSPLASIA,96-101-107-116,69,LSIL,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74.",116,69,116,69,125,73,1,RO-disease_has_finding,901864,"More recent evidence suggests that HIV-positive women with ASC-US or LSIL have similar rates of high-grade cervical dysplasia to HIV-negative women, although a trend towards increased rates of CIN-II or worse was observed among women with worsening immunosuppression ( 74",dysplasia,LSIL
503223643,7/15/2014 10:19:28,,1323482476,7/15/2014 10:19:21,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,0-12,42-49,FACTOR VIII,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223643,7/15/2014 10:20:02,,1323482881,7/15/2014 10:19:47,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,0-12,42-49-54,FACTOR VIII (fVIII),Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223643,7/15/2014 10:24:23,,1323485499,7/15/2014 10:24:13,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,0-12,42-49,FACTOR VIII,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223643,7/15/2014 11:18:39,,1323523066,7/15/2014 11:18:27,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,0-12,0-12-42-49,Haemophilia A FACTOR VIII,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223643,7/15/2014 11:30:54,,1323529957,7/15/2014 11:30:12,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A (fVIII) antibody (Ab) inhibitors to fVIII.,0-12-54-74-83-88-99-102,42-49-54-74-83-88-99-102-0,Haemophilia FACTOR VIII (fVIII) antibody (Ab) inhibitors to fVIII.,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223643,7/15/2014 11:32:38,,1323530932,7/15/2014 11:32:26,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,0-12,36-42-49,human FACTOR VIII,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223643,7/15/2014 11:39:06,,1323534762,7/15/2014 11:38:44,prodege,1,6316959,GBR,,,46.208.145.114,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,0-12,36-42-49-54,human FACTOR VIII (fVIII),Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223643,7/15/2014 11:44:03,,1323537744,7/15/2014 11:43:47,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,0-12,36-42-49-54,human FACTOR VIII (fVIII),Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223643,7/15/2014 11:54:42,,1323544132,7/15/2014 11:54:20,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,0-12,36-42-49,human FACTOR VIII,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223643,7/15/2014 11:55:06,,1323544297,7/15/2014 11:54:35,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,0,42,,,13,53,HAEMOPHILIA A,FACTOR VIII,HAEMOPHILIA A,0-12,36-42-49-54,human FACTOR VIII (fVIII),Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII.,0 12,42 49,0,42,13,53,1,RO-may_treat,908174,Haemophilia A patients treated with human factor VIII (fVIII) may develop antibody (Ab) inhibitors to fVIII,Haemophilia A,factor VIII
503223644,7/15/2014 10:25:38,,1323486302,7/15/2014 10:25:22,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,0-11,46,NEOSTIGMINE,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223644,7/15/2014 10:28:30,,1323488256,7/15/2014 10:27:58,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,0-11,46-58,NEOSTIGMINE test.,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223644,7/15/2014 10:32:15,,1323490702,7/15/2014 10:32:03,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,0-11,46,NEOSTIGMINE,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223644,7/15/2014 10:45:27,,1323499650,7/15/2014 10:45:18,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,0-11,46,NEOSTIGMINE,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223644,7/15/2014 10:50:57,,1323503719,7/15/2014 10:50:34,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS positive neostigmine test.,0-11-37-46-58,0-37-46-58-11,Myasthenia gravis positive NEOSTIGMINE test.,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223644,7/15/2014 10:52:19,,1323504675,7/15/2014 10:51:59,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,0-11,46,NEOSTIGMINE,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223644,7/15/2014 11:03:24,,1323511521,7/15/2014 11:03:07,instagc,1,23149109,USA,NC,Durham,75.189.206.205,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,0-11,37-46-58,positive NEOSTIGMINE test.,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223644,7/15/2014 11:21:30,,1323524712,7/15/2014 11:21:15,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,0-11,46,NEOSTIGMINE,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223644,7/15/2014 11:59:23,,1323546533,7/15/2014 11:59:08,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,0-11,37-46-58,positive NEOSTIGMINE test.,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223644,7/15/2014 12:01:34,,1323547458,7/15/2014 12:01:23,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,0,46,,,17,57,MYASTHENIA GRAVIS,NEOSTIGMINE,MYASTHENIA GRAVIS,0-11,35-37-46-58,a positive NEOSTIGMINE test.,Myasthenia gravis was confirmed by a positive neostigmine test.,0 11,46,0,46,17,57,1,RO-may_diagnose,906866,Myasthenia gravis was confirmed by a positive neostigmine test,Myasthenia gravis,neostigmine
503223645,7/15/2014 10:22:31,,1323484535,7/15/2014 10:21:38,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,in GRAVES' DISEASE,98-115-123,149-157,Graves' THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223645,7/15/2014 10:23:40,,1323485142,7/15/2014 10:23:28,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,115-123,149-157,Graves' THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223645,7/15/2014 10:32:51,,1323491059,7/15/2014 10:32:38,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,115-123,157,THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223645,7/15/2014 10:49:32,,1323502800,7/15/2014 10:48:59,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,postpartum GRAVES' DISEASE Graves' thyrotoxicosis.,87-115-123-149-157,115-123-149-157-87,postpartum Graves' disease Graves' THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223645,7/15/2014 11:04:02,,1323511943,7/15/2014 11:03:20,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,115-123,149-157,Graves' THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223645,7/15/2014 11:48:56,,1323540352,7/15/2014 11:48:45,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,115-123,149-157,Graves' THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223645,7/15/2014 11:57:15,,1323545479,7/15/2014 11:56:41,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,115-123,149-157,Graves' THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223645,7/15/2014 12:02:04,,1323547633,7/15/2014 12:01:53,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,in patients with GRAVES' DISEASE,98-101-110-115-123,135-144-149-157,relapsed into Graves' THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223645,7/15/2014 12:02:08,,1323547667,7/15/2014 12:01:46,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,115-123,149-157,Graves' THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223645,7/15/2014 12:04:18,,1323548434,7/15/2014 12:04:04,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,115,157,,,130,171,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,115-123,149-157,Graves' THYROTOXICOSIS.,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis.",115 123,157,115,157,130,171,-1,RO-cause_of,900460,"In contrast, we did not find a definite increase in the LGL percentage within 6 months postpartum in patients with Graves' disease who relapsed into Graves' thyrotoxicosis",Graves' disease,thyrotoxicosis
503223646,7/15/2014 10:19:50,,1323482769,7/15/2014 10:19:40,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,WARTS:,158,104,PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223646,7/15/2014 10:26:14,,1323486643,7/15/2014 10:25:59,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,penile WARTS:,151-158,104,PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223646,7/15/2014 10:27:42,,1323487619,7/15/2014 10:27:04,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,WARTS:,158,104,PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223646,7/15/2014 10:31:46,,1323490378,7/15/2014 10:31:31,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,penile WARTS:,151-158,104,PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223646,7/15/2014 10:46:14,,1323500253,7/15/2014 10:46:02,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,WARTS:,158,104,PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223646,7/15/2014 10:55:17,,1323506630,7/15/2014 10:54:46,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,penile WARTS:,151-158,104,PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223646,7/15/2014 10:55:33,,1323506812,7/15/2014 10:55:00,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,penile WARTS:,151-158,104,PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223646,7/15/2014 11:13:33,,1323519766,7/15/2014 11:13:14,instagc,1,13763729,USA,,,75.182.89.225,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,penile WARTS:,151-158,104,PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223646,7/15/2014 11:41:34,,1323536218,7/15/2014 11:41:06,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,self treatment of penile WARTS:,133-138-148-151-158,104,PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223646,7/15/2014 11:45:16,,1323538327,7/15/2014 11:44:50,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,158,104,,,163,119,WARTS,PODOPHYLLOTOXIN,Chapman Drake Jayaweera Podophyllin WARTS:,28-48-77-158-39,14-28-104-48,Billingham Chapman Jayaweera PODOPHYLLOTOXIN,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.",158,104,158,104,163,119,1,RO-may_treat,907713,"1]  White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, et al. Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study",warts,podophyllotoxin
503223647,7/15/2014 10:19:30,,1323482539,7/15/2014 10:19:16,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,111,141,,,124,148,BREAST CANCER,NUMBERS,BREAST CANCER,111-118,141-149-152-159,"NUMBERS of breast cancers,","The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223647,7/15/2014 10:23:15,,1323484883,7/15/2014 10:22:59,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,111,141,,,124,148,BREAST CANCER,NUMBERS,BREAST CANCER,111-118,141,NUMBERS,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223647,7/15/2014 10:26:05,,1323486551,7/15/2014 10:25:50,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,111,141,,,124,148,BREAST CANCER,NUMBERS,BREAST CANCER,111-118,141,NUMBERS,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223647,7/15/2014 11:03:25,,1323511532,7/15/2014 11:03:02,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,111,141,,,124,148,BREAST CANCER,NUMBERS,BREAST CANCER,111-118,141-152-159-149,"NUMBERS of breast cancers,","The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223647,7/15/2014 11:05:31,,1323513241,7/15/2014 11:05:17,clixsense,1,27969116,NLD,,,91.213.37.165,111,141,,,124,148,BREAST CANCER,NUMBERS,BREAST CANCER,111-118,132-141-149-152-159-128,"the expected NUMBERS of breast cancers,","The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223647,7/15/2014 11:09:34,,1323516978,7/15/2014 11:09:22,instagc,1,23149109,USA,NC,Durham,75.189.206.205,111,141,,,124,148,BREAST CANCER,NUMBERS,numbers of BREAST CANCER,100-108-111-118,125-128-132-141-149-152-159,"by the expected NUMBERS of breast cancers,","The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223647,7/15/2014 11:34:18,,1323531994,7/15/2014 11:33:53,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,111,141,,,124,148,BREAST CANCER,NUMBERS,BREAST CANCER,111-118,141,NUMBERS,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223647,7/15/2014 11:35:12,,1323532521,7/15/2014 11:34:44,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,111,141,,,124,148,BREAST CANCER,NUMBERS,breast cancer BREAST CANCER,45-52-111-118,141-152-159,"NUMBERS breast cancers,","The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223647,7/15/2014 11:48:44,,1323540203,7/15/2014 11:48:27,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,111,141,,,124,148,BREAST CANCER,NUMBERS,BREAST CANCER,111-118,141,NUMBERS,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223647,7/15/2014 11:59:37,,1323546675,7/15/2014 11:59:14,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,111,141,,,124,148,BREAST CANCER,NUMBERS,BREAST CANCER,111-118,141,NUMBERS,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries.",111 118,141,111,141,124,148,-1,RO-has_manifestation,906244,"The standardised incidence ratios (SIRs) for breast cancer were calculated by dividing the observed numbers of breast cancer by the expected numbers of breast cancers, based on the rates in the provincial cancer registries",breast cancer,numbers
503223648,7/15/2014 10:35:16,,1323492674,7/15/2014 10:35:03,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"VENTRICULAR TACHYCARDIA,",233-245,258,DISOPYRAMIDE,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223648,7/15/2014 11:10:46,,1323517864,7/15/2014 11:10:37,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"VENTRICULAR TACHYCARDIA,",233-245,258,DISOPYRAMIDE,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223648,7/15/2014 11:44:16,,1323537873,7/15/2014 11:43:58,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"VENTRICULAR TACHYCARDIA, disopyramide arrhythmias.",233-245-258-300,245-258-300,"tachycardia, DISOPYRAMIDE arrhythmias.","In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223648,7/15/2014 12:00:19,,1323546930,7/15/2014 12:00:08,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"in 100% of VENTRICULAR TACHYCARDIA,",222-225-230-233-245,258-271-275-283-286-296-300,DISOPYRAMIDE was capable to interrupt the arrhythmias.,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223648,7/15/2014 12:04:37,,1323548551,7/15/2014 12:04:16,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"VENTRICULAR TACHYCARDIA, disopyramide",233-245-258,258,DISOPYRAMIDE,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223648,7/15/2014 12:05:48,,1323548938,7/15/2014 12:05:26,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"VENTRICULAR TACHYCARDIA,",233-245,258,DISOPYRAMIDE,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223648,7/15/2014 12:07:51,,1323549625,7/15/2014 12:07:29,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"VENTRICULAR TACHYCARDIA,",233-245,258,DISOPYRAMIDE,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223648,7/15/2014 12:09:50,,1323550374,7/15/2014 12:09:10,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"VENTRICULAR TACHYCARDIA,",233-245,258,DISOPYRAMIDE,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223648,7/15/2014 12:10:10,,1323550467,7/15/2014 12:09:45,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"VENTRICULAR TACHYCARDIA,",233-245,258,DISOPYRAMIDE,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223648,7/15/2014 12:11:44,,1323551009,7/15/2014 12:10:33,prodege,1,11864493,GBR,Z4,Wrexham,212.219.196.69,233,258,,,256,270,VENTRICULAR TACHYCARDIA,DISOPYRAMIDE,"VENTRICULAR TACHYCARDIA,",233-245,258,DISOPYRAMIDE,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias.",233 245,258,233,258,256,270,1,RO-may_prevent,907380,"In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias",ventricular tachycardia,disopyramide
503223650,7/15/2014 10:14:45,,1323479292,7/15/2014 10:14:17,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,102,182,ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223650,7/15/2014 10:22:25,,1323484453,7/15/2014 10:21:56,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY to thi antibiotic,102-119-122-126,155-164-179-182,clinical manifestations of ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223650,7/15/2014 10:26:59,,1323487079,7/15/2014 10:26:43,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,102,155-164-179-182,clinical manifestations of ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223650,7/15/2014 10:33:43,,1323491585,7/15/2014 10:33:27,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,102,182,ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223650,7/15/2014 10:47:25,,1323501031,7/15/2014 10:47:13,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,102,182,ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223650,7/15/2014 11:01:01,,1323509984,7/15/2014 11:00:43,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,102,182,ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223650,7/15/2014 11:12:42,,1323519289,7/15/2014 11:12:27,instagc,1,13763729,USA,,,75.182.89.225,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,102,182,ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223650,7/15/2014 11:44:46,,1323538054,7/15/2014 11:44:28,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,102,182,ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223650,7/15/2014 11:57:47,,1323545751,7/15/2014 11:57:28,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,102,182,ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223650,7/15/2014 12:00:34,,1323547069,7/15/2014 12:00:15,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,102,182,,,118,189,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,102,182,ALLERGY,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children.",102,182,102,182,118,189,-1,RO-cause_of,900315,"On the basis of phenomenon of PFC count increase in the presence of penicillin in specimens in vitro, hypersensitivity to thi antibiotic in the absence of clinical manifestations of allergy was detected in 27% of children",hypersensitivity,allergy
503223651,7/15/2014 10:25:06,,1323485971,7/15/2014 10:24:51,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS erythematosus,0-9-15,29-41-50-56,[ SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223651,7/15/2014 10:35:45,,1323493017,7/15/2014 10:35:32,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS erythematosus,0-9-15,41-50-56,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223651,7/15/2014 10:49:26,,1323502708,7/15/2014 10:49:16,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,9,41-50-56,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223651,7/15/2014 10:58:32,,1323508564,7/15/2014 10:58:03,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS erythematosus,0-9-15,41-50-56-35,15:IV SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223651,7/15/2014 11:33:58,,1323531771,7/15/2014 11:33:34,prodege,1,23999031,AUS,8,Perth,203.59.238.194,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS erythematosus Systemic Lupus Erythematosus,0-9-15-41-50-56,0-9-41-50-56-15,Systemic lupus erythematosus SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223651,7/15/2014 11:42:16,,1323536721,7/15/2014 11:41:52,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS erythematosus Systemic Lupus Erythematosus bullae degeneration of basal cells.,0-9-15-41-50-56-94-112-125-128-134,0-9-15-29-41-50-56-94-112-125-128-134,Systemic lupus erythematosus [ SYSTEMIC LUPUS ERYTHEMATOSUS bullae degeneration of basal cells.,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223651,7/15/2014 11:53:12,,1323543440,7/15/2014 11:52:55,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS erythematosus,0-9-15,41-50-56,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223651,7/15/2014 12:01:03,,1323547276,7/15/2014 12:00:11,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS erythematosus,0-9-15,41-50-56,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223651,7/15/2014 12:04:30,,1323548512,7/15/2014 12:04:13,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS erythematosus,0-9-15,41-50-56,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223651,7/15/2014 12:07:10,,1323549403,7/15/2014 12:06:58,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,9,41,,,14,69,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic LUPUS erythematosus,0-9-15,41-50-56,SYSTEMIC LUPUS ERYTHEMATOSUS,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells.,9,41 50 56,9,41,14,69,-1,RO-has_manifestation,906198,Systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ] occasionally produces bullae by causing degeneration of basal cells,lupus,Systemic Lupus Erythematosus
503223652,7/15/2014 10:19:20,,1323482437,7/15/2014 10:19:10,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE,134,94-103,NEONATAL SEIZURE,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223652,7/15/2014 10:30:03,,1323489160,7/15/2014 10:29:50,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE predisposition,134-142,94-103,NEONATAL SEIZURE,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223652,7/15/2014 10:33:12,,1323491289,7/15/2014 10:32:55,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE,134,94-103,NEONATAL SEIZURE,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223652,7/15/2014 10:34:10,,1323491925,7/15/2014 10:33:52,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE,134,94-103,NEONATAL SEIZURE,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223652,7/15/2014 10:56:07,,1323507100,7/15/2014 10:55:42,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE,134,94-103,NEONATAL SEIZURE,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223652,7/15/2014 11:13:00,,1323519475,7/15/2014 11:12:50,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE predisposition,134-142,94-103-111,NEONATAL SEIZURE susceptibility,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223652,7/15/2014 11:22:42,,1323525295,7/15/2014 11:22:26,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE,134,94-103,NEONATAL SEIZURE,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223652,7/15/2014 11:51:19,,1323542004,7/15/2014 11:50:57,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE,134,94-103,NEONATAL SEIZURE,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223652,7/15/2014 11:56:47,,1323545267,7/15/2014 11:56:26,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE,134,94-103,NEONATAL SEIZURE,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223652,7/15/2014 11:58:37,,1323546220,7/15/2014 11:58:10,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,134,94,,,141,110,SEIZURE,NEONATAL SEIZURE,SEIZURE predisposition,134-142,94-103,NEONATAL SEIZURE,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth.,134,94 103,134,94,141,110,-1,RO-has_definitional_manifestation,904787,The genetically epilepsy-prone rat (GEPR) provides a valuable model to study the mechanism of neonatal seizure susceptibility because seizure predisposition in GEPRs is determined by factors present from birth,seizure,neonatal seizure
503223653,7/15/2014 10:15:13,,1323479602,7/15/2014 10:14:52,vivatic,1,25451531,GBR,,,83.67.28.193,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,free LUNG cells;,265-270-275,289-299,BRONCHIAL CARCINOMA,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223653,7/15/2014 10:25:17,,1323486121,7/15/2014 10:25:02,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,free LUNG cells;,265-270-275,289-299,BRONCHIAL CARCINOMA,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223653,7/15/2014 10:27:24,,1323487391,7/15/2014 10:27:08,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,free LUNG cells;,265-270-275,289-299,BRONCHIAL CARCINOMA,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223653,7/15/2014 10:32:45,,1323491005,7/15/2014 10:32:33,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,LUNG cells;,270-275,289-299,BRONCHIAL CARCINOMA,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223653,7/15/2014 11:13:32,,1323519753,7/15/2014 11:13:10,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,pulmonary fibrosis LUNG,140-150-270,140-150-289-299,pulmonary fibrosis BRONCHIAL CARCINOMA,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223653,7/15/2014 11:15:05,,1323520707,7/15/2014 11:14:05,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,pulmonary fibrosis morphology LUNG cells; bronchial carcinoma tumour.,140-150-230-270-275-289-299-354,140-230-270-275-289-299-354-150,pulmonary fibrosis morphology lung cells; BRONCHIAL CARCINOMA tumour.,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223653,7/15/2014 11:24:28,,1323526381,7/15/2014 11:24:12,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,LUNG,270,289-299,BRONCHIAL CARCINOMA,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223653,7/15/2014 11:33:32,,1323531474,7/15/2014 11:33:02,prodege,1,23999031,AUS,8,Perth,203.59.238.194,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,pulmonary fibrosis LUNG bronchial carcinoma,140-270-289-299-150,140-289-299-150,pulmonary fibrosis BRONCHIAL CARCINOMA,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223653,7/15/2014 11:35:40,,1323532765,7/15/2014 11:34:43,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,"recurrent chest infections, detect abnormalities local cellular immunity; pulmonary fibrosis LUNG cells; bronchial carcinoma local immune responses tumour.",57-67-73-88-95-112-118-127-140-150-270-275-289-299-324-330-337-354,57-67-73-88-95-112-118-127-140-150-270-275-289-299-324-330-337-354,"recurrent chest infections, detect abnormalities local cellular immunity; pulmonary fibrosis lung cells; BRONCHIAL CARCINOMA local immune responses tumour.","Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223653,7/15/2014 12:00:21,,1323546942,7/15/2014 12:00:01,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,270,289,,,274,308,LUNG,BRONCHIAL CARCINOMA,LUNG,270,289-299,BRONCHIAL CARCINOMA,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour.",270,289 299,270,289,274,308,1,RO-disease_has_primary_anatomic_site,902226,"Such studies are of particular interest in patients with recurrent chest infections, to detect abnormalities of local cellular immunity; in pulmonary fibrosis to assess activity of the disease and effect of treatment by observing morphology and testing function of free lung cells; and in bronchial carcinoma to investigate local immune responses to the tumour",lung,bronchial carcinoma
503223654,7/15/2014 10:13:53,,1323478723,7/15/2014 10:13:21,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION,284,210,(DCIS),"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223654,7/15/2014 10:17:05,,1323480853,7/15/2014 10:16:37,vivatic,1,25451531,GBR,,,83.67.28.193,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION clusters,284-303,185-192-202-205-210,ductal carcinoma in situ (DCIS),"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223654,7/15/2014 10:28:21,,1323488169,7/15/2014 10:27:49,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION clusters,284-303,185-192-202-205,ductal carcinoma in situ,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223654,7/15/2014 10:29:03,,1323488599,7/15/2014 10:28:48,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION clusters,284-303,202-205-210,in situ (DCIS),"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223654,7/15/2014 10:49:41,,1323502903,7/15/2014 10:49:28,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION,284,210,(DCIS),"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223654,7/15/2014 10:57:01,,1323507624,7/15/2014 10:56:26,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION clusters,284-303,205-210,situ (DCIS),"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223654,7/15/2014 10:57:12,,1323507698,7/15/2014 10:56:50,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION,284,185-192-202-205-210,ductal carcinoma in situ (DCIS),"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223654,7/15/2014 11:12:40,,1323519266,7/15/2014 11:12:30,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION clusters,284-303,202-205-210,in situ (DCIS),"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223654,7/15/2014 11:14:49,,1323520544,7/15/2014 11:14:31,instagc,1,13763729,USA,,,75.182.89.225,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION clusters,284-303,210,(DCIS),"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223654,7/15/2014 11:31:09,,1323530070,7/15/2014 11:30:42,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,284,211,,,302,215,MICROCALCIFICATION,DCIS,MICROCALCIFICATION clusters,284-303,210,(DCIS),"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy.",284,,284,211,302,215,1,RO-disease_may_have_finding,902514,"However, despite the additional information provided by MRI, mammography is still an extremely important diagnostic imaging modality, particularly for several common conditions such as ductal carcinoma in situ (DCIS) where it has been shown that there is a strong correlation between microcalcification clusters and malignancy",microcalcification,DCIS
503223655,7/15/2014 10:19:41,,1323482688,7/15/2014 10:19:37,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,the concept of SYSTEMIC INFLAMMATORY RESPONSE SYNDROME and the,5-9-17-20-29-42-51-67-71,71-75-86-89-97-100-104,"the definition of SEPSIS, as the systemic","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223655,7/15/2014 10:22:47,,1323484694,7/15/2014 10:22:33,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,20-29-42-51,89,"SEPSIS,","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223655,7/15/2014 10:35:44,,1323493014,7/15/2014 10:34:48,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,"SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) sepsis,",20-29-42-51-60-89,29-42-51-60-89-20,"systemic inflammatory response syndrome (SIRS) SEPSIS,","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223655,7/15/2014 10:59:48,,1323509317,7/15/2014 10:59:05,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS),20-29-42-51-60,89-100-104-113,"SEPSIS, the systemic response","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223655,7/15/2014 11:13:44,,1323519951,7/15/2014 11:13:17,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,20-29-42-51,89,"SEPSIS,","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223655,7/15/2014 11:35:49,,1323532843,7/15/2014 11:35:14,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME sepsis,20-29-42-51-269,51-89-60,"syndrome (SIRS) SEPSIS,","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223655,7/15/2014 11:48:25,,1323540082,7/15/2014 11:48:09,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,20-29-42-51,89,"SEPSIS,","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223655,7/15/2014 11:55:48,,1323544707,7/15/2014 11:55:23,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,20-29-42-51,89,"SEPSIS,","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223655,7/15/2014 11:58:52,,1323546313,7/15/2014 11:58:26,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS),20-29-42-51-60,75-86-89-97-100-104-113-122-125,"definition of SEPSIS, as the systemic response to infection,","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223655,7/15/2014 12:03:57,,1323548297,7/15/2014 12:03:39,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,20,89,,,59,95,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME,SEPSIS,SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS),20-29-42-51-60,89,"SEPSIS,","Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques.",20 29 42 51,89,20,89,59,95,-1,RO-cause_of,900115,"Both the concept of systemic inflammatory response syndrome (SIRS) and the definition of sepsis, as the systemic response to infection, have actually been overwhelming and its generalization is contributing on the better prognosis after treatment for the patients with sepsis and also on the pioneer researches in this field, using molecular biology techniques",systemic inflammatory response syndrome,sepsis
503223656,7/15/2014 10:21:30,,1323483895,7/15/2014 10:20:56,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,136,114,,,147,121,NON-ALLERGY,ALLERGY,NON ALLERGY group.,136-140-148,114-122,ALLERGY group,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223656,7/15/2014 10:30:47,,1323489674,7/15/2014 10:30:34,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,136,114,,,147,121,NON-ALLERGY,ALLERGY,NON ALLERGY,136-140,107-114,nickel ALLERGY,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223656,7/15/2014 10:44:19,,1323498841,7/15/2014 10:44:07,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,136,114,,,147,121,NON-ALLERGY,ALLERGY,NON ALLERGY,136-140,114,ALLERGY,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223656,7/15/2014 10:45:38,,1323499792,7/15/2014 10:43:58,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,136,114,,,147,121,NON-ALLERGY,ALLERGY,nickel allergy group NON ALLERGY,107-114-136-140-122,95-103-107-114-122-128-132-60,TEWL between the nickel ALLERGY group and the,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223656,7/15/2014 11:12:29,,1323519148,7/15/2014 11:12:19,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,136,114,,,147,121,NON-ALLERGY,ALLERGY,NON ALLERGY group.,136-140-148,107-114,nickel ALLERGY,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223656,7/15/2014 11:15:58,,1323521222,7/15/2014 11:15:45,instagc,1,13763729,USA,,,75.182.89.225,136,114,,,147,121,NON-ALLERGY,ALLERGY,NON ALLERGY group.,136-140-148,107-114-122,nickel ALLERGY group,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223656,7/15/2014 11:19:21,,1323523566,7/15/2014 11:19:00,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,136,114,,,147,121,NON-ALLERGY,ALLERGY,nickel allergy NON ALLERGY,107-114-136-140,107-114,nickel ALLERGY,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223656,7/15/2014 11:24:49,,1323526604,7/15/2014 11:24:13,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,136,114,,,147,121,NON-ALLERGY,ALLERGY,TEWL SLS nickel allergy NON ALLERGY,60-75-107-114-136-140,60-107-114-136-140-75,TEWL SLS nickel ALLERGY non allergy,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223656,7/15/2014 11:43:01,,1323537118,7/15/2014 11:42:17,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,136,114,,,147,121,NON-ALLERGY,ALLERGY,TEWL SLS irritation test nickel allergy group the NON ALLERGY group.,60-75-79-90-107-122-132-136-140-148-114,60-75-79-90-107-114-122-128-132-136-140-148,TEWL SLS irritation test nickel ALLERGY group and the non allergy group.,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223656,7/15/2014 11:45:15,,1323538342,7/15/2014 11:44:47,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,136,114,,,147,121,NON-ALLERGY,ALLERGY,NON ALLERGY,136-140,107-114,nickel ALLERGY,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group.,136 140,114,136,114,147,121,-1,RO-cause_of,900444,There was no difference in the visual scoring system or the TEWL after the SLS irritation test between the nickel-allergy group and the non-allergy group,non-allergy,allergy
503223657,7/15/2014 10:23:04,,1323484788,7/15/2014 10:22:47,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,THROMBOEMBOLIC EVENTS,72-87,29,FONDAPARINUX,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223657,7/15/2014 10:26:20,,1323486726,7/15/2014 10:25:56,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,THROMBOEMBOLIC EVENTS,72-87,29,FONDAPARINUX,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223657,7/15/2014 10:34:03,,1323491852,7/15/2014 10:33:51,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,THROMBOEMBOLIC EVENTS,72-87,29,FONDAPARINUX,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223657,7/15/2014 11:25:25,,1323526839,7/15/2014 11:25:07,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,THROMBOEMBOLIC EVENTS,72-87,29,FONDAPARINUX,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223657,7/15/2014 11:25:50,,1323527073,7/15/2014 11:25:19,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,fondaparinux THROMBOEMBOLIC EVENTS enoxaparin; fondaparinux,29-72-87-142-154,29-72-87-142-154,FONDAPARINUX thromboembolic events enoxaparin; fondaparinux,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223657,7/15/2014 11:34:51,,1323532304,7/15/2014 11:34:20,prodege,1,23999031,AUS,8,Perth,203.59.238.194,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,THROMBOEMBOLIC EVENTS,72-87,29-72-87,FONDAPARINUX thromboembolic events,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223657,7/15/2014 11:37:05,,1323533553,7/15/2014 11:36:45,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,THROMBOEMBOLIC EVENTS,72-87,29,FONDAPARINUX,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223657,7/15/2014 11:46:33,,1323539087,7/15/2014 11:46:08,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,THROMBOEMBOLIC EVENTS,72-87,29,FONDAPARINUX,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223657,7/15/2014 11:47:52,,1323539796,7/15/2014 11:47:31,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,THROMBOEMBOLIC EVENTS,72-87,7-13-19-29,"trial based analysis, FONDAPARINUX","In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223657,7/15/2014 11:54:19,,1323543994,7/15/2014 11:53:54,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,72,29,,,93,41,THROMBOEMBOLIC EVENTS,FONDAPARINUX,THROMBOEMBOLIC EVENTS,72-87,29,FONDAPARINUX,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge.",72 87,29,72,29,93,41,1,RO-may_prevent,907030,"In the trial-based analysis, fondaparinux was estimated to prevent 15.1 thromboembolic events per 1000 patients at three months compared with enoxaparin; fondaparinux produced cost savings per patient at 30 days, 3 months, and 5 years postdischarge",thromboembolic events,fondaparinux
503223658,7/15/2014 10:20:22,,1323483098,7/15/2014 10:20:18,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,the diagnosis of MYASTHENIA GRAVIS.,76-80-90-93-104,0-2-10-33-38,A bedside EDROPHONIUM test in,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223658,7/15/2014 10:21:51,,1323484084,7/15/2014 10:21:36,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,diagnosis of MYASTHENIA GRAVIS.,80-90-93-104,10-22,EDROPHONIUM (Tensilon),A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223658,7/15/2014 10:48:37,,1323502008,7/15/2014 10:48:27,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,MYASTHENIA GRAVIS.,93-104,10,EDROPHONIUM,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223658,7/15/2014 11:01:23,,1323510270,7/15/2014 11:00:56,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,MYASTHENIA GRAVIS.,93-104,10,EDROPHONIUM,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223658,7/15/2014 11:41:45,,1323536379,7/15/2014 11:41:30,prodege,1,23999031,AUS,8,Perth,203.59.238.194,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,MYASTHENIA GRAVIS.,93-104,10-93-104,EDROPHONIUM myasthenia gravis.,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223658,7/15/2014 11:45:20,,1323538366,7/15/2014 11:45:07,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,the diagnosis of MYASTHENIA GRAVIS.,76-80-90-93-104,0-2-10-22-33,A bedside EDROPHONIUM (Tensilon) test,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223658,7/15/2014 11:54:10,,1323543956,7/15/2014 11:52:51,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,MYASTHENIA GRAVIS.,93-104,10-22,EDROPHONIUM (Tensilon),A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223658,7/15/2014 12:01:27,,1323547421,7/15/2014 12:01:13,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,MYASTHENIA GRAVIS.,93-104,10,EDROPHONIUM,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223658,7/15/2014 12:05:58,,1323549033,7/15/2014 12:05:26,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,diagnosis of MYASTHENIA GRAVIS.,80-90-93-104,2-10-22-33,bedside EDROPHONIUM (Tensilon) test,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223658,7/15/2014 12:09:10,,1323550062,7/15/2014 12:08:39,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,93,10,,,110,21,MYASTHENIA GRAVIS,EDROPHONIUM,the MYASTHENIA GRAVIS.,76-93-104,10-22-33,EDROPHONIUM (Tensilon) test,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis.,93 104,10,93,10,110,21,1,RO-may_diagnose,906604,A bedside edrophonium (Tensilon) test in our emergency department confirmed the diagnosis of myasthenia gravis,myasthenia gravis,edrophonium
503223659,7/15/2014 11:01:47,,1323510495,7/15/2014 11:01:27,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,387,400,,,395,408,SEIZURES,EPILEPSY,SEIZURES,387,400,"EPILEPSY,","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223659,7/15/2014 11:26:28,,1323527379,7/15/2014 11:25:51,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,387,400,,,395,408,SEIZURES,EPILEPSY,"seizure disorders seizures epilepsy SEIZURES epilepsy, epilepsy.",68-76-248-315-387-400-445,68-76-248-387-400-414-445,"seizure disorders seizures seizures EPILEPSY, the epilepsy.","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223659,7/15/2014 11:30:10,,1323529569,7/15/2014 11:29:34,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,387,400,,,395,408,SEIZURES,EPILEPSY,"epidemiologic SEIZURES epilepsy,",387-400-332,332-387-400,"epidemiologic seizures EPILEPSY,","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223659,7/15/2014 11:41:28,,1323536167,7/15/2014 11:40:51,prodege,1,23999031,AUS,8,Perth,203.59.238.194,387,400,,,395,408,SEIZURES,EPILEPSY,"epilepsy SEIZURES epilepsy, epilepsy.",261-387-400-445,400-315,"epilepsy EPILEPSY,","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223659,7/15/2014 12:02:10,,1323547668,7/15/2014 12:01:43,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,387,400,,,395,408,SEIZURES,EPILEPSY,SEIZURES,387,400,"EPILEPSY,","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223659,7/15/2014 12:02:11,,1323547686,7/15/2014 12:01:55,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,387,400,,,395,408,SEIZURES,EPILEPSY,SEIZURES,387,400,"EPILEPSY,","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223659,7/15/2014 12:02:48,,1323547928,7/15/2014 12:02:12,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,387,400,,,395,408,SEIZURES,EPILEPSY,"the prognosis of SEIZURES and epilepsy,",370-374-384-387-396-400,400,"EPILEPSY,","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223659,7/15/2014 12:07:21,,1323549446,7/15/2014 12:07:08,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,387,400,,,395,408,SEIZURES,EPILEPSY,SEIZURES,387,400,"EPILEPSY,","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223659,7/15/2014 12:10:36,,1323550598,7/15/2014 12:10:19,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,387,400,,,395,408,SEIZURES,EPILEPSY,SEIZURES,387,400,"EPILEPSY,","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223659,7/15/2014 12:12:29,,1323551285,7/15/2014 12:11:47,prodege,1,11864493,GBR,Z4,Wrexham,212.219.196.69,387,400,,,395,408,SEIZURES,EPILEPSY,SEIZURES,387,400,"EPILEPSY,","The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy.",387,400,387,400,395,408,-1,RO-has_definitional_manifestation,904831,"The objectives of this article are to present the classification of seizure disorders in population studies and family studies, the basic measures of occurrence and association that are used in genetic and epidemiologic studies, the frequencies of seizures and epilepsy in populations, the major acquired causes of epilepsy and the epidemiologic evidence for causation, the prognosis of seizures and epilepsy, and the role of genetic factors in epilepsy",seizures,epilepsy
503223660,7/15/2014 10:20:12,,1323482954,7/15/2014 10:20:08,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,effective vaccines against AVIAN INFLUENZA VIRUS of the H5N1,35-45-54-62-68-78-84-87-91,78-84-87-91-96-104-109,virus of the H5N1 subtype will be,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223660,7/15/2014 10:23:25,,1323484981,7/15/2014 10:23:08,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,AVIAN INFLUENZA VIRUS,62-68-78,91,H5N1,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223660,7/15/2014 11:02:42,,1323510982,7/15/2014 11:02:23,instagc,1,23149109,USA,NC,Durham,75.189.206.205,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,AVIAN INFLUENZA VIRUS of the H5N1 subtype,62-68-78-84-87-91-96,78-84-87-91-96,virus of the H5N1 subtype,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223660,7/15/2014 11:16:55,,1323521798,7/15/2014 11:16:39,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,AVIAN INFLUENZA VIRUS,62-68-78,62-68-78-84-91,avian influenza virus of H5N1,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223660,7/15/2014 11:50:14,,1323541237,7/15/2014 11:50:01,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,AVIAN INFLUENZA VIRUS,62-68-78,91,H5N1,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223660,7/15/2014 11:59:49,,1323546781,7/15/2014 11:59:35,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,AVIAN INFLUENZA VIRUS of the H5N1,62-68-78-84-87-91,78-84-87-91-96,virus of the H5N1 subtype,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223660,7/15/2014 12:00:58,,1323547240,7/15/2014 12:00:41,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,AVIAN INFLUENZA VIRUS,62-68-78,91,H5N1,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223660,7/15/2014 12:03:24,,1323548098,7/15/2014 12:03:01,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,AVIAN INFLUENZA VIRUS,62-68-78,78-84-87-91-96,virus of the H5N1 subtype,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223660,7/15/2014 12:08:20,,1323549770,7/15/2014 12:08:06,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,AVIAN INFLUENZA VIRUS,62-68-78,91-96,H5N1 subtype,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223660,7/15/2014 12:10:18,,1323550492,7/15/2014 12:08:16,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,62,91,,,83,95,AVIAN INFLUENZA VIRUS,H5N1,AVIAN INFLUENZA VIRUS,62-68-78,78-84-87-91-96,virus of the H5N1 subtype,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic.,62 68 78,91,62,91,83,95,-1,RO-has_causative_agent,903813,The timely development of safe and effective vaccines against avian influenza virus of the H5N1 subtype will be of the utmost importance in the event of a pandemic,avian influenza virus,H5N1
503223661,7/15/2014 10:18:55,,1323482049,7/15/2014 10:18:53,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,278,231,,,280,239,PD,LEVODOPA,untreated patients with PD.,254-264-273-278,208-213-223-231-240-243-254,with immediate release LEVODOPA in previously untreated,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223661,7/15/2014 10:19:01,,1323482206,7/15/2014 10:18:49,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,278,231,,,280,239,PD,LEVODOPA,PD.,278,231,LEVODOPA,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223661,7/15/2014 10:21:54,,1323484121,7/15/2014 10:21:31,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,278,231,,,280,239,PD,LEVODOPA,PD.,278,231-240,LEVODOPA in,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223661,7/15/2014 10:24:43,,1323485659,7/15/2014 10:24:24,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,278,231,,,280,239,PD,LEVODOPA,PD.,278,231,LEVODOPA,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223661,7/15/2014 10:25:03,,1323485920,7/15/2014 10:24:51,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,278,231,,,280,239,PD,LEVODOPA,PD.,278,213-223-231,immediate release LEVODOPA,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223661,7/15/2014 10:32:38,,1323490931,7/15/2014 10:32:18,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,278,231,,,280,239,PD,LEVODOPA,PD.,278,231,LEVODOPA,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223661,7/15/2014 10:33:52,,1323491730,7/15/2014 10:32:59,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,278,231,,,280,239,PD,LEVODOPA,selegiline dopamine agonists levodopa PD.,115-146-231-278-155,146-155-231-278-115,selegiline dopamine agonists LEVODOPA PD.,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223661,7/15/2014 11:33:52,,1323531723,7/15/2014 11:33:33,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,278,231,,,280,239,PD,LEVODOPA,PD.,278,213-231-223,immediate release LEVODOPA,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223661,7/15/2014 11:37:22,,1323533688,7/15/2014 11:36:59,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,278,231,,,280,239,PD,LEVODOPA,PD.,278,213-223-231,immediate release LEVODOPA,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223661,7/15/2014 11:43:00,,1323537110,7/15/2014 11:42:45,prodege,1,6316959,GBR,,,46.208.145.114,278,231,,,280,239,PD,LEVODOPA,PD.,278,213-223-231,immediate release LEVODOPA,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD.,278,231,278,231,280,239,1,RO-may_treat,907810,STUDY SELECTION  English-language studies were selected if they evaluated the neuroprotective effects or safety of selegiline or if they compared dopamine agonists with levodopa or sustained-release levodopa with immediate-release levodopa in previously untreated patients with PD,PD,levodopa
503223662,7/15/2014 10:18:47,,1323481981,7/15/2014 10:18:33,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,58,75,,,65,83,ASCITES,HEPATOMA,ASCITES,58,75,"HEPATOMA,","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223662,7/15/2014 10:19:28,,1323482484,7/15/2014 10:19:26,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,58,75,,,65,83,ASCITES,HEPATOMA,"in various rat ASCITES cells of hepatoma,",43-46-54-58-66-72-75,58-66-72-75-85-89-95,"ascites cells of HEPATOMA, and fetal and","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223662,7/15/2014 10:33:55,,1323491757,7/15/2014 10:33:44,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,58,75,,,65,83,ASCITES,HEPATOMA,ASCITES,58,75,"HEPATOMA,","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223662,7/15/2014 10:35:47,,1323493034,7/15/2014 10:35:04,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,58,75,,,65,83,ASCITES,HEPATOMA,ASCITES cells,58-66,75,"HEPATOMA,","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223662,7/15/2014 10:58:19,,1323508417,7/15/2014 10:57:59,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,58,75,,,65,83,ASCITES,HEPATOMA,ASCITES,58,75,"HEPATOMA,","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223662,7/15/2014 11:01:48,,1323510505,7/15/2014 11:00:53,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,58,75,,,65,83,ASCITES,HEPATOMA,"nucleoside diphosphatase in ASCITES cells hepatoma, fetal neonatal",18-29-43-58-66-75-89-99,18-29-58-66-75-89-99,"nucleoside diphosphatase ascites cells HEPATOMA, fetal neonatal","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223662,7/15/2014 11:06:20,,1323513957,7/15/2014 11:06:01,clixsense,1,27969116,NLD,,,91.213.37.165,58,75,,,65,83,ASCITES,HEPATOMA,"rat ASCITES cells of hepatoma,",54-58-66-72-75,54-58-66-72-75,"rat ascites cells of HEPATOMA,","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223662,7/15/2014 11:13:13,,1323519574,7/15/2014 11:13:00,instagc,1,13763729,USA,,,75.182.89.225,58,75,,,65,83,ASCITES,HEPATOMA,ASCITES,58,75,"HEPATOMA,","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223662,7/15/2014 11:29:34,,1323529140,7/15/2014 11:28:46,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,58,75,,,65,83,ASCITES,HEPATOMA,"nucleoside diphosphatase ASCITES hepatoma, fetal neonatal liver.",18-29-58-75-89-99-164,18-29-58-75-85-89-99-164,"nucleoside diphosphatase ascites HEPATOMA, and fetal neonatal liver.","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223662,7/15/2014 11:37:48,,1323533980,7/15/2014 11:37:28,prodege,1,6316959,GBR,,,46.208.145.114,58,75,,,65,83,ASCITES,HEPATOMA,ASCITES,58,75,"HEPATOMA,","The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver.",58,75,58,75,65,83,-1,RO-disease_may_have_finding,902643,"The activities of nucleoside diphosphatase in various rat ascites cells of hepatoma, and fetal and neonatal rat liver were much lower than that of normal adult rat liver",ascites,hepatoma
503223663,7/15/2014 10:19:53,,1323482800,7/15/2014 10:19:50,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"allergic diseases (ALLERGIC RHINITIS, atopic dermatitis, asthma),",87-96-105-115-125-132-144,40-46-55-62-69-78-87,"birth history, family ATOPIC history, specific allergic","This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223663,7/15/2014 10:24:59,,1323485827,7/15/2014 10:23:16,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"(ALLERGIC RHINITIS,",105-115,55-62-69,"family ATOPIC history,","This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223663,7/15/2014 10:25:53,,1323486409,7/15/2014 10:25:29,vivatic,1,25451531,GBR,,,83.67.28.193,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"(ALLERGIC RHINITIS,",105-115,62-69,"ATOPIC history,","This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223663,7/15/2014 10:26:41,,1323486926,7/15/2014 10:26:28,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"RHINITIS,",115,62,ATOPIC,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223663,7/15/2014 10:27:59,,1323487867,7/15/2014 10:27:39,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"(ALLERGIC RHINITIS,",105-115,55-62-69,"family ATOPIC history,","This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223663,7/15/2014 10:29:46,,1323489012,7/15/2014 10:29:32,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"(ALLERGIC RHINITIS,",105-115,55-62-69,"family ATOPIC history,","This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223663,7/15/2014 10:35:56,,1323493094,7/15/2014 10:35:41,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"(ALLERGIC RHINITIS,",105-115,62,ATOPIC,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223663,7/15/2014 11:02:29,,1323510894,7/15/2014 11:01:55,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"(ALLERGIC RHINITIS,",105-115,55-62-69,"family ATOPIC history,","This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223663,7/15/2014 11:33:17,,1323531314,7/15/2014 11:32:59,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"(ALLERGIC RHINITIS,",105-115,62-69,"ATOPIC history,","This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223663,7/15/2014 11:42:22,,1323536747,7/15/2014 11:41:59,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,106,62,,,123,68,ALLERGIC RHINITIS,ATOPIC,"(ALLERGIC RHINITIS, dermatitis, asthma),",105-115-132-144,62-132-144-208-218-200,"ATOPIC dermatitis, asthma), chronic cough asthma.","This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma.",115,62,106,62,123,68,-1,RO-cause_of,900149,"This entailed further analysis of their birth history, family atopic history, specific allergic diseases (allergic rhinitis, atopic dermatitis, asthma), hernia type (direct or indirect), the onset of chronic cough and asthma",allergic rhinitis,atopic
503223664,7/15/2014 10:15:23,,1323479739,7/15/2014 10:14:58,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,PRIMARY LESION;,108-116,84-90,RENAL LYMPHOMA,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223664,7/15/2014 10:22:12,,1323484281,7/15/2014 10:21:56,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,PRIMARY LESION;,108-116,84-90,RENAL LYMPHOMA,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223664,7/15/2014 10:50:18,,1323503244,7/15/2014 10:49:40,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,renal lymphoma PRIMARY LESION;,84-108-116-90,84-90-108-116,RENAL LYMPHOMA primary lesion;,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223664,7/15/2014 11:37:50,,1323533996,7/15/2014 11:37:13,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,renal lymphoma PRIMARY LESION; primary renal lymphoma extrarenal lymphomatous disease renal tumor;,84-90-108-116-149-157-163-185-196-209-256-250,84-90-106-108-116-149-157-163-185-196-209-250-256,RENAL LYMPHOMA a primary lesion; primary renal lymphoma extrarenal lymphomatous disease renal tumor;,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223664,7/15/2014 11:49:09,,1323540440,7/15/2014 11:48:56,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,PRIMARY LESION;,108-116,84-90,RENAL LYMPHOMA,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223664,7/15/2014 11:57:24,,1323545575,7/15/2014 11:57:09,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,PRIMARY LESION;,108-116,84-90,RENAL LYMPHOMA,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223664,7/15/2014 12:03:01,,1323547972,7/15/2014 12:02:28,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,PRIMARY LESION;,108-116,84-90,RENAL LYMPHOMA,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223664,7/15/2014 12:06:20,,1323549125,7/15/2014 12:05:59,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,PRIMARY LESION;,108-116,84-90,RENAL LYMPHOMA,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223664,7/15/2014 12:08:37,,1323549899,7/15/2014 12:08:19,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,PRIMARY LESION;,108-116,84-90,RENAL LYMPHOMA,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223664,7/15/2014 12:09:25,,1323550174,7/15/2014 12:08:20,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,108,84,,,122,98,PRIMARY LESION,RENAL LYMPHOMA,PRIMARY LESION;,108-116,84-90,RENAL LYMPHOMA,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare.,108 116,84 90,108,84,122,98,1,RO-disease_has_finding,901633,From these cases three conclusions have been drawn: it is reasonable to assume that renal lymphoma can be a primary lesion; almost all patients with primary renal lymphoma will develop extrarenal lymphomatous disease shortly after diagnosis of their renal tumor; and survival for more than 1 year after diagnosis is rare,primary lesion,renal lymphoma
503223665,7/15/2014 10:18:08,,1323481513,7/15/2014 10:17:59,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,HEMORRHAGE,48,104,NEUROBLASTOMA,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223665,7/15/2014 10:25:23,,1323486170,7/15/2014 10:24:32,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,spontaneous adrenal HEMORRHAGE,28-40-48,104,NEUROBLASTOMA,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223665,7/15/2014 10:26:31,,1323486836,7/15/2014 10:26:15,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,spontaneous adrenal HEMORRHAGE,28-40-48,93-104,simulating NEUROBLASTOMA,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223665,7/15/2014 10:35:31,,1323492876,7/15/2014 10:35:18,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,spontaneous adrenal HEMORRHAGE,40-48-28,104,NEUROBLASTOMA,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223665,7/15/2014 10:45:40,,1323499852,7/15/2014 10:45:29,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,HEMORRHAGE,48,104,NEUROBLASTOMA,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223665,7/15/2014 11:01:59,,1323510617,7/15/2014 11:01:32,clixsense,1,27969116,NLD,,,91.213.37.165,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,spontaneous adrenal HEMORRHAGE,28-40-48,77-85-93-104-118-121-128,"adrenal masses, simulating NEUROBLASTOMA or Wilms' tumor.","Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223665,7/15/2014 11:22:47,,1323525359,7/15/2014 11:22:29,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,spontaneous adrenal HEMORRHAGE,28-40-48,28-40-48-104,spontaneous adrenal hemorrhage NEUROBLASTOMA,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223665,7/15/2014 11:41:44,,1323536349,7/15/2014 11:41:25,prodege,1,6316959,GBR,,,46.208.145.114,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,spontaneous adrenal HEMORRHAGE,28-40-48,104,NEUROBLASTOMA,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223665,7/15/2014 11:52:54,,1323543232,7/15/2014 11:52:36,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,adrenal HEMORRHAGE,40-48,104,NEUROBLASTOMA,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223665,7/15/2014 11:57:39,,1323545679,7/15/2014 11:57:25,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,48,104,,,58,117,HEMORRHAGE,NEUROBLASTOMA,HEMORRHAGE,48,104,NEUROBLASTOMA,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor.",48,104,48,104,58,117,-1,RO-disease_may_have_finding,902782,"Less commonly, in newborns, spontaneous adrenal hemorrhage may produce large adrenal masses, simulating neuroblastoma or Wilms' tumor",hemorrhage,neuroblastoma
503223666,7/15/2014 10:25:18,,1323486126,7/15/2014 10:25:07,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,171,108,,,179,116,HEADACHE,MIGRAINE,IHS tension type HEADACHE.,154-158-166-171,97-100-104-108,as non IHS MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223666,7/15/2014 10:25:32,,1323486215,7/15/2014 10:25:21,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,171,108,,,179,116,HEADACHE,MIGRAINE,IHS tension type HEADACHE.,154-158-166-171,100-104-108,non IHS MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223666,7/15/2014 10:36:59,,1323493798,7/15/2014 10:36:47,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,171,108,,,179,116,HEADACHE,MIGRAINE,IHS tension type HEADACHE.,154-158-166-171,100-108-104,non IHS MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223666,7/15/2014 11:01:26,,1323510302,7/15/2014 11:00:55,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,171,108,,,179,116,HEADACHE,MIGRAINE,IHS tension type HEADACHE.,154-158-166-171,100-104-108,non IHS MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223666,7/15/2014 11:04:27,,1323512264,7/15/2014 11:04:09,clixsense,1,27969116,NLD,,,91.213.37.165,171,108,,,179,116,HEADACHE,MIGRAINE,IHS tension type HEADACHE.,154-158-166-171,100-104-108,non IHS MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223666,7/15/2014 11:11:27,,1323518356,7/15/2014 11:10:59,instagc,1,13763729,USA,,,75.182.89.225,171,108,,,179,116,HEADACHE,MIGRAINE,IHS tension type HEADACHE.,158-166-171-154,100-104-108,non IHS MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223666,7/15/2014 11:21:28,,1323524685,7/15/2014 11:21:07,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,171,108,,,179,116,HEADACHE,MIGRAINE,IHS tension type HEADACHE.,154-158-166-171,100-104-108,non IHS MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223666,7/15/2014 11:22:57,,1323525486,7/15/2014 11:22:43,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,171,108,,,179,116,HEADACHE,MIGRAINE,HEADACHE.,171,108,MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223666,7/15/2014 11:59:16,,1323546455,7/15/2014 11:59:02,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,171,108,,,179,116,HEADACHE,MIGRAINE,HEADACHE.,171,108,MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223666,7/15/2014 12:01:43,,1323547529,7/15/2014 12:01:34,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,171,108,,,179,116,HEADACHE,MIGRAINE,IHS tension type HEADACHE.,154-158-166-171,97-100-104-108,as non IHS MIGRAINE,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache.",171,108,171,108,179,116,-1,RO-has_definitional_manifestation,904728,"Of these headaches, 114 were classified per IHS criteria as migraine; 76 as tension-type; and 42 as non-IHS migraine (not classifiable as IHS migraine or IHS tension-type headache",headache,migraine
503223667,7/15/2014 10:17:58,,1323481334,7/15/2014 10:17:36,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,DYSPLASIA,44,93-101,COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223667,7/15/2014 10:22:01,,1323484192,7/15/2014 10:21:43,vivatic,1,25451531,GBR,,,83.67.28.193,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,DYSPLASIA,44,93-101,COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223667,7/15/2014 10:28:06,,1323487930,7/15/2014 10:27:56,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,DYSPLASIA,44,93-101,COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223667,7/15/2014 10:33:09,,1323491227,7/15/2014 10:33:00,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,DYSPLASIA,44,93-101,COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223667,7/15/2014 10:57:30,,1323507900,7/15/2014 10:57:21,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,DYSPLASIA,44,93-101,COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223667,7/15/2014 10:59:39,,1323509265,7/15/2014 10:58:54,clixsense,1,27969116,NLD,,,91.213.37.165,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,pre - malignant lesions include DYSPLASIA seen in inflammatory bowel disease,14-18-28-36-44-54-59-62-75-81-17,75-81-89-93-101,bowel disease and COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223667,7/15/2014 11:17:13,,1323522116,7/15/2014 11:17:00,instagc,1,13763729,USA,,,75.182.89.225,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,DYSPLASIA,44,93-101,COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223667,7/15/2014 11:21:05,,1323524474,7/15/2014 11:20:40,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,pre malignant lesions include DYSPLASIA seen in inflammatory bowel disease and colonic adenomas.,14-18-28-36-44-54-59-62-75-81-89-93-101,75-81-89-93-101-62,inflammatory bowel disease and COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223667,7/15/2014 11:33:00,,1323531155,7/15/2014 11:32:38,prodege,1,23999031,AUS,8,Perth,203.59.238.194,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,pre malignant lesions DYSPLASIA inflammatory bowel disease colonic adenomas.,14-18-28-44-62-75-81-93-101,14-18-28-62-75-81-93-101-44,pre malignant lesions dysplasia inflammatory bowel disease COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223667,7/15/2014 11:42:45,,1323536946,7/15/2014 11:42:29,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,44,93,,,53,109,DYSPLASIA,COLONIC ADENOMAS,pre - malignant lesions include DYSPLASIA,14-17-18-28-36-44,75-81-89-93-101-62,inflammatory bowel disease and COLONIC ADENOMAS.,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas.",44,93 101,44,93,53,109,1,RO-disease_has_finding,901870,"In the colon, pre-malignant lesions include dysplasia seen in inflammatory bowel disease and colonic adenomas",dysplasia,colonic adenomas
503223668,7/15/2014 10:20:01,,1323482882,7/15/2014 10:19:59,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,for treatment of PERTUSSIS: the Erythromycin Study,78-82-92-95-106-110-123,92-95-106-110-123-129,of pertussis: the ERYTHROMYCIN Study Group.,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223668,7/15/2014 10:22:46,,1323484688,7/15/2014 10:22:27,vivatic,1,25451531,GBR,,,83.67.28.193,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,PERTUSSIS:,95,110,ERYTHROMYCIN,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223668,7/15/2014 10:26:57,,1323487064,7/15/2014 10:25:56,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,PERTUSSIS:,95,110,ERYTHROMYCIN,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223668,7/15/2014 11:02:46,,1323511031,7/15/2014 11:02:35,clixsense,1,27969116,NLD,,,91.213.37.165,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,PERTUSSIS: the Erythromycin Study,95-106-110-123,95-106-110-123-129,pertussis: the ERYTHROMYCIN Study Group.,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223668,7/15/2014 11:03:42,,1323511715,7/15/2014 11:03:21,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,PERTUSSIS:,95,110,ERYTHROMYCIN,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223668,7/15/2014 11:34:53,,1323532318,7/15/2014 11:34:37,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,PERTUSSIS:,95,110,ERYTHROMYCIN,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223668,7/15/2014 11:56:09,,1323544929,7/15/2014 11:55:49,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,PERTUSSIS:,95,110,ERYTHROMYCIN,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223668,7/15/2014 12:01:33,,1323547453,7/15/2014 12:01:21,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,treatment of PERTUSSIS:,82-92-95,106-110-123-129,the ERYTHROMYCIN Study Group.,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223668,7/15/2014 12:02:28,,1323547747,7/15/2014 12:02:13,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,PERTUSSIS:,95,110,ERYTHROMYCIN,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223668,7/15/2014 12:05:33,,1323548876,7/15/2014 12:04:53,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,95,110,,,104,122,PERTUSSIS,ERYTHROMYCIN,PERTUSSIS:,95,110,ERYTHROMYCIN,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group.,95,110,95,110,104,122,1,RO-may_treat,907514,Hoppe JE: Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis: the Erythromycin Study Group,pertussis,Erythromycin
503223669,7/15/2014 10:20:15,,1323483019,7/15/2014 10:20:12,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,mortality in severe CONGESTIVE HEART FAILURE: results of the,24-34-37-44-55-61-70-78-81,85-97-103-116-126-135,cooperative North Scandinavian ENALAPRIL survival study,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223669,7/15/2014 10:21:41,,1323484031,7/15/2014 10:21:25,vivatic,1,25451531,GBR,,,83.67.28.193,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,severe CONGESTIVE HEART FAILURE:,37-44-55-61,116,ENALAPRIL,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223669,7/15/2014 10:26:45,,1323486968,7/15/2014 10:26:32,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,severe CONGESTIVE HEART FAILURE:,37-44-55-61,116,ENALAPRIL,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223669,7/15/2014 10:50:57,,1323503708,7/15/2014 10:50:34,clixsense,1,6416850,USA,VA,Midlothian,108.4.51.140,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,CONGESTIVE HEART FAILURE:,44-55-61,116,ENALAPRIL,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223669,7/15/2014 10:58:15,,1323508371,7/15/2014 10:57:46,clixsense,1,27969116,NLD,,,91.213.37.165,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,mortality CONGESTIVE HEART FAILURE:,44-55-61-24,116,ENALAPRIL,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223669,7/15/2014 11:02:11,,1323510745,7/15/2014 11:01:53,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,severe CONGESTIVE HEART FAILURE:,37-44-55-61,116,ENALAPRIL,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223669,7/15/2014 11:03:19,,1323511443,7/15/2014 11:02:54,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,CONGESTIVE HEART FAILURE:,44-55-61,116,ENALAPRIL,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223669,7/15/2014 11:20:57,,1323524421,7/15/2014 11:20:40,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,CONGESTIVE HEART FAILURE:,44-55-61,116,ENALAPRIL,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223669,7/15/2014 11:29:31,,1323529138,7/15/2014 11:28:46,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,enalapril CONGESTIVE HEART FAILURE:,11-44-55-61,44-55-61-116,congestive heart failure: ENALAPRIL,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223669,7/15/2014 11:35:09,,1323532512,7/15/2014 11:34:54,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,44,116,,,68,125,CONGESTIVE HEART FAILURE,ENALAPRIL,CONGESTIVE HEART FAILURE:,44-55-61,116,ENALAPRIL,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus.,44 55 61,116,44,116,68,125,1,RO-may_treat,907551,Effects of enalapril on mortality in severe congestive heart failure: results of the cooperative North Scandinavian enalapril survival study (consensus,congestive heart failure,enalapril
503223670,7/15/2014 10:20:49,,1323483431,7/15/2014 10:20:32,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION,70-81,172-180,HEPARIN treated,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223670,7/15/2014 10:24:08,,1323485379,7/15/2014 10:23:54,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION,70-81,172,HEPARIN,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223670,7/15/2014 10:32:48,,1323491021,7/15/2014 10:32:19,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION,70-81,172,HEPARIN,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223670,7/15/2014 10:34:26,,1323492067,7/15/2014 10:34:04,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION,70-81,172-180-188-179,HEPARIN - treated patients.,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223670,7/15/2014 10:38:50,,1323494979,7/15/2014 10:38:36,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION,70-81,172,HEPARIN,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223670,7/15/2014 10:48:39,,1323502074,7/15/2014 10:47:35,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION enoxaparin treated,70-81-136-147,155-164-169-172-180-188,patients than in HEPARIN treated patients.,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223670,7/15/2014 11:11:37,,1323518476,7/15/2014 11:11:28,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION,70-81,172-180-188,HEPARIN treated patients.,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223670,7/15/2014 11:24:10,,1323526227,7/15/2014 11:23:54,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION,70-81,172,HEPARIN,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223670,7/15/2014 11:45:41,,1323538574,7/15/2014 11:45:21,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION,70-81,172-180-188,HEPARIN treated patients.,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223670,7/15/2014 11:46:32,,1323539024,7/15/2014 11:46:01,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,70,172,,,91,179,MYOCARDIAL INFARCTION,HEPARIN,MYOCARDIAL INFARCTION enoxaparin heparin,70-81-136-172,136-172,enoxaparin HEPARIN,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients.,70 81,172,70,172,91,179,1,RO-may_treat,908250,A meta-analysis of these two studies showed that the risk of death or myocardial infarction was consistently approximately 20% lower in enoxaparin-treated patients than in heparin-treated patients,myocardial infarction,heparin
503223671,7/15/2014 10:25:55,,1323486438,7/15/2014 10:25:25,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,NUCLEAR PLEOMORPHISM,80-88,117-128,SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223671,7/15/2014 10:26:30,,1323486829,7/15/2014 10:26:19,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,NUCLEAR PLEOMORPHISM,80-88,117-128,SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223671,7/15/2014 10:29:50,,1323489027,7/15/2014 10:29:37,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,NUCLEAR PLEOMORPHISM,80-88,117-128,SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223671,7/15/2014 10:49:29,,1323502771,7/15/2014 10:48:26,clixsense,1,6416850,USA,VA,Midlothian,108.4.51.140,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,NUCLEAR PLEOMORPHISM symplastic leiomyoma.,80-88-117-128,88-117-128-80,nuclear pleomorphism SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223671,7/15/2014 10:52:35,,1323504875,7/15/2014 10:51:48,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,Histopathological tumor NUCLEAR PLEOMORPHISM symplastic leiomyoma.,0-33-80-88-117-128,33-80-88-117-128-0,Histopathological tumor nuclear pleomorphism SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223671,7/15/2014 11:01:19,,1323510249,7/15/2014 11:01:02,clixsense,1,27969116,NLD,,,91.213.37.165,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,NUCLEAR PLEOMORPHISM consistent with symplastic leiomyoma.,80-88-101-112-117-128,88-101-112-117-128,pleomorphism consistent with SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223671,7/15/2014 11:15:18,,1323520822,7/15/2014 11:14:53,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,NUCLEAR PLEOMORPHISM symplastic leiomyoma.,80-88-117-128,88-101-112-117-128-80,nuclear pleomorphism consistent with SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223671,7/15/2014 11:36:33,,1323533268,7/15/2014 11:36:21,prodege,1,6316959,GBR,,,46.208.145.114,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,NUCLEAR PLEOMORPHISM,80-88,117-128,SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223671,7/15/2014 11:42:53,,1323537043,7/15/2014 11:42:28,prodege,1,23999031,AUS,8,Perth,203.59.238.194,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,NUCLEAR PLEOMORPHISM symplastic leiomyoma.,80-88-117-128,117-128,SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223671,7/15/2014 11:56:39,,1323545221,7/15/2014 11:56:24,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,80,117,,,100,137,NUCLEAR PLEOMORPHISM,SYMPLASTIC LEIOMYOMA,NUCLEAR PLEOMORPHISM,80-88,117-128,SYMPLASTIC LEIOMYOMA.,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.,80 88,117 128,80,117,100,137,1,RO-disease_has_finding,901865,Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma,nuclear pleomorphism,symplastic leiomyoma
503223672,7/15/2014 10:15:30,,1323479844,7/15/2014 10:15:14,vivatic,1,25451531,GBR,,,83.67.28.193,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,ARRHYTHMIAS,58,88-103-108,"ANTIARRHYTHMIC DRUG efficacy,","While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223672,7/15/2014 10:20:50,,1323483441,7/15/2014 10:20:47,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,for detection of ARRHYTHMIAS and assessment of,41-45-55-58-70-74-85,70-74-85-88-103-108-118-122,"and assessment of ANTIARRHYTHMIC DRUG efficacy, few reports","While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223672,7/15/2014 10:25:55,,1323486439,7/15/2014 10:25:41,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,ARRHYTHMIAS,58,88-103-108,"ANTIARRHYTHMIC DRUG efficacy,","While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223672,7/15/2014 10:25:59,,1323486502,7/15/2014 10:25:45,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,ARRHYTHMIAS,58,88-103-108,"ANTIARRHYTHMIC DRUG efficacy,","While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223672,7/15/2014 10:56:31,,1323507328,7/15/2014 10:56:12,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,ARRHYTHMIAS,58,88-103-108,"ANTIARRHYTHMIC DRUG efficacy,","While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223672,7/15/2014 10:57:21,,1323507823,7/15/2014 10:56:45,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,"ARRHYTHMIAS antiarrhythmic drug efficacy,",58-88-103-108,88-103-108-58,"arrhythmias ANTIARRHYTHMIC DRUG efficacy,","While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223672,7/15/2014 11:25:18,,1323526805,7/15/2014 11:24:47,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,"ARRHYTHMIAS antiarrhythmic drug efficacy, malignant ventricular arrhythmias.",58-88-103-108-192-202-214,58-88-103-108-192-202-214,"arrhythmias ANTIARRHYTHMIC DRUG efficacy, malignant ventricular arrhythmias.","While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223672,7/15/2014 11:26:05,,1323527165,7/15/2014 11:25:46,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,ARRHYTHMIAS,58,88-103,ANTIARRHYTHMIC DRUG,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223672,7/15/2014 11:35:11,,1323532515,7/15/2014 11:34:49,prodege,1,6316959,GBR,,,46.208.145.114,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,ARRHYTHMIAS,58,88-103,ANTIARRHYTHMIC DRUG,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223672,7/15/2014 11:40:29,,1323535552,7/15/2014 11:40:08,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,58,88,,,69,107,ARRHYTHMIAS,ANTIARRHYTHMIC DRUG,ARRHYTHMIAS antiarrhythmic arrhythmias.,58-88-214,58-88-103-214,arrhythmias ANTIARRHYTHMIC DRUG arrhythmias.,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias.",58,88 103,58,88,69,107,1,RO-may_prevent,907090,"While maximal exercise testing is useful for detection of arrhythmias and assessment of antiarrhythmic drug efficacy, few reports have documented the safety of this procedure in patients with malignant ventricular arrhythmias",arrhythmias,antiarrhythmic drug
503223673,7/15/2014 10:20:13,,1323482993,7/15/2014 10:20:02,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,CHOREA,131,187-200,"HUNTINGTON'S DISEASE,","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223673,7/15/2014 10:22:40,,1323484646,7/15/2014 10:21:56,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,CHOREA,131,187-200,"HUNTINGTON'S DISEASE,","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223673,7/15/2014 10:24:40,,1323485671,7/15/2014 10:24:24,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,CHOREA caused by various,131-145-148-138,187-200,"HUNTINGTON'S DISEASE,","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223673,7/15/2014 10:32:02,,1323490537,7/15/2014 10:31:47,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,CHOREA,131,187-200,"HUNTINGTON'S DISEASE,","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223673,7/15/2014 10:55:48,,1323506936,7/15/2014 10:55:32,clixsense,1,27969116,NLD,,,91.213.37.165,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,CHOREA,131,187-200,"HUNTINGTON'S DISEASE,","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223673,7/15/2014 11:02:16,,1323510776,7/15/2014 11:01:48,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,CHOREA,131,187-200,"HUNTINGTON'S DISEASE,","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223673,7/15/2014 11:03:58,,1323511904,7/15/2014 11:03:48,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,CHOREA,131,187-200,"HUNTINGTON'S DISEASE,","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223673,7/15/2014 11:21:14,,1323524559,7/15/2014 11:20:59,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,CHOREA,131,187-200,"HUNTINGTON'S DISEASE,","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223673,7/15/2014 11:39:16,,1323534854,7/15/2014 11:38:46,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,"CHOREA aetiologies Huntington's acanthocytosis, erythematosus",131-156-187-225-271,187-200-218-225-271,"HUNTINGTON'S DISEASE, chorea acanthocytosis, erythematosus","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223673,7/15/2014 11:44:54,,1323538073,7/15/2014 11:44:37,prodege,1,6316959,GBR,,,46.208.145.114,131,187,,,137,207,CHOREA,HUNTINGTON'S DISEASE,CHOREA,131,187-200,"HUNTINGTON'S DISEASE,","Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology.",131,187 200,131,187,137,207,1,RO-has_manifestation,906390,"Intracortical inhibition of the motor cortex was investigated using a paired pulse magnetic stimulation method in 14 patients with chorea caused by various aetiologies (six patients with Huntington's disease, one with chorea acanthocytosis, a patient with systemic lupus erythematosus with a vascular lesion in the caudate, three with senile chorea and three with chorea of unknown aetiology",chorea,Huntington's disease
503223674,7/15/2014 10:55:31,,1323506805,7/15/2014 10:55:18,clixsense,1,27969116,NLD,,,91.213.37.165,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,symptoms of SCHIZOPHRENIA.,92-101-104,0-12-15-18-27-41,RISPERIDONE is an atypical antipsychotic agent,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223674,7/15/2014 11:10:07,,1323517372,7/15/2014 11:09:42,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,SCHIZOPHRENIA.,104,0,RISPERIDONE,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223674,7/15/2014 11:11:13,,1323518187,7/15/2014 11:11:06,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,SCHIZOPHRENIA.,104,0,RISPERIDONE,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223674,7/15/2014 11:11:38,,1323518488,7/15/2014 11:11:28,instagc,1,13763729,USA,,,75.182.89.225,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,SCHIZOPHRENIA.,104,0,RISPERIDONE,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223674,7/15/2014 11:16:03,,1323521288,7/15/2014 11:15:50,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,SCHIZOPHRENIA.,104,0-104,RISPERIDONE schizophrenia.,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223674,7/15/2014 11:37:22,,1323533696,7/15/2014 11:37:10,prodege,1,23999031,AUS,8,Perth,203.59.238.194,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,SCHIZOPHRENIA.,104,0-104,RISPERIDONE schizophrenia.,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223674,7/15/2014 11:38:14,,1323534254,7/15/2014 11:37:51,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,Risperidone atypical antipsychotic agent SCHIZOPHRENIA.,0-18-27-41-104,0-18-27-41-104,RISPERIDONE atypical antipsychotic agent schizophrenia.,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223674,7/15/2014 12:01:26,,1323547417,7/15/2014 12:01:12,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,SCHIZOPHRENIA.,104,0,RISPERIDONE,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223674,7/15/2014 12:01:40,,1323547497,7/15/2014 12:01:29,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,SCHIZOPHRENIA.,104,0,RISPERIDONE,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223674,7/15/2014 12:05:04,,1323548715,7/15/2014 12:04:38,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,104,0,,,117,11,SCHIZOPHRENIA,RISPERIDONE,negative symptoms of SCHIZOPHRENIA.,83-92-101-104,0,RISPERIDONE,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia.,104,0,104,0,117,11,1,RO-may_treat,907998,Risperidone is an atypical antipsychotic agent with efficacy for both positive and negative symptoms of schizophrenia,schizophrenia,Risperidone
503223675,7/15/2014 10:18:26,,1323481700,7/15/2014 10:18:02,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,pulmonary EOSINOPHILIA,151-161,194-204,PULMONARY EOSINOPHILIA,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223675,7/15/2014 10:19:25,,1323482465,7/15/2014 10:18:57,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,EOSINOPHILIA,161,194-204,PULMONARY EOSINOPHILIA,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223675,7/15/2014 10:27:39,,1323487575,7/15/2014 10:27:26,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,prolonged pulmonary EOSINOPHILIA without asthma;,141-151-161-174-182,194-204-217-222,PULMONARY EOSINOPHILIA with asthma,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223675,7/15/2014 10:32:54,,1323491110,7/15/2014 10:32:40,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,pulmonary EOSINOPHILIA without asthma;,151-161-174-182,194-204,PULMONARY EOSINOPHILIA,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223675,7/15/2014 10:46:50,,1323500745,7/15/2014 10:46:34,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,EOSINOPHILIA,161,194-204,PULMONARY EOSINOPHILIA,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223675,7/15/2014 10:59:17,,1323508961,7/15/2014 10:57:26,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,peripheral eosinophilia (PIE): pulmonary eosinophilia (Loffler syndrome); prolonged pulmonary EOSINOPHILIA asthma; tropical pulmonary eosinophilia; pulmonary vasculitis (allergic granulomatosis angiitis) Multifocal Lung Disease hypereosinophilic syndrome Nonmalignant Disorders of Leukocytes acute eosinophilic pneumonia.,52-63-76-94-104-117-126-141-151-161-182-255-264-274-292-302-313-323-342-374-385-390-405-423-444-457-467-470-492-498-511,52-63-76-94-104-117-126-141-151-161-182-190-194-204-255-264-274-292-302-313-323-342-374-385-390-405-423-444-457-467-470-492-498-511,peripheral eosinophilia (PIE): pulmonary eosinophilia (Loffler syndrome); prolonged pulmonary eosinophilia asthma; (3) PULMONARY EOSINOPHILIA tropical pulmonary eosinophilia; pulmonary vasculitis (allergic granulomatosis angiitis) Multifocal Lung Disease hypereosinophilic syndrome Nonmalignant Disorders of Leukocytes acute eosinophilic pneumonia.,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223675,7/15/2014 11:27:37,,1323528114,7/15/2014 11:26:30,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,pulmonary infiltrates peripheral eosinophilia (PIE): simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary EOSINOPHILIA without asthma; pulmonary eosinophilia with asthma Asthma tropical pulmonary eosinophilia; pulmonary vasculitis (allergic granulomatosis angiitis) Multifocal Lung Disease hypereosinophilic syndrome Nonmalignant Disorders of Leukocytes acute eosinophilic pneumonia.,25-52-63-76-87-94-104-117-126-137-141-151-161-174-182-194-204-217-222-241-255-264-274-292-302-313-323-342-374-385-390-405-423-444-457-467-470-492-498-511-35,25-35-52-63-87-94-104-117-126-141-151-161-174-182-190-194-204-217-222-231-241-255-264-274-292-302-313-323-338-342-364-370-374-385-390-405-423-444-457-467-470-492-498-511,pulmonary infiltrates peripheral eosinophilia simple pulmonary eosinophilia (Loffler syndrome); prolonged pulmonary eosinophilia without asthma; (3) PULMONARY EOSINOPHILIA with asthma see Asthma tropical pulmonary eosinophilia; pulmonary vasculitis (allergic granulomatosis and angiitis) Focal and Multifocal Lung Disease hypereosinophilic syndrome Nonmalignant Disorders of Leukocytes acute eosinophilic pneumonia.,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223675,7/15/2014 11:27:42,,1323528159,7/15/2014 11:27:21,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,EOSINOPHILIA,161,194-204,PULMONARY EOSINOPHILIA,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223675,7/15/2014 12:02:33,,1323547776,7/15/2014 12:02:23,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,(2) prolonged pulmonary EOSINOPHILIA without asthma;,137-141-151-161-174-182,194-204-217-222-231,PULMONARY EOSINOPHILIA with asthma see,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223675,7/15/2014 12:05:04,,1323548714,7/15/2014 12:04:31,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,161,194,,,173,216,EOSINOPHILIA,PULMONARY EOSINOPHILIA,pulmonary EOSINOPHILIA without asthma;,151-161-174-182,194-204-217-222,PULMONARY EOSINOPHILIA with asthma,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia.,161,194 204,161,194,173,216,-1,RO-has_definitional_manifestation,904785,There are seven forms of pulmonary infiltrates with peripheral eosinophilia (PIE): (1) simple pulmonary eosinophilia (Loffler syndrome); (2) prolonged pulmonary eosinophilia without asthma; (3) pulmonary eosinophilia with asthma [ see 14:II Asthma ]; (4) tropical pulmonary eosinophilia; (5) pulmonary vasculitis (allergic granulomatosis and angiitis) [ see 14:IV Focal and Multifocal Lung Disease ]; (6) hypereosinophilic syndrome [ see 5:VII Nonmalignant Disorders of Leukocytes ]; and (7) acute eosinophilic pneumonia,eosinophilia,pulmonary eosinophilia
503223676,7/15/2014 10:18:58,,1323482162,7/15/2014 10:18:56,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,93,56,,,98,68,SUGAR,CARBOHYDRATE,(up to three SUGAR residues) chains composed,80-84-87-93-99-109-116,43-46-50-56-70-74,"of the total CARBOHYDRATE, are short","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223676,7/15/2014 10:21:55,,1323484163,7/15/2014 10:21:39,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,93,56,,,98,68,SUGAR,CARBOHYDRATE,SUGAR residues),93-99,56,"CARBOHYDRATE,","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223676,7/15/2014 10:22:39,,1323484650,7/15/2014 10:22:23,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,93,56,,,98,68,SUGAR,CARBOHYDRATE,SUGAR,93,56,"CARBOHYDRATE,","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223676,7/15/2014 10:24:32,,1323485579,7/15/2014 10:24:02,vivatic,1,25451531,GBR,,,83.67.28.193,93,56,,,98,68,SUGAR,CARBOHYDRATE,SUGAR residues),93-99,50-56,"total CARBOHYDRATE,","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223676,7/15/2014 10:30:58,,1323489814,7/15/2014 10:30:42,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,93,56,,,98,68,SUGAR,CARBOHYDRATE,SUGAR residues),93-99,56,"CARBOHYDRATE,","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223676,7/15/2014 11:03:06,,1323511292,7/15/2014 11:02:44,instagc,1,23149109,USA,NC,Durham,75.189.206.205,93,56,,,98,68,SUGAR,CARBOHYDRATE,SUGAR residues),93-99,50-56,"total CARBOHYDRATE,","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223676,7/15/2014 11:34:35,,1323532138,7/15/2014 11:34:19,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,93,56,,,98,68,SUGAR,CARBOHYDRATE,SUGAR,93,56,"CARBOHYDRATE,","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223676,7/15/2014 11:35:59,,1323532989,7/15/2014 11:35:34,prodege,1,23999031,AUS,8,Perth,203.59.238.194,93,56,,,98,68,SUGAR,CARBOHYDRATE,SUGAR,93,56,"CARBOHYDRATE,","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223676,7/15/2014 11:42:03,,1323536559,7/15/2014 11:41:46,prodege,1,6316959,GBR,,,46.208.145.114,93,56,,,98,68,SUGAR,CARBOHYDRATE,SUGAR,93,56,"CARBOHYDRATE,","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223676,7/15/2014 11:54:04,,1323543929,7/15/2014 11:53:51,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,93,56,,,98,68,SUGAR,CARBOHYDRATE,SUGAR residues),93-99,56,"CARBOHYDRATE,","The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues.",93,56,93,56,98,68,1,RO-has_ingredient,905595,"The O-glycosidic sugars, which make up 50% of the total carbohydrate, are short (up to three sugar residues) chains composed of Ara, Gal and Xyl and are exclusively bound to Thr residues",sugar,carbohydrate
503223677,7/15/2014 10:21:18,,1323483737,7/15/2014 10:20:47,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"SEVERE DYSPLASIA),",138-145,102-106,CIN III,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223677,7/15/2014 11:09:08,,1323516612,7/15/2014 11:08:51,instagc,1,23149109,USA,NC,Durham,75.189.206.205,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"SEVERE DYSPLASIA),",138-145,102-106,CIN III,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223677,7/15/2014 11:17:28,,1323522338,7/15/2014 11:16:56,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"SEVERE DYSPLASIA),",138-145,102-106-138-145,"CIN III severe dysplasia),","In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223677,7/15/2014 11:33:53,,1323531735,7/15/2014 11:32:58,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"dysplasia CIN III carcinoma SEVERE DYSPLASIA), CIN II (moderate dysplasia) CIN (mild dysplasia.",44-102-106-115-138-145-171-175-178-188-217-223-229,44-102-106-115-138-145-171-175-178-188-217-221-223-229,"dysplasia CIN III carcinoma severe dysplasia), CIN II (moderate dysplasia) CIN I (mild dysplasia.","In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223677,7/15/2014 11:39:49,,1323535112,7/15/2014 11:39:07,prodege,1,6316959,GBR,,,46.208.145.114,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"SEVERE DYSPLASIA),",138-145,102-106,CIN III,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223677,7/15/2014 11:40:49,,1323535701,7/15/2014 11:40:09,prodege,1,23999031,AUS,8,Perth,203.59.238.194,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"dysplasia carcinoma SEVERE DYSPLASIA), (moderate dysplasia) (mild dysplasia.",44-115-138-145-178-188-223-229,44-102-106-115-125-138-145-178-188-229-223,"dysplasia CIN III carcinoma in severe dysplasia), (moderate dysplasia) (mild dysplasia.","In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223677,7/15/2014 11:52:35,,1323543025,7/15/2014 11:52:12,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"SEVERE DYSPLASIA),",138-145,102-106,CIN III,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223677,7/15/2014 11:54:34,,1323544096,7/15/2014 11:54:02,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"SEVERE DYSPLASIA),",138-145,102-106,CIN III,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223677,7/15/2014 11:54:59,,1323544262,7/15/2014 11:54:33,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"in situ, SEVERE DYSPLASIA),",125-128-138-145,102-106,CIN III,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223677,7/15/2014 11:55:22,,1323544438,7/15/2014 11:54:49,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,138,102,,,154,109,SEVERE DYSPLASIA,CIN III,"SEVERE DYSPLASIA),",138-145,102-106,CIN III,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia.",138 145,102 106,138,102,154,109,-1,RO-disease_has_finding,901644,"In five of the 29 false negative cases with dysplasia histological follow-up has shown three cases of CIN III (two carcinoma in situ, one severe dysplasia), one case with CIN II (moderate dysplasia) and one case with CIN I (mild dysplasia",severe dysplasia,CIN III
503223678,7/15/2014 10:13:20,,1323478393,7/15/2014 10:13:08,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,DEPRESSION,134,26-36,TRICYCLIC ANTIDEPRESSANT,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223678,7/15/2014 10:19:45,,1323482720,7/15/2014 10:19:31,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,delusional DEPRESSION,123-134,26-36,TRICYCLIC ANTIDEPRESSANT,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223678,7/15/2014 10:22:46,,1323484669,7/15/2014 10:22:26,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,delusional DEPRESSION,123-134,26-36,TRICYCLIC ANTIDEPRESSANT,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223678,7/15/2014 10:27:33,,1323487500,7/15/2014 10:27:17,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,delusional DEPRESSION,123-134,26-36,TRICYCLIC ANTIDEPRESSANT,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223678,7/15/2014 10:33:35,,1323491509,7/15/2014 10:33:20,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,DEPRESSION,134,26-36,TRICYCLIC ANTIDEPRESSANT,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223678,7/15/2014 10:35:40,,1323492975,7/15/2014 10:35:25,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,delusional DEPRESSION,123-134,26-36,TRICYCLIC ANTIDEPRESSANT,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223678,7/15/2014 11:00:05,,1323509476,7/15/2014 10:59:23,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,tricyclic antidepressant delusional DEPRESSION,26-36-123-134,26-36-123-134,TRICYCLIC ANTIDEPRESSANT delusional depression,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223678,7/15/2014 11:02:55,,1323511139,7/15/2014 11:02:36,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,delusional DEPRESSION,123-134,26-36,TRICYCLIC ANTIDEPRESSANT,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223678,7/15/2014 11:03:02,,1323511242,7/15/2014 11:02:46,clixsense,1,27969116,NLD,,,91.213.37.165,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,delusional DEPRESSION should be,123-134-145-152,26-36,TRICYCLIC ANTIDEPRESSANT,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223678,7/15/2014 11:18:04,,1323522702,7/15/2014 11:17:46,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,134,26,,,144,50,DEPRESSION,TRICYCLIC ANTIDEPRESSANT,DEPRESSION,134,26-36-134,TRICYCLIC ANTIDEPRESSANT depression,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression.",134,26 36,134,26,144,50,1,RO-may_treat,908308,"Since the introduction of tricyclic antidepressant for the treatment of depressive patients, it has been discussed whether delusional depression should be designated as a distinct syndrome or merely a severe variant of major depression",depression,tricyclic antidepressant
503223679,7/15/2014 10:26:13,,1323486630,7/15/2014 10:26:00,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,65,98,,,72,106,SEIZURE,EPILEPSY,SEIZURE control,65-73,98,EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223679,7/15/2014 10:28:00,,1323487902,7/15/2014 10:27:48,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,65,98,,,72,106,SEIZURE,EPILEPSY,SEIZURE,65,98,EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223679,7/15/2014 10:47:46,,1323501295,7/15/2014 10:47:37,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,65,98,,,72,106,SEIZURE,EPILEPSY,SEIZURE,65,98,EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223679,7/15/2014 11:08:11,,1323515754,7/15/2014 11:08:04,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,65,98,,,72,106,SEIZURE,EPILEPSY,SEIZURE control,65-73,98,EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223679,7/15/2014 11:08:33,,1323516012,7/15/2014 11:08:10,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,65,98,,,72,106,SEIZURE,EPILEPSY,antiepileptic drugs (AED) SEIZURE epilepsy.,15-29-35-65-98,29-35-65-98-15,antiepileptic drugs (AED) seizure EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223679,7/15/2014 11:10:17,,1323517478,7/15/2014 11:10:05,instagc,1,23149109,USA,NC,Durham,75.189.206.205,65,98,,,72,106,SEIZURE,EPILEPSY,chance of SEIZURE control,55-62-65-73,84-93-98,patients with EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223679,7/15/2014 11:37:52,,1323534025,7/15/2014 11:37:37,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,65,98,,,72,106,SEIZURE,EPILEPSY,antiepileptic SEIZURE epilepsy.,15-65-98,98-15,antiepileptic EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223679,7/15/2014 11:42:11,,1323536638,7/15/2014 11:41:58,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,65,98,,,72,106,SEIZURE,EPILEPSY,the chance of SEIZURE control,51-55-62-65-73,93-98,with EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223679,7/15/2014 12:01:11,,1323547344,7/15/2014 12:00:59,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,65,98,,,72,106,SEIZURE,EPILEPSY,SEIZURE,65,98,EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223679,7/15/2014 12:03:28,,1323548114,7/15/2014 12:03:20,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,65,98,,,72,106,SEIZURE,EPILEPSY,SEIZURE control in patients,65-73-81-84,81-84-93-98,in patients with EPILEPSY.,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy.,65,98,65,98,72,106,-1,RO-has_definitional_manifestation,904589,Treatment with antiepileptic drugs (AED) increases the chance of seizure control in patients with epilepsy,seizure,epilepsy
503223680,7/15/2014 10:24:11,,1323485424,7/15/2014 10:23:55,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"PHOSPHATURIA,",54,0-10,ONCOGENIC OSTEOMALACIA,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223680,7/15/2014 10:27:54,,1323487799,7/15/2014 10:27:44,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"PHOSPHATURIA,",54,0-10,ONCOGENIC OSTEOMALACIA,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223680,7/15/2014 11:04:36,,1323512514,7/15/2014 11:04:20,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"PHOSPHATURIA,",54,0-10,ONCOGENIC OSTEOMALACIA,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223680,7/15/2014 11:23:18,,1323525690,7/15/2014 11:23:07,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"Oncogenic osteomalacia PHOSPHATURIA,",0-10-54,0-10,ONCOGENIC OSTEOMALACIA,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223680,7/15/2014 11:31:32,,1323530330,7/15/2014 11:30:47,prodege,1,23999031,AUS,8,Perth,203.59.238.194,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"Oncogenic osteomalacia PHOSPHATURIA, hypophosphatemia, reduced vitamin D levels, osteomalacia.",0-10-54-68-86-94-102-116-104,0-10-54-68-86-94-102-104-116,"ONCOGENIC OSTEOMALACIA phosphaturia, hypophosphatemia, reduced vitamin D levels, osteomalacia.","Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223680,7/15/2014 11:36:43,,1323533355,7/15/2014 11:36:29,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"PHOSPHATURIA,",54,0-10,ONCOGENIC OSTEOMALACIA,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223680,7/15/2014 11:37:13,,1323533641,7/15/2014 11:36:54,prodege,1,6316959,GBR,,,46.208.145.114,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"PHOSPHATURIA,",54,0-10,ONCOGENIC OSTEOMALACIA,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223680,7/15/2014 11:37:44,,1323533969,7/15/2014 11:37:23,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"syndrome characterized by PHOSPHATURIA,",28-37-51-54,0-10-23-26-28,ONCOGENIC OSTEOMALACIA is a syndrome,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223680,7/15/2014 11:40:52,,1323535735,7/15/2014 11:40:30,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"Oncogenic osteomalacia PHOSPHATURIA, hypophosphatemia, osteomalacia.",0-10-54-68-116,0-10-54-68-116,"ONCOGENIC OSTEOMALACIA phosphaturia, hypophosphatemia, osteomalacia.","Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223680,7/15/2014 11:45:44,,1323538645,7/15/2014 11:45:16,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,54,0,,,66,22,PHOSPHATURIA,ONCOGENIC OSTEOMALACIA,"PHOSPHATURIA,",54,0-10-28,ONCOGENIC OSTEOMALACIA syndrome,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia.",54,0 10,54,0,66,22,1,RO-disease_has_finding,901839,"Oncogenic osteomalacia is a syndrome characterized by phosphaturia, hypophosphatemia, reduced vitamin D levels, and osteomalacia",phosphaturia,Oncogenic osteomalacia
503223681,7/15/2014 10:18:02,,1323481409,7/15/2014 10:17:39,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,heterozygous familial HYPERCHOLESTEROLEMIA.,64-77-86,31,COLESTIPOL,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223681,7/15/2014 10:36:24,,1323493427,7/15/2014 10:36:14,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,heterozygous familial HYPERCHOLESTEROLEMIA.,64-77-86,31,COLESTIPOL,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223681,7/15/2014 10:48:53,,1323502269,7/15/2014 10:48:21,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,severe heterozygous HYPERCHOLESTEROLEMIA.,57-64-86,31-57-64-86,COLESTIPOL severe heterozygous hypercholesterolemia.,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223681,7/15/2014 11:00:15,,1323509598,7/15/2014 10:59:58,clixsense,1,27969116,NLD,,,91.213.37.165,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,severe heterozygous familial HYPERCHOLESTEROLEMIA.,57-64-77-86,31-64-77-86,COLESTIPOL heterozygous familial hypercholesterolemia.,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223681,7/15/2014 11:22:54,,1323525398,7/15/2014 11:22:26,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,severe heterozygous familial HYPERCHOLESTEROLEMIA.,57-64-77-86,31-57-64-77-86,COLESTIPOL severe heterozygous familial hypercholesterolemia.,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223681,7/15/2014 11:27:19,,1323527959,7/15/2014 11:27:05,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,HYPERCHOLESTEROLEMIA.,86,31,COLESTIPOL,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223681,7/15/2014 11:59:30,,1323546624,7/15/2014 11:59:16,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,HYPERCHOLESTEROLEMIA.,86,31,COLESTIPOL,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223681,7/15/2014 12:00:43,,1323547172,7/15/2014 12:00:19,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,severe heterozygous familial HYPERCHOLESTEROLEMIA.,57-64-77-86,31-42-45,COLESTIPOL in therapy,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223681,7/15/2014 12:04:30,,1323548513,7/15/2014 12:04:07,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,severe heterozygous familial HYPERCHOLESTEROLEMIA.,57-64-77-86,31,COLESTIPOL,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223681,7/15/2014 12:04:52,,1323548678,7/15/2014 12:04:19,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,86,31,,,106,41,HYPERCHOLESTEROLEMIA,COLESTIPOL,heterozygous familial HYPERCHOLESTEROLEMIA.,64-77-86,31,COLESTIPOL,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.,86,31,86,31,106,41,1,RO-may_treat,907609,Illingworth DR. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia,hypercholesterolemia,colestipol
503223682,7/15/2014 10:20:58,,1323483548,7/15/2014 10:20:55,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,patient with moderate SPLENOMEGALY and the leukemic,2-10-15-24-37-41-45,45-54-60-63-69-74-83-93-98,leukemic phase of HAIRY CELL LEUKEMIA presented with a,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223682,7/15/2014 10:21:37,,1323483985,7/15/2014 10:21:04,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,SPLENOMEGALY,24,63-69-74,HAIRY CELL LEUKEMIA,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223682,7/15/2014 10:22:02,,1323484198,7/15/2014 10:21:52,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,SPLENOMEGALY,24,63-69-74,HAIRY CELL LEUKEMIA,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223682,7/15/2014 10:24:19,,1323485462,7/15/2014 10:24:04,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,SPLENOMEGALY,24,63-69-74,HAIRY CELL LEUKEMIA,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223682,7/15/2014 10:28:37,,1323488337,7/15/2014 10:28:23,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,moderate SPLENOMEGALY,15-24,63-69-74,HAIRY CELL LEUKEMIA,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223682,7/15/2014 10:31:47,,1323490394,7/15/2014 10:31:28,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,SPLENOMEGALY,24,63-69-74,HAIRY CELL LEUKEMIA,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223682,7/15/2014 10:33:25,,1323491396,7/15/2014 10:33:11,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,moderate SPLENOMEGALY,15-24,63-69-74,HAIRY CELL LEUKEMIA,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223682,7/15/2014 10:36:10,,1323493275,7/15/2014 10:35:57,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,moderate SPLENOMEGALY,15-24,63-69-74,HAIRY CELL LEUKEMIA,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223682,7/15/2014 10:55:25,,1323506731,7/15/2014 10:54:33,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,moderate SPLENOMEGALY hairy cell leukemia white blood cell count (WBC),15-24-63-69-74-100-106-112-123-117,24-63-69-74-106-112-117-123-15,moderate splenomegaly HAIRY CELL LEUKEMIA blood cell count (WBC),"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223682,7/15/2014 10:55:42,,1323506883,7/15/2014 10:55:14,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,24,63,,,36,82,SPLENOMEGALY,HAIRY CELL LEUKEMIA,SPLENOMEGALY,24,63-69-74,HAIRY CELL LEUKEMIA,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3.",24,63 69 74,24,63,36,82,-1,RO-disease_has_finding,901599,"A patient with moderate splenomegaly and the leukemic phase of hairy cell leukemia presented with a white blood cell count (WBC) of 85,600/mm3 with 87% hairy cells and platelets of 125,000/mm3",splenomegaly,hairy cell leukemia
503223683,7/15/2014 10:21:28,,1323483865,7/15/2014 10:21:19,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS,13-21,91-105,EXTRASKELETAL OSTEOCHONDROMA,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223683,7/15/2014 10:57:36,,1323507957,7/15/2014 10:57:13,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS,13-21,91-105,EXTRASKELETAL OSTEOCHONDROMA,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223683,7/15/2014 11:21:33,,1323524745,7/15/2014 11:21:16,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS extraskeletal osteochondroma,13-21-91-105,91-105,EXTRASKELETAL OSTEOCHONDROMA,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223683,7/15/2014 11:21:46,,1323524878,7/15/2014 11:21:32,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS,13-21,91-105,EXTRASKELETAL OSTEOCHONDROMA,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223683,7/15/2014 11:45:18,,1323538353,7/15/2014 11:45:00,prodege,1,23999031,AUS,8,Perth,203.59.238.194,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS extraskeletal osteochondroma,13-21-91-105,91-105,EXTRASKELETAL OSTEOCHONDROMA,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223683,7/15/2014 11:57:30,,1323545604,7/15/2014 11:57:11,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS formed an encapsulated mass,13-21-30-37-40-53,91-105-120-124,EXTRASKELETAL OSTEOCHONDROMA was diagnosed.,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223683,7/15/2014 11:57:57,,1323545818,7/15/2014 11:57:40,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS,13-21,91-105,EXTRASKELETAL OSTEOCHONDROMA,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223683,7/15/2014 12:07:00,,1323549362,7/15/2014 12:06:22,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS,13-21,91-105,EXTRASKELETAL OSTEOCHONDROMA,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223683,7/15/2014 12:07:46,,1323549598,7/15/2014 12:07:31,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS,13-21,91-105,EXTRASKELETAL OSTEOCHONDROMA,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223683,7/15/2014 12:10:13,,1323550477,7/15/2014 12:09:51,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,13,91,,,29,119,CALCIUM DEPOSITS,EXTRASKELETAL OSTEOCHONDROMA,CALCIUM DEPOSITS,13-21,91-105,EXTRASKELETAL OSTEOCHONDROMA,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed.",13 21,91 105,13,91,29,119,1,RO-disease_may_have_finding,902718,"Two isolated calcium deposits formed an encapsulated mass in the iliopsoas muscle, and the extraskeletal osteochondroma was diagnosed",calcium deposits,extraskeletal osteochondroma
503223684,7/15/2014 10:19:49,,1323482745,7/15/2014 10:19:33,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HEMOPHAGOCYTOSIS,159,196-211,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223684,7/15/2014 10:21:23,,1323483822,7/15/2014 10:21:09,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HEMOPHAGOCYTOSIS,159,196-211,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223684,7/15/2014 10:22:37,,1323484622,7/15/2014 10:22:26,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HEMOPHAGOCYTOSIS,159,196-211,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223684,7/15/2014 10:26:43,,1323486982,7/15/2014 10:26:21,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HEMOPHAGOCYTOSIS,159,196-211,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223684,7/15/2014 10:37:21,,1323493903,7/15/2014 10:36:21,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"progressive hyperferritinemia anemia (hemoglobin: LDH / HEMOPHAGOCYTOSIS bone marrow, hemophagocytic lymphohistiocytosis",16-28-60-67-138-150-159-183-188-211-196,16-28-60-67-91-138-183-188-196-211-159,"progressive hyperferritinemia anemia (hemoglobin: hypertriglyceridemia LDH hemophagocytosis bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS","On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223684,7/15/2014 11:07:52,,1323515442,7/15/2014 11:07:37,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HEMOPHAGOCYTOSIS,159,196-211,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223684,7/15/2014 11:12:59,,1323519441,7/15/2014 11:12:43,instagc,1,13763729,USA,,,75.182.89.225,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HEMOPHAGOCYTOSIS,159,196-211,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223684,7/15/2014 11:39:35,,1323534992,7/15/2014 11:38:14,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"progressive hyperferritinemia anemia (hemoglobin: hypertriglyceridemia IU l) with HEMOPHAGOCYTOSIS bone marrow, hemophagocytic lymphohistiocytosis",16-28-60-67-91-148-151-154-159-183-196-211-188,16-28-60-67-91-159-179-183-188-196-211,"progressive hyperferritinemia anemia (hemoglobin: hypertriglyceridemia hemophagocytosis the bone marrow, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS","On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223684,7/15/2014 11:56:23,,1323545032,7/15/2014 11:55:57,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,HEMOPHAGOCYTOSIS,159,196-211,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223684,7/15/2014 11:59:56,,1323546818,7/15/2014 11:59:39,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,159,196,,,175,230,HEMOPHAGOCYTOSIS,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS,"HEMOPHAGOCYTOSIS in the bone marrow,",159-176-179-183-188,196-211-231-235,HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS was diagnosed.,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed.",159,196 211,159,196,175,230,1,RO-disease_has_finding,901897,"On the basis of progressive hyperferritinemia (1323 ng/ml), anemia (hemoglobin: 5.2 g/dl), hypertriglyceridemia (547 mg/dl) and increased LDH (1063 IU/l) with hemophagocytosis in the bone marrow, hemophagocytic lymphohistiocytosis was diagnosed",hemophagocytosis,hemophagocytic lymphohistiocytosis
503223685,7/15/2014 10:21:51,,1323484086,7/15/2014 10:21:41,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,ATYPIA,245,289-298,ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223685,7/15/2014 10:23:39,,1323485131,7/15/2014 10:23:25,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,ATYPIA,245,289-298,ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223685,7/15/2014 10:32:25,,1323490792,7/15/2014 10:32:09,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,ATYPIA,245,289-298,ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223685,7/15/2014 10:34:38,,1323492194,7/15/2014 10:34:27,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,ATYPIA,245,289-298,ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223685,7/15/2014 10:36:10,,1323493269,7/15/2014 10:35:48,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,ATYPIA,245,289-298,ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223685,7/15/2014 11:09:10,,1323516667,7/15/2014 11:08:37,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,hyperplasia without ATYPIA,225-237-245,270-289-298-285,adenocarcinoma and ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223685,7/15/2014 11:40:21,,1323535464,7/15/2014 11:40:06,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,hyperplasia without ATYPIA,225-237-245,267-270-285-289-298-261,group of adenocarcinoma and ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223685,7/15/2014 11:44:05,,1323537756,7/15/2014 11:43:46,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,ATYPIA,245,289-298,ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223685,7/15/2014 11:57:10,,1323545465,7/15/2014 11:56:42,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,of hyperplasia without ATYPIA,222-225-237-245,267-270-285-289-298,of adenocarcinoma and ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223685,7/15/2014 11:58:55,,1323546322,7/15/2014 11:58:41,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,245,289,,,251,309,ATYPIA,ATYPICAL HYPERPLASIA,ATYPIA,245,289-298,ATYPICAL HYPERPLASIA.,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia.",245,289 298,245,289,251,309,1,RO-disease_has_finding,901792,"A combination of cytomorphology and the morphometric variables assessed in this study can yield useful information on the cytologic state of endometrium, with special reference to the possible differentiation of the group of hyperplasia without atypia from the group of adenocarcinoma and atypical hyperplasia",atypia,atypical hyperplasia
503223686,7/15/2014 10:58:45,,1323508674,7/15/2014 10:58:33,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,HYPERKERATOSIS,115,76-84-90-95,VERRUCA plana type lesion,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223686,7/15/2014 11:20:02,,1323523953,7/15/2014 11:19:31,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,verruca plana type lesion with minimal HYPERKERATOSIS and acanthotic areas,76-84-95-102-107-115-130-134-145-90,39-57-71-74-76-84-90-95-102-107-115-130-134-145,epidermodysplasia verruciformis is a VERRUCA plana type lesion with minimal hyperkeratosis and acanthotic areas,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223686,7/15/2014 11:32:57,,1323531126,7/15/2014 11:32:40,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,HYPERKERATOSIS,115,76-84-90-95,VERRUCA plana type lesion,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223686,7/15/2014 11:47:12,,1323539446,7/15/2014 11:46:35,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,HYPERKERATOSIS,115,76-84-90-95,VERRUCA plana type lesion,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223686,7/15/2014 11:55:00,,1323544264,7/15/2014 11:54:43,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,HYPERKERATOSIS,115,76,VERRUCA,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223686,7/15/2014 11:56:04,,1323544850,7/15/2014 11:55:17,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,HYPERKERATOSIS,115,76-84-90-95,VERRUCA plana type lesion,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223686,7/15/2014 12:01:52,,1323547602,7/15/2014 12:01:43,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,lesion with minimal HYPERKERATOSIS,95-102-107-115,57-71-74-76-84-90-95,verruciformis is a VERRUCA plana type lesion,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223686,7/15/2014 12:07:45,,1323549571,7/15/2014 12:07:11,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,minimal HYPERKERATOSIS,107-115,57-71-74-76-84-90-95-39,epidermodysplasia verruciformis is a VERRUCA plana type lesion,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223686,7/15/2014 12:08:15,,1323549758,7/15/2014 12:07:52,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,HYPERKERATOSIS,115,76-84-90-95,VERRUCA plana type lesion,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223686,7/15/2014 12:09:44,,1323550301,7/15/2014 12:09:26,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,115,76,,,129,83,HYPERKERATOSIS,VERRUCA,HYPERKERATOSIS,115,76-84-90-95,VERRUCA plana type lesion,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor.,115,76,115,76,129,83,-1,RO-disease_has_finding,901815,The classic histologic presentation of epidermodysplasia verruciformis is a verruca plana-type lesion with minimal hyperkeratosis and acanthotic areas where the cells contain perinuclear halos and blue-gray pallor,hyperkeratosis,verruca
503223687,7/15/2014 10:24:30,,1323485576,7/15/2014 10:23:35,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"STEVENS JOHNSON SYNDROME,",100-108-116,67-84,HYPERSENSITIVITY reaction,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223687,7/15/2014 10:25:23,,1323486171,7/15/2014 10:25:07,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"STEVENS JOHNSON SYNDROME,",100-108-116,67-84,HYPERSENSITIVITY reaction,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223687,7/15/2014 10:28:39,,1323488328,7/15/2014 10:28:25,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"STEVENS JOHNSON SYNDROME,",100-108-116,67-84,HYPERSENSITIVITY reaction,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223687,7/15/2014 10:46:31,,1323500504,7/15/2014 10:44:00,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"Cautions Contraindications hypersensitivity reaction STEVENS JOHNSON SYNDROME, erythema multiforme, toxic skin eruption) efavirenz",3-13-67-84-100-108-116-126-135-147-153-158-171,3-13-67-84-100-108-116-126-135-147-153-158-171,"Cautions Contraindications HYPERSENSITIVITY reaction Stevens Johnson syndrome, erythema multiforme, toxic skin eruption) efavirenz","1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223687,7/15/2014 10:49:15,,1323502548,7/15/2014 10:49:05,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"STEVENS JOHNSON SYNDROME,",100-108-116,67,HYPERSENSITIVITY,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223687,7/15/2014 10:54:44,,1323506279,7/15/2014 10:54:16,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"STEVENS JOHNSON SYNDROME,",100-108-116,67-84,HYPERSENSITIVITY reaction,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223687,7/15/2014 11:09:26,,1323516881,7/15/2014 11:09:12,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"STEVENS JOHNSON SYNDROME,",100-108-116,67-84,HYPERSENSITIVITY reaction,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223687,7/15/2014 11:22:05,,1323524998,7/15/2014 11:21:30,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"hypersensitivity reaction STEVENS JOHNSON SYNDROME, erythema multiforme, toxic skin eruption)",67-84-100-108-116-126-135-147-153-158,46-57-67-84-100-108-116,"clinically important HYPERSENSITIVITY reaction Stevens Johnson syndrome,","1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223687,7/15/2014 11:41:50,,1323536433,7/15/2014 11:41:18,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"hypersensitivity reaction STEVENS JOHNSON SYNDROME, erythema multiforme, toxic skin eruption) efavirenz",67-84-100-108-116-126-135-147-153-158-171,46-67-84-100-108-116-126-135-147-153-158-171,"clinically HYPERSENSITIVITY reaction Stevens Johnson syndrome, erythema multiforme, toxic skin eruption) efavirenz","1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223687,7/15/2014 11:59:08,,1323546409,7/15/2014 11:58:53,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,100,67,,,124,83,STEVENS-JOHNSON SYNDROME,HYPERSENSITIVITY,"hypersensitivity reaction (e.g., STEVENS JOHNSON SYNDROME,",67-84-93-100-108-116,67-84,HYPERSENSITIVITY reaction,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation.",100 108 116,67,100,67,124,83,-1,RO-cause_of,900450,"1  Cautions  Contraindications  ?  History of clinically important hypersensitivity reaction (e.g., Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption) to efavirenz or any ingredient in the formulation",Stevens-Johnson syndrome,hypersensitivity
503223688,7/15/2014 10:31:14,,1323490006,7/15/2014 10:30:59,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,DIABETIC KETOACIDOSIS;,63-72,35-40-42-51,type 1 DIABETES mellitus,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223688,7/15/2014 11:05:15,,1323512997,7/15/2014 11:05:01,clixsense,1,27969116,NLD,,,91.213.37.165,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,diabetes mellitus or DIABETIC KETOACIDOSIS;,42-51-60-63-72,35-40-42-51-60-63-72,type 1 DIABETES mellitus or diabetic ketoacidosis;,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223688,7/15/2014 11:06:37,,1323514302,7/15/2014 11:06:20,instagc,1,23149109,USA,NC,Durham,75.189.206.205,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,DIABETIC KETOACIDOSIS;,63-72,35-40-42-51,type 1 DIABETES mellitus,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223688,7/15/2014 11:10:03,,1323517352,7/15/2014 11:09:51,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,DIABETIC KETOACIDOSIS;,63-72,35-40-42-51,type 1 DIABETES mellitus,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223688,7/15/2014 11:20:55,,1323524391,7/15/2014 11:20:31,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,diabetes mellitus DIABETIC KETOACIDOSIS;,42-51-63-72,42-51-63-72,DIABETES mellitus diabetic ketoacidosis;,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223688,7/15/2014 11:24:10,,1323526226,7/15/2014 11:23:43,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,type 1 diabetes mellitus DIABETIC KETOACIDOSIS; insulin,35-42-51-63-72-86-40,35-40-42-51-63-72-86,type 1 DIABETES mellitus diabetic ketoacidosis; insulin,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223688,7/15/2014 11:27:03,,1323527735,7/15/2014 11:26:47,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,DIABETIC KETOACIDOSIS;,63-72,42,DIABETES,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223688,7/15/2014 11:32:24,,1323530825,7/15/2014 11:32:08,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,DIABETIC KETOACIDOSIS;,63-72,35-40-42-51,type 1 DIABETES mellitus,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223688,7/15/2014 11:40:39,,1323535625,7/15/2014 11:40:22,prodege,1,6316959,GBR,,,46.208.145.114,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,DIABETIC KETOACIDOSIS;,63-72,35-40-42-51,type 1 DIABETES mellitus,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223688,7/15/2014 11:53:29,,1323543606,7/15/2014 11:53:12,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,63,42,,,84,50,DIABETIC KETOACIDOSIS,DIABETES,DIABETIC KETOACIDOSIS;,63-72,42-51,DIABETES mellitus,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary.,63 72,42,63,42,84,50,-1,RO-cause_of,900005,Not  effective as sole therapy for type 1 diabetes mellitus or diabetic ketoacidosis; insulin is necessary,diabetic ketoacidosis,diabetes
503223689,7/15/2014 10:24:30,,1323485611,7/15/2014 10:24:20,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS,0,21,SVT,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223689,7/15/2014 10:50:52,,1323503621,7/15/2014 10:50:18,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS include SVT (supraventricular tachycardia) VT (ventricular tachycardia.,0-13-21-25-43-60-63-76,21-25-43,SVT (supraventricular tachycardia),Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223689,7/15/2014 11:02:16,,1323510777,7/15/2014 11:02:01,clixsense,1,27969116,NLD,,,91.213.37.165,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS include SVT,0-13-21,0-13-21,Tachycardias include SVT,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223689,7/15/2014 11:03:13,,1323511407,7/15/2014 11:02:56,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS,0,21-25-43,SVT (supraventricular tachycardia),Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223689,7/15/2014 11:11:48,,1323518616,7/15/2014 11:11:38,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS,0,21,SVT,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223689,7/15/2014 11:28:29,,1323528640,7/15/2014 11:28:16,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS,0,21,SVT,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223689,7/15/2014 11:53:52,,1323543831,7/15/2014 11:53:22,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS,0,21,SVT,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223689,7/15/2014 12:00:10,,1323546893,7/15/2014 11:59:49,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS,0,21-25-43,SVT (supraventricular tachycardia),Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223689,7/15/2014 12:04:54,,1323548679,7/15/2014 12:04:31,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS,0,21-25-43,SVT (supraventricular tachycardia),Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223689,7/15/2014 12:07:30,,1323549505,7/15/2014 12:07:23,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,0,21,,,12,24,TACHYCARDIAS,SVT,TACHYCARDIAS,0,21,SVT,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia.,0,21,0,21,12,24,-1,RO-has_definitional_manifestation,904561,Tachycardias include SVT (supraventricular tachycardia) and VT (ventricular tachycardia,Tachycardias,SVT
503223690,7/15/2014 10:19:24,,1323482464,7/15/2014 10:18:59,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,56,0,,,60,12,BONE,OSTEOPOROSIS,favorable effects on BONE size and cortical,35-45-53-56-61-66-70,0-13-25-29,OSTEOPOROSIS medications can exert,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223690,7/15/2014 10:19:59,,1323482872,7/15/2014 10:19:46,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,56,0,,,60,12,BONE,OSTEOPOROSIS,BONE,56,0,OSTEOPOROSIS,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223690,7/15/2014 10:22:57,,1323484763,7/15/2014 10:22:40,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,56,0,,,60,12,BONE,OSTEOPOROSIS,BONE size and cortical thickness.,56-61-66-70-79,0-13,OSTEOPOROSIS medications,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223690,7/15/2014 10:24:07,,1323485376,7/15/2014 10:23:56,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,56,0,,,60,12,BONE,OSTEOPOROSIS,BONE,56,0,OSTEOPOROSIS,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223690,7/15/2014 10:25:43,,1323486327,7/15/2014 10:25:30,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,56,0,,,60,12,BONE,OSTEOPOROSIS,BONE,56,0,OSTEOPOROSIS,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223690,7/15/2014 10:25:44,,1323486341,7/15/2014 10:25:33,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,56,0,,,60,12,BONE,OSTEOPOROSIS,BONE size and cortical thickness.,56-61-66-70-79,0,OSTEOPOROSIS,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223690,7/15/2014 10:47:36,,1323501184,7/15/2014 10:47:26,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,56,0,,,60,12,BONE,OSTEOPOROSIS,BONE,56,0,OSTEOPOROSIS,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223690,7/15/2014 10:56:25,,1323507289,7/15/2014 10:55:34,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,56,0,,,60,12,BONE,OSTEOPOROSIS,BONE,56,0,OSTEOPOROSIS,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223690,7/15/2014 11:15:44,,1323521096,7/15/2014 11:15:29,instagc,1,13763729,USA,,,75.182.89.225,56,0,,,60,12,BONE,OSTEOPOROSIS,BONE size,56-61,0,OSTEOPOROSIS,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223690,7/15/2014 11:20:07,,1323524022,7/15/2014 11:19:56,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,56,0,,,60,12,BONE,OSTEOPOROSIS,Osteoporosis BONE,0-56,0,OSTEOPOROSIS,Osteoporosis medications can exert favorable effects on bone size and cortical thickness.,56,0,56,0,60,12,1,RO-disease_has_primary_anatomic_site,902388,Osteoporosis medications can exert favorable effects on bone size and cortical thickness,bone,Osteoporosis
503223691,7/15/2014 10:21:08,,1323483615,7/15/2014 10:20:50,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,102,56,PHAEOCHROMOCYTOMA,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223691,7/15/2014 10:25:02,,1323485914,7/15/2014 10:24:33,vivatic,1,25451531,GBR,,,83.67.28.193,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,clonidine withdrawal HYPERTENSION,81-91-102,56,PHAEOCHROMOCYTOMA,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223691,7/15/2014 10:25:31,,1323486253,7/15/2014 10:25:17,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,clonidine withdrawal HYPERTENSION,81-91-102,56,PHAEOCHROMOCYTOMA,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223691,7/15/2014 10:34:11,,1323491931,7/15/2014 10:33:42,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,clonidine withdrawal HYPERTENSION,81-91-102,56,PHAEOCHROMOCYTOMA,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223691,7/15/2014 10:34:23,,1323492044,7/15/2014 10:34:10,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,102,56,PHAEOCHROMOCYTOMA,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223691,7/15/2014 10:48:15,,1323501664,7/15/2014 10:47:34,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,phaeochromocytoma clonidine withdrawal HYPERTENSION,56-81-91-102,56-81-91-102,PHAEOCHROMOCYTOMA clonidine withdrawal hypertension,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223691,7/15/2014 10:58:52,,1323508723,7/15/2014 10:58:17,clixsense,1,27969116,NLD,,,91.213.37.165,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,clonidine withdrawal HYPERTENSION,81-91-102,43-53-56,Treatment of PHAEOCHROMOCYTOMA,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223691,7/15/2014 11:02:32,,1323510930,7/15/2014 11:02:12,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,HYPERTENSION,102,56,PHAEOCHROMOCYTOMA,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223691,7/15/2014 11:36:43,,1323533352,7/15/2014 11:36:22,prodege,1,23999031,AUS,8,Perth,203.59.238.194,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,phaeochromocytoma clonidine withdrawal HYPERTENSION,56-81-102-91,56-81-91-102,PHAEOCHROMOCYTOMA clonidine withdrawal hypertension,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223691,7/15/2014 11:50:57,,1323541697,7/15/2014 11:50:33,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,102,56,,,114,73,HYPERTENSION,PHAEOCHROMOCYTOMA,clonidine withdrawal HYPERTENSION,81-91-102,56,PHAEOCHROMOCYTOMA,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol.",102,56,102,56,114,73,-1,RO-disease_may_have_finding,902599,"Agabiti-Rosei E, Brown JJ, Lever AF et al. Treatment of phaeochromocytoma and of clonidine withdrawal hypertension with labetalol",hypertension,phaeochromocytoma
503223692,7/15/2014 10:14:16,,1323478999,7/15/2014 10:14:05,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,KIDNEY,107,168-175,KIDNEY DISEASE.,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223692,7/15/2014 10:21:56,,1323484149,7/15/2014 10:21:09,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,KIDNEY mediated kidney disease.,107-159-168-175,140-143-159-168-175,an immunologically mediated KIDNEY DISEASE.,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223692,7/15/2014 10:27:16,,1323487270,7/15/2014 10:27:02,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,KIDNEY,107,168-175,KIDNEY DISEASE.,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223692,7/15/2014 10:30:23,,1323489370,7/15/2014 10:29:16,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,KIDNEY,107,143-168-175-159,immunologically mediated KIDNEY DISEASE.,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223692,7/15/2014 10:40:57,,1323496397,7/15/2014 10:40:22,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,"dominant idiotypes, KIDNEY immunologically mediated kidney disease.",55-64-107-143-159-168-175,55-107-143-159-168-175-64,"dominant idiotypes, kidney immunologically mediated KIDNEY DISEASE.","In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223692,7/15/2014 11:18:59,,1323523342,7/15/2014 11:18:40,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,KIDNEY immunologically mediated kidney disease.,107-143-159-168-175,143-159-168-175,immunologically mediated KIDNEY DISEASE.,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223692,7/15/2014 11:32:57,,1323531142,7/15/2014 11:32:30,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,"idiotypes, KIDNEY immunologically mediated kidney disease.",64-107-143-159-168-175,64-107-143-159-168-175,"idiotypes, kidney immunologically mediated KIDNEY DISEASE.","In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223692,7/15/2014 11:36:19,,1323533115,7/15/2014 11:36:01,prodege,1,23999031,AUS,8,Perth,203.59.238.194,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,KIDNEY immunologically mediated kidney disease.,107-143-159-168-175,140-143-168-175-159,an immunologically mediated KIDNEY DISEASE.,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223692,7/15/2014 11:41:31,,1323536195,7/15/2014 11:41:12,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,KIDNEY of immunologically,107-123-143,143-168-175,immunologically KIDNEY DISEASE.,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223692,7/15/2014 11:50:00,,1323541018,7/15/2014 11:49:39,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,107,168,,,113,182,KIDNEY,KIDNEY DISEASE,KIDNEY,107,168-175,KIDNEY DISEASE.,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease.",107,168 175,107,168,113,182,1,RO-has_finding_site,905266,"In addition, we studied the species specificity of the dominant idiotypes, by monitoring their presence in kidney sections of patients with an immunologically mediated kidney disease",kidney,kidney disease
503223693,7/15/2014 10:20:54,,1323483521,7/15/2014 10:20:52,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,162,140,,,167,150,FUNGI,EUMYCETOMA,eumycetoma (caused by FUNGI) have a poorer,140-151-159-162-169-174-176,122-128-137-140-159-162,those affected by EUMYCETOMA by fungi),"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223693,7/15/2014 10:23:09,,1323484816,7/15/2014 10:22:47,vivatic,1,25451531,GBR,,,83.67.28.193,162,140,,,167,150,FUNGI,EUMYCETOMA,eumycetoma (caused by FUNGI),140-151-159-162,140-159-162-151,EUMYCETOMA (caused by fungi),"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223693,7/15/2014 10:25:20,,1323486144,7/15/2014 10:24:42,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,162,140,,,167,150,FUNGI,EUMYCETOMA,FUNGI),162,140,EUMYCETOMA,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223693,7/15/2014 10:36:02,,1323493143,7/15/2014 10:35:46,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,162,140,,,167,150,FUNGI,EUMYCETOMA,FUNGI),162,140,EUMYCETOMA,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223693,7/15/2014 10:36:46,,1323493679,7/15/2014 10:36:27,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,162,140,,,167,150,FUNGI,EUMYCETOMA,FUNGI),162,140,EUMYCETOMA,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223693,7/15/2014 10:57:47,,1323508092,7/15/2014 10:57:31,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,162,140,,,167,150,FUNGI,EUMYCETOMA,FUNGI),162,140,EUMYCETOMA,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223693,7/15/2014 11:05:14,,1323512979,7/15/2014 11:05:00,instagc,1,23149109,USA,NC,Durham,75.189.206.205,162,140,,,167,150,FUNGI,EUMYCETOMA,eumycetoma (caused by FUNGI),140-151-159-162,140-159-162-151,EUMYCETOMA (caused by fungi),"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223693,7/15/2014 11:22:55,,1323525469,7/15/2014 11:22:07,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,162,140,,,167,150,FUNGI,EUMYCETOMA,eumycetoma (caused by FUNGI),140-151-159-162,140-159-162-151,EUMYCETOMA (caused by fungi),"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223693,7/15/2014 11:36:27,,1323533177,7/15/2014 11:36:10,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,162,140,,,167,150,FUNGI,EUMYCETOMA,FUNGI),162,140,EUMYCETOMA,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223693,7/15/2014 11:40:05,,1323535333,7/15/2014 11:39:43,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,162,140,,,167,150,FUNGI,EUMYCETOMA,(caused by FUNGI),151-159-162,128-137-140-159-162-151,affected by EUMYCETOMA (caused by fungi),"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy.",162,140,162,140,167,150,1,RO-has_causative_agent,903606,"Although such therapy may cure over half of those with actinomycetoma (caused by bacteria, mainly aerobic actinomycetes), those affected by eumycetoma (caused by fungi) have a poorer prognosis and may require many years of drug therapy",fungi,eumycetoma
503223694,7/15/2014 10:25:09,,1323486031,7/15/2014 10:24:59,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,93,0,,,100,8,ASCITES,HEPATOMA,ASCITES.,93,0,HEPATOMA,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223694,7/15/2014 10:38:36,,1323494755,7/15/2014 10:37:26,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,93,0,,,100,8,ASCITES,HEPATOMA,Hepatoma ASCITES.,0-93,0-93,HEPATOMA ascites.,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223694,7/15/2014 11:01:31,,1323510363,7/15/2014 11:01:20,clixsense,1,27969116,NLD,,,91.213.37.165,93,0,,,100,8,ASCITES,HEPATOMA,presence of ASCITES.,81-90-93,0,HEPATOMA,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223694,7/15/2014 11:03:26,,1323511536,7/15/2014 11:03:15,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,93,0,,,100,8,ASCITES,HEPATOMA,ASCITES.,93,0,HEPATOMA,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223694,7/15/2014 11:06:08,,1323513774,7/15/2014 11:05:44,instagc,1,23149109,USA,NC,Durham,75.189.206.205,93,0,,,100,8,ASCITES,HEPATOMA,presence of ASCITES.,81-90-93,0,HEPATOMA,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223694,7/15/2014 11:28:42,,1323528755,7/15/2014 11:28:22,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,93,0,,,100,8,ASCITES,HEPATOMA,Hepatoma ASCITES.,0-93,0-93,HEPATOMA ascites.,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223694,7/15/2014 11:34:12,,1323531914,7/15/2014 11:33:54,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,93,0,,,100,8,ASCITES,HEPATOMA,Hepatoma ASCITES.,0-93,0-93,HEPATOMA ascites.,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223694,7/15/2014 11:45:38,,1323538490,7/15/2014 11:45:19,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,93,0,,,100,8,ASCITES,HEPATOMA,Hepatoma ASCITES.,93-0,0-93,HEPATOMA ascites.,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223694,7/15/2014 11:57:28,,1323545598,7/15/2014 11:57:16,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,93,0,,,100,8,ASCITES,HEPATOMA,ASCITES.,93,0,HEPATOMA,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223694,7/15/2014 11:57:44,,1323545723,7/15/2014 11:57:31,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,93,0,,,100,8,ASCITES,HEPATOMA,Hepatoma the presence of ASCITES.,77-81-90-93-0,0-9-12-16-24-28-38,HEPATOMA in one patient was correctly identified,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites.",93,0,93,0,100,8,1,RO-disease_may_have_finding,902957,"Hepatoma in one patient was correctly identified by both methods, as well as the presence of ascites",ascites,Hepatoma
503223695,7/15/2014 10:18:46,,1323481944,7/15/2014 10:18:27,vivatic,1,25451531,GBR,,,83.67.28.193,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93,GANCICLOVIR,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223695,7/15/2014 10:19:16,,1323482354,7/15/2014 10:19:00,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93,GANCICLOVIR,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223695,7/15/2014 10:19:45,,1323482718,7/15/2014 10:19:33,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93,GANCICLOVIR,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223695,7/15/2014 10:25:02,,1323485912,7/15/2014 10:24:43,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93,GANCICLOVIR,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223695,7/15/2014 10:29:36,,1323488929,7/15/2014 10:29:04,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93,GANCICLOVIR,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223695,7/15/2014 11:18:26,,1323522937,7/15/2014 11:18:05,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93-123-127,GANCICLOVIR CMV infection,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223695,7/15/2014 11:18:55,,1323523288,7/15/2014 11:18:28,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93,GANCICLOVIR,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223695,7/15/2014 11:29:24,,1323529095,7/15/2014 11:29:07,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93,GANCICLOVIR,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223695,7/15/2014 11:43:55,,1323537706,7/15/2014 11:43:36,prodege,1,6316959,GBR,,,46.208.145.114,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93,GANCICLOVIR,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223695,7/15/2014 11:57:45,,1323545728,7/15/2014 11:57:28,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,123,93,,,136,104,CMV INFECTION,GANCICLOVIR,CMV INFECTION,123-127,93,GANCICLOVIR,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take.,123 127,93,123,93,136,104,1,RO-may_prevent,907219,An example of AIDS research being helpful in the treatment of other conditions is the use of ganciclovir for prevention of CMV infection in transplant patients--who are vulnerable to infections because of the immune-suppressive drugs they must take,CMV infection,ganciclovir
503223696,7/15/2014 10:16:56,,1323480733,7/15/2014 10:15:57,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,383,396,,,394,398,TACHYCARDIA,VT,TACHYCARDIA VT,383-396,396,VT,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223696,7/15/2014 10:59:24,,1323509032,7/15/2014 10:58:47,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,383,396,,,394,398,TACHYCARDIA,VT,SVT supraventricular TACHYCARDIA,359-366-383,396-402-414,VT ventricular tachycardia,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223696,7/15/2014 11:00:37,,1323509739,7/15/2014 11:00:13,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,383,396,,,394,398,TACHYCARDIA,VT,SVT supraventricular TACHYCARDIA,359-366-383,359-396-402-414,SVT VT ventricular tachycardia,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223696,7/15/2014 11:45:06,,1323538202,7/15/2014 11:44:04,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,383,396,,,394,398,TACHYCARDIA,VT,sudden cardiac death SVT supraventricular TACHYCARDIA VT ventricular tachycardia WPW  Wolff - Parkinson - White syndrome,337-344-352-359-366-383-396-402-414-427-432-434-439-440-449-450-456,337-344-352-359-364-366-383-396-402-414-427-432-434-439-440-449-450-456,sudden cardiac death SVT  supraventricular tachycardia VT ventricular tachycardia WPW  Wolff - Parkinson - White syndrome,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223696,7/15/2014 11:56:39,,1323545217,7/15/2014 11:56:24,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,383,396,,,394,398,TACHYCARDIA,VT,TACHYCARDIA,383,396,VT,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223696,7/15/2014 11:58:25,,1323546122,7/15/2014 11:58:07,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,383,396,,,394,398,TACHYCARDIA,VT,supraventricular TACHYCARDIA VT,366-383-396,366-383-396,supraventricular tachycardia VT,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223696,7/15/2014 12:00:14,,1323546902,7/15/2014 11:59:37,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,383,396,,,394,398,TACHYCARDIA,VT,SVT supraventricular TACHYCARDIA,359-366-383,396-402-414,VT ventricular tachycardia,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223696,7/15/2014 12:03:44,,1323548228,7/15/2014 12:03:14,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,383,396,,,394,398,TACHYCARDIA,VT,SVT supraventricular TACHYCARDIA VT ventricular tachycardia,359-366-383-396-402-414,359-366-383-396-402-414-427-434-440-450-456,SVT supraventricular tachycardia VT ventricular tachycardia WPW Wolff Parkinson White syndrome,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223696,7/15/2014 12:05:26,,1323548825,7/15/2014 12:05:05,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,383,396,,,394,398,TACHYCARDIA,VT,supraventricular TACHYCARDIA,366-383,366-383-396-402-414-427,supraventricular tachycardia VT ventricular tachycardia WPW,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223696,7/15/2014 12:08:19,,1323549784,7/15/2014 12:07:45,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,383,396,,,394,398,TACHYCARDIA,VT,SVT supraventricular TACHYCARDIA,359-366-383,396-402-414,VT ventricular tachycardia,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American.,383,396,383,396,394,398,-1,RO-has_definitional_manifestation,904759,atrial enlargement  LBBB  - left bundle-branch block  LV  - left ventricle  LVH  - left ventricular hypertrophy  MI  - myocardial infarction  OR  - odds ratio  QTc  - QT corrected for heart rate  RBBB  - right bundle-branch block  RCA  - right coronary artery  RV  - right ventricular  SAECG  - signal-averaged electrocardiogram  SCD  - sudden cardiac death  SVT  - supraventricular tachycardia  VT  - ventricular tachycardia  WPW  - Wolff-Parkinson-White syndrome  ACC/AHA  - American College of Cardiology/American Heart Association  AHA  - American,tachycardia,VT
503223697,7/15/2014 10:19:31,,1323482546,7/15/2014 10:19:29,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,disease of the SKIN and mucous membranes,47-55-58-62-67-71-78,0-10-19-22-25,PEMPHIGUS VULGARIS is an autoimmune,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223697,7/15/2014 10:28:21,,1323488167,7/15/2014 10:28:07,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,SKIN,62,0-10,PEMPHIGUS VULGARIS,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223697,7/15/2014 10:37:12,,1323493874,7/15/2014 10:37:01,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,SKIN,62,0-10,PEMPHIGUS VULGARIS,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223697,7/15/2014 11:04:08,,1323512021,7/15/2014 11:03:55,clixsense,1,27969116,NLD,,,91.213.37.165,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,disease of the SKIN and mucous membranes,47-55-58-62-67-71-78,0-10-19-22-25-36-47,PEMPHIGUS VULGARIS is an autoimmune blistering disease,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223697,7/15/2014 11:12:05,,1323518829,7/15/2014 11:10:45,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,Pemphigus vulgaris autoimmune blistering disease of the SKIN mucous membranes anti desmoglein,0-10-25-36-47-55-58-62-71-78-106-111,0-10-25-36-47-55-58-71-78-106-111,PEMPHIGUS VULGARIS autoimmune blistering disease of the mucous membranes anti desmoglein,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223697,7/15/2014 11:17:21,,1323522249,7/15/2014 11:16:56,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,autoimmune blistering disease of the SKIN and mucous membranes,25-47-55-58-62-67-71-78-36,0-10-19-22-25-36-47-55-58-62-67-71-78,PEMPHIGUS VULGARIS is an autoimmune blistering disease of the skin and mucous membranes,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223697,7/15/2014 11:57:43,,1323545703,7/15/2014 11:57:29,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,disease of the SKIN,47-55-58-62,0-10,PEMPHIGUS VULGARIS,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223697,7/15/2014 12:00:51,,1323547195,7/15/2014 12:00:44,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,disease of the SKIN,47-55-58-62,0-10-19-22-25-36-47,PEMPHIGUS VULGARIS is an autoimmune blistering disease,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223697,7/15/2014 12:05:49,,1323548950,7/15/2014 12:05:14,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,autoimmune blistering disease of the SKIN and mucous membranes,25-47-55-58-62-67-71-78-36,0-10,PEMPHIGUS VULGARIS,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223697,7/15/2014 12:07:28,,1323549483,7/15/2014 12:07:03,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,62,0,,,66,18,SKIN,PEMPHIGUS VULGARIS,disease of the SKIN and mucous membranes,47-55-58-62-67-71-78,0-10,PEMPHIGUS VULGARIS,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies.,62,0 10,62,0,66,18,1,RO-disease_has_primary_anatomic_site,902397,Pemphigus vulgaris is an autoimmune blistering disease of the skin and mucous membranes that is caused by anti-desmoglein 3 IgG autoantibodies,skin,Pemphigus vulgaris
503223698,7/15/2014 10:33:51,,1323491712,7/15/2014 10:33:36,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,32,81,,,40,91,BACTERIA,BACTEREMIA,BACTERIA,32,81,"BACTEREMIA,","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223698,7/15/2014 10:46:01,,1323500126,7/15/2014 10:45:41,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,32,81,,,40,91,BACTERIA,BACTEREMIA,BACTERIA,32,81,"BACTEREMIA,","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223698,7/15/2014 11:01:49,,1323510512,7/15/2014 11:01:23,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,32,81,,,40,91,BACTERIA,BACTEREMIA,BACTERIA,32,71-74-81,"S. panama BACTEREMIA,","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223698,7/15/2014 11:03:01,,1323511229,7/15/2014 11:02:46,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,32,81,,,40,91,BACTERIA,BACTEREMIA,BACTERIA,32,71-74-81,"S. panama BACTEREMIA,","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223698,7/15/2014 11:08:47,,1323516263,7/15/2014 11:08:37,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,32,81,,,40,91,BACTERIA,BACTEREMIA,BACTERIA,32,71-74-81,"S. panama BACTEREMIA,","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223698,7/15/2014 11:35:32,,1323532726,7/15/2014 11:34:52,prodege,1,23999031,AUS,8,Perth,203.59.238.194,32,81,,,40,91,BACTERIA,BACTEREMIA,"BACTERIA acute urinary tract infections recurrent urinary tract infection,",32-181-187-195-201-233-241-247-223,81-181-187-195-201-223-233-247-241,"BACTEREMIA, acute urinary tract infections recurrent urinary tract infection,","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223698,7/15/2014 11:37:12,,1323533605,7/15/2014 11:36:04,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,32,81,,,40,91,BACTERIA,BACTEREMIA,"bacteriological efficacy, BACTERIA S. panama bacteremia, CTRX administration tract infections recurrent urinary tract infection, E. coli, acute urinary tract infection P. mirabilis.",6-22-32-71-74-81-145-150-195-201-223-233-241-247-275-278-304-312-318-333-336-298,6-22-32-71-74-81-145-150-201-223-233-241-247-275-278-304-312-318-333-336-298,"bacteriological efficacy, bacteria S. panama BACTEREMIA, CTRX administration infections recurrent urinary tract infection, E. coli, acute urinary tract infection P. mirabilis.","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223698,7/15/2014 11:43:11,,1323537210,7/15/2014 11:42:47,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,32,81,,,40,91,BACTERIA,BACTEREMIA,bacteriological BACTERIA CTRX,6-32-145,81-145,"BACTEREMIA, CTRX","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223698,7/15/2014 11:44:27,,1323537916,7/15/2014 11:44:06,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,32,81,,,40,91,BACTERIA,BACTEREMIA,BACTERIA,32,81,"BACTEREMIA,","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223698,7/15/2014 11:44:36,,1323538025,7/15/2014 11:44:18,prodege,1,6316959,GBR,,,46.208.145.114,32,81,,,40,91,BACTERIA,BACTEREMIA,BACTERIA,32,71-74-81,"S. panama BACTEREMIA,","As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis.",32,81,32,81,40,91,-1,RO-has_causative_agent,903807,"As to bacteriological efficacy, bacteria were reduced in the case with S. panama bacteremia, while they were eradicated within 2 to 5 days after CTRX administration in 2 cases with acute urinary tract infections and 1 with recurrent urinary tract infection, both caused with E. coli, and in 1 with acute urinary tract infection with P. mirabilis",bacteria,bacteremia
503223699,7/15/2014 10:20:18,,1323483051,7/15/2014 10:20:15,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,5,40,,,9,55,PAIN,ANGINA PECTORIS,Such PAIN may be indistinguishable,0-5-10-14-17,14-17-35-40-47,be indistinguishable from ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223699,7/15/2014 10:27:26,,1323487397,7/15/2014 10:27:15,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,5,40,,,9,55,PAIN,ANGINA PECTORIS,PAIN,5,40-47,ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223699,7/15/2014 11:05:13,,1323512976,7/15/2014 11:04:51,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,5,40,,,9,55,PAIN,ANGINA PECTORIS,PAIN indistinguishable angina pectoris.,5-17-40-47,5-17-40-47,pain indistinguishable ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223699,7/15/2014 11:07:20,,1323514985,7/15/2014 11:07:08,instagc,1,23149109,USA,NC,Durham,75.189.206.205,5,40,,,9,55,PAIN,ANGINA PECTORIS,PAIN,5,40-47,ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223699,7/15/2014 11:09:41,,1323517089,7/15/2014 11:09:30,instagc,1,13763729,USA,,,75.182.89.225,5,40,,,9,55,PAIN,ANGINA PECTORIS,PAIN,5,40-47,ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223699,7/15/2014 11:28:14,,1323528540,7/15/2014 11:28:00,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,5,40,,,9,55,PAIN,ANGINA PECTORIS,PAIN,5,40-47,ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223699,7/15/2014 11:30:45,,1323529894,7/15/2014 11:29:18,prodege,1,23999031,AUS,8,Perth,203.59.238.194,5,40,,,9,55,PAIN,ANGINA PECTORIS,PAIN angina pectoris.,5-47-40,40-47,ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223699,7/15/2014 11:59:44,,1323546759,7/15/2014 11:59:32,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,5,40,,,9,55,PAIN,ANGINA PECTORIS,PAIN,5,40-47,ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223699,7/15/2014 12:03:38,,1323548178,7/15/2014 12:03:24,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,5,40,,,9,55,PAIN,ANGINA PECTORIS,PAIN,5,40-47,ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223699,7/15/2014 12:03:52,,1323548277,7/15/2014 12:03:42,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,5,40,,,9,55,PAIN,ANGINA PECTORIS,PAIN may be indistinguishable,5-10-14-17,5-14-17-35-40-47-10,pain may be indistinguishable from ANGINA PECTORIS.,Such pain may be indistinguishable from angina pectoris.,5,40 47,5,40,9,55,-1,RO-has_definitional_manifestation,904812,Such pain may be indistinguishable from angina pectoris,pain,angina pectoris
503223700,7/15/2014 10:20:46,,1323483369,7/15/2014 10:20:16,vivatic,1,25451531,GBR,,,83.67.28.193,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,"a complex of somatic abnormalities, termed ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO.",29-31-39-42-50-65-72-81-92-107,14-18,PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223700,7/15/2014 10:22:27,,1323484472,7/15/2014 10:22:13,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO.,72-81-92-107,14-18,PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223700,7/15/2014 10:26:45,,1323486974,7/15/2014 10:26:31,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,ALBRIGHT HEREDITARY OSTEODYSTROPHY,72-81-92,14-18,PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223700,7/15/2014 10:30:05,,1323489202,7/15/2014 10:29:51,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO.,72-81-92-107,14-18,PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223700,7/15/2014 10:32:29,,1323490842,7/15/2014 10:32:16,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO.,72-81-92-107,14-18,PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223700,7/15/2014 10:39:31,,1323495545,7/15/2014 10:39:20,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,ALBRIGHT HEREDITARY OSTEODYSTROPHY,72-81-92,14-18,PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223700,7/15/2014 11:03:21,,1323511471,7/15/2014 11:02:56,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,ALBRIGHT HEREDITARY OSTEODYSTROPHY (AHO.,72-81-92-107,14-18,PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223700,7/15/2014 11:03:57,,1323511899,7/15/2014 11:03:25,instagc,1,23149109,USA,NC,Durham,75.189.206.205,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,termed ALBRIGHT HEREDITARY OSTEODYSTROPHY,72-81-92-65,0-14-18-9,Patients with PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223700,7/15/2014 11:10:58,,1323517994,7/15/2014 11:10:43,instagc,1,13763729,USA,,,75.182.89.225,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,ALBRIGHT HEREDITARY OSTEODYSTROPHY,72-81-92,14-18,PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223700,7/15/2014 11:12:49,,1323519346,7/15/2014 11:12:34,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,72,14,,,106,20,ALBRIGHT HEREDITARY OSTEODYSTROPHY,PHP IA,ALBRIGHT HEREDITARY OSTEODYSTROPHY,72-81-92,14-18,PHP IA,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO.",72 81 92,14 18,72,14,106,20,-1,RO-has_manifestation,906061,"Patients with PHP Ia exhibit a complex of somatic abnormalities, termed Albright hereditary osteodystrophy (AHO",Albright hereditary osteodystrophy,PHP Ia
503223701,7/15/2014 10:27:11,,1323487238,7/15/2014 10:27:00,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,53,8,,,59,19,ASTHMA,MONTELUKAST,"ASTHMA,",53,8,MONTELUKAST,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223701,7/15/2014 10:55:56,,1323507030,7/15/2014 10:55:43,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,53,8,,,59,19,ASTHMA,MONTELUKAST,"ASTHMA,",53,8,MONTELUKAST,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223701,7/15/2014 11:02:21,,1323510813,7/15/2014 11:01:52,instagc,1,23149109,USA,NC,Durham,75.189.206.205,53,8,,,59,19,ASTHMA,MONTELUKAST,"patients with ASTHMA,",39-48-53,8,MONTELUKAST,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223701,7/15/2014 11:23:14,,1323525666,7/15/2014 11:22:59,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,53,8,,,59,19,ASTHMA,MONTELUKAST,"ASTHMA,",53,8,MONTELUKAST,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223701,7/15/2014 11:43:09,,1323537205,7/15/2014 11:42:46,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,53,8,,,59,19,ASTHMA,MONTELUKAST,"ASTHMA,",53,8-20-23,MONTELUKAST is efficacious,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223701,7/15/2014 11:58:22,,1323546073,7/15/2014 11:58:09,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,53,8,,,59,19,ASTHMA,MONTELUKAST,"ASTHMA,",53,8,MONTELUKAST,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223701,7/15/2014 12:01:20,,1323547375,7/15/2014 12:01:07,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,53,8,,,59,19,ASTHMA,MONTELUKAST,"for patients with ASTHMA,",35-39-48-53,8-20-23-35-39-48-53,"MONTELUKAST is efficacious for patients with asthma,","Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223701,7/15/2014 12:01:22,,1323547376,7/15/2014 12:01:04,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,53,8,,,59,19,ASTHMA,MONTELUKAST,"ASTHMA,",53,8,MONTELUKAST,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223701,7/15/2014 12:01:54,,1323547613,7/15/2014 12:01:40,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,53,8,,,59,19,ASTHMA,MONTELUKAST,"ASTHMA,",53,8,MONTELUKAST,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223701,7/15/2014 12:10:32,,1323550588,7/15/2014 12:10:13,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,53,8,,,59,19,ASTHMA,MONTELUKAST,"ASTHMA,",53,8,MONTELUKAST,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast.",53,8,53,8,59,19,1,RO-may_treat,907799,"Because montelukast is efficacious for patients with asthma, selected patients with mild asthma and rhinitis may be good candidates for montelukast",asthma,montelukast
503223702,7/15/2014 10:26:29,,1323486799,7/15/2014 10:26:18,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,84,28,,,89,34,BRAIN,STROKE,BRAIN.,84,28,STROKE,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223702,7/15/2014 10:30:33,,1323489495,7/15/2014 10:30:22,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,84,28,,,89,34,BRAIN,STROKE,BRAIN.,84,28,STROKE,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223702,7/15/2014 10:36:15,,1323493321,7/15/2014 10:35:49,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,84,28,,,89,34,BRAIN,STROKE,stroke vascular abnormalities BRAIN.,54-63-84-28,28-54-63-84,STROKE vascular abnormalities brain.,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223702,7/15/2014 10:39:19,,1323495390,7/15/2014 10:39:07,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,84,28,,,89,34,BRAIN,STROKE,BRAIN.,84,28,STROKE,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223702,7/15/2014 10:51:57,,1323504510,7/15/2014 10:50:52,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,84,28,,,89,34,BRAIN,STROKE,vascular BRAIN.,84-54,28-54-63,STROKE vascular abnormalities,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223702,7/15/2014 11:10:58,,1323518003,7/15/2014 11:10:48,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,84,28,,,89,34,BRAIN,STROKE,BRAIN.,84,28,STROKE,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223702,7/15/2014 11:34:18,,1323531998,7/15/2014 11:33:59,prodege,1,23999031,AUS,8,Perth,203.59.238.194,84,28,,,89,34,BRAIN,STROKE,stroke the BRAIN.,28-80-84,28,STROKE,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223702,7/15/2014 11:58:32,,1323546185,7/15/2014 11:58:13,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,84,28,,,89,34,BRAIN,STROKE,BRAIN.,84,28,STROKE,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223702,7/15/2014 12:04:15,,1323548419,7/15/2014 12:04:02,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,84,28,,,89,34,BRAIN,STROKE,abnormalities in the BRAIN.,63-77-80-84,28,STROKE,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223702,7/15/2014 12:05:13,,1323548749,7/15/2014 12:04:55,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,84,28,,,89,34,BRAIN,STROKE,vascular abnormalities in the BRAIN.,63-77-80-84-54,28,STROKE,In most of the patients the stroke came as a debut of vascular abnormalities in the brain.,84,28,84,28,89,34,1,RO-disease_has_primary_anatomic_site,902042,In most of the patients the stroke came as a debut of vascular abnormalities in the brain,brain,stroke
503223703,7/15/2014 10:25:28,,1323486202,7/15/2014 10:25:03,vivatic,1,25451531,GBR,,,83.67.28.193,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,NICOTINE,151,33-42,NICOTINE DEPENDENCE,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223703,7/15/2014 10:30:41,,1323489617,7/15/2014 10:30:24,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,NICOTINE,151,33-42,NICOTINE DEPENDENCE,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223703,7/15/2014 11:02:52,,1323511133,7/15/2014 11:02:30,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,NICOTINE,151,33-42,NICOTINE DEPENDENCE,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223703,7/15/2014 11:02:54,,1323511140,7/15/2014 11:02:35,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,NICOTINE,151,33-42,NICOTINE DEPENDENCE,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223703,7/15/2014 11:19:19,,1323523556,7/15/2014 11:18:36,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,NICOTINE ameliorate,151-170,33-42-170,NICOTINE DEPENDENCE ameliorate,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223703,7/15/2014 11:30:38,,1323529840,7/15/2014 11:30:11,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,nicotine dependence NICOTINE,33-42-151,33-42-151,NICOTINE DEPENDENCE nicotine,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223703,7/15/2014 11:38:45,,1323534607,7/15/2014 11:38:21,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,nicotine NICOTINE ameliorate,151-170-33,33-42-151-170,NICOTINE DEPENDENCE nicotine ameliorate,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223703,7/15/2014 11:46:08,,1323538818,7/15/2014 11:45:45,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,NICOTINE,151,33-42,NICOTINE DEPENDENCE,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223703,7/15/2014 11:56:23,,1323545033,7/15/2014 11:56:04,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,NICOTINE use,151-160,33-42,NICOTINE DEPENDENCE,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223703,7/15/2014 11:58:47,,1323546302,7/15/2014 11:57:58,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,151,33,,,159,52,NICOTINE,NICOTINE DEPENDENCE,NICOTINE,151,33-42,NICOTINE DEPENDENCE,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect.,151,33 42,151,33,159,52,1,RO-has_causative_agent,903738,An affective model suggests that nicotine dependence should be related to an individual's tendency to experience negative affect and expectations that nicotine use would ameliorate such affect,nicotine,nicotine dependence
503223704,7/15/2014 10:28:53,,1323488510,7/15/2014 10:28:19,bitcoinget,1,24792414,USA,,,166.181.81.37,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,unpigmented SKIN sites,74-86-91,111-123,"INTRADERMAL NEVUS,","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223704,7/15/2014 10:45:16,,1323499531,7/15/2014 10:45:03,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,SKIN,86,111-123,"INTRADERMAL NEVUS,","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223704,7/15/2014 11:08:25,,1323515959,7/15/2014 11:08:12,instagc,1,23149109,USA,NC,Durham,75.189.206.205,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,unpigmented SKIN sites,74-86-91,97-111-123,"[nonpigmented INTRADERMAL NEVUS,","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223704,7/15/2014 11:10:32,,1323517688,7/15/2014 11:09:35,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,"pigmented skin sites pigmented nevi) unpigmented SKIN sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",15-25-30-54-64-74-86-91-97-111-123-130-144-152-163-173-179-184-195-204-209-220-229-241-249-256-261,15-25-30-54-64-86-91-97-111-123-130-144-152-163-173-179-184-195-204-209-220-229-241-249-256-261-74,"pigmented skin sites pigmented nevi) unpigmented skin sites [nonpigmented INTRADERMAL NEVUS, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223704,7/15/2014 11:13:58,,1323520103,7/15/2014 11:13:33,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,"SKIN malignant basal cell carcinoma,",86-163-173-179-184,111-123-163-173-179-184,"INTRADERMAL NEVUS, malignant basal cell carcinoma,","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223704,7/15/2014 11:35:44,,1323532783,7/15/2014 11:35:10,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,SKIN,86,111-123-97,"[nonpigmented INTRADERMAL NEVUS,","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223704,7/15/2014 11:36:11,,1323533066,7/15/2014 11:35:51,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,"pigmented SKIN carcinoma, carcinoma,",15-86-209-184,111-123-130-144-152-184-195,"INTRADERMAL NEVUS, neurofibroma, actinic keratosis, carcinoma, squamous","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223704,7/15/2014 11:39:42,,1323535066,7/15/2014 11:39:07,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,unpigmented SKIN sites,74-86-91,111-123-130-144-152-163-173-179-184-195-204-209-220-229-241-249-256-261,"INTRADERMAL NEVUS, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223704,7/15/2014 11:59:59,,1323546833,7/15/2014 11:59:45,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,SKIN,86,111-123,"INTRADERMAL NEVUS,","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223704,7/15/2014 12:08:04,,1323549688,7/15/2014 12:07:47,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,86,111,,,90,128,SKIN,INTRADERMAL NEVUS,unpigmented SKIN,86-74,111-123,"INTRADERMAL NEVUS,","Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar.",86,111 123,86,111,90,128,1,RO-has_finding_site,905150,"Images include pigmented skin sites (freckle, tattoo, pigmented nevi) and unpigmented skin sites [nonpigmented intradermal nevus, neurofibroma, actinic keratosis, malignant basal cell carcinoma, squamous cell carcinoma, vascular abnormality (venous lake), burn scar",skin,intradermal nevus
503223705,7/15/2014 10:16:36,,1323480450,7/15/2014 10:16:21,vivatic,1,25451531,GBR,,,83.67.28.193,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS,72-82,105-110,oral METRONIDAZOLE,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223705,7/15/2014 10:20:47,,1323483385,7/15/2014 10:20:15,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS,72-82,110,METRONIDAZOLE,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223705,7/15/2014 10:34:09,,1323491923,7/15/2014 10:33:57,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS,72-82,110-124-128-136,METRONIDAZOLE and topical clindamycin.,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223705,7/15/2014 10:53:10,,1323505244,7/15/2014 10:52:41,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS oral metronidazole topical clindamycin.,72-82-105-110-128-136,82-105-110-128-136-72,bacterial vaginosis oral METRONIDAZOLE topical clindamycin.,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223705,7/15/2014 11:00:11,,1323509567,7/15/2014 10:59:50,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS,72-82,110-105,oral METRONIDAZOLE,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223705,7/15/2014 11:04:30,,1323512350,7/15/2014 11:04:13,instagc,1,23149109,USA,NC,Durham,75.189.206.205,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS,72-82,105-110-124-128-136,oral METRONIDAZOLE and topical clindamycin.,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223705,7/15/2014 11:09:29,,1323516926,7/15/2014 11:09:15,instagc,1,13763729,USA,,,75.182.89.225,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS,72-82,110,METRONIDAZOLE,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223705,7/15/2014 11:19:55,,1323523904,7/15/2014 11:19:39,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS,72-82,72-82-110,bacterial vaginosis METRONIDAZOLE,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223705,7/15/2014 11:21:28,,1323524684,7/15/2014 11:20:30,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS oral metronidazole topical clindamycin.,72-82-105-110-128-136,72-82-105-110-128-136,bacterial vaginosis oral METRONIDAZOLE topical clindamycin.,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223705,7/15/2014 11:23:31,,1323525792,7/15/2014 11:23:15,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,72,110,,,91,123,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS,72-82,110,METRONIDAZOLE,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.",72 82,110,72,110,91,123,1,RO-may_treat,907961,"Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin",bacterial vaginosis,metronidazole
503223706,7/15/2014 10:18:59,,1323482200,7/15/2014 10:18:27,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,344,382,,,357,386,TIC DISORDERS,TICS,OCD TIC DISORDERS,340-344-348,376-382,vocal TICS,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223706,7/15/2014 10:20:00,,1323482873,7/15/2014 10:19:51,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,344,382,,,357,386,TIC DISORDERS,TICS,TIC DISORDERS,344-348,382,TICS,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223706,7/15/2014 10:20:16,,1323483030,7/15/2014 10:19:53,vivatic,1,25451531,GBR,,,83.67.28.193,344,382,,,357,386,TIC DISORDERS,TICS,OCD TIC DISORDERS,340-344-348,376-382,vocal TICS,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223706,7/15/2014 10:24:43,,1323485683,7/15/2014 10:24:26,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,344,382,,,357,386,TIC DISORDERS,TICS,OCD TIC DISORDERS,340-344-348,382,TICS,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223706,7/15/2014 10:29:36,,1323488884,7/15/2014 10:29:18,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,344,382,,,357,386,TIC DISORDERS,TICS,OCD TIC DISORDERS,340-344-348,382,TICS,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223706,7/15/2014 11:14:14,,1323520217,7/15/2014 11:13:45,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,344,382,,,357,386,TIC DISORDERS,TICS,OCD TIC DISORDERS Complex motor,340-344-348-359-367,359-367-373-376-382-388,Complex motor or vocal TICS Tics,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223706,7/15/2014 11:15:59,,1323521247,7/15/2014 11:15:09,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,344,382,,,357,386,TIC DISORDERS,TICS,Hypochondriasis Fear OCD TIC DISORDERS Complex motor vocal tics,86-103-340-344-348-359-367-376-382,86-340-344-348-359-367-373-376-382-388-464-103,Hypochondriasis Fear OCD Tic disorders Complex motor or vocal TICS Tics discomfort.,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223706,7/15/2014 11:24:46,,1323526547,7/15/2014 11:24:29,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,344,382,,,357,386,TIC DISORDERS,TICS,TIC DISORDERS,344-348,382,TICS,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223706,7/15/2014 11:32:29,,1323530859,7/15/2014 11:31:34,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,344,382,,,357,386,TIC DISORDERS,TICS,Hypochondriasis OCD TIC DISORDERS Complex motor or vocal tics Tics,86-340-344-348-367-373-376-382-388-359,86-340-344-348-359-367-373-376-382-388,Hypochondriasis OCD Tic disorders Complex motor or vocal TICS Tics,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223706,7/15/2014 12:01:11,,1323547343,7/15/2014 12:00:34,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,344,382,,,357,386,TIC DISORDERS,TICS,OCD TIC DISORDERS,340-344-348,359-367-373-376-382,Complex motor or vocal TICS,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort.",344 348,382,344,382,357,386,-1,RO-has_definitional_manifestation,904813,"In addition, attacks of panic disorder are often independent of any triggering events Hypochondriasis  Fear of serious disease in response to misinterpreted physical signs or symptoms  Disturbing thoughts of illness and urges to seek medical tests and care are not resisted, in contrast to the typical resistance to the compulsive urges of OCD Tic disorders  Complex motor or vocal tics  Tics are purposeless and may be preceded by premonitory tension or physical discomfort",Tic disorders,tics
503223707,7/15/2014 10:22:58,,1323484774,7/15/2014 10:22:47,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,type III (GSD III),25-30-34-39,0-9-17-25-30,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223707,7/15/2014 10:35:02,,1323492520,7/15/2014 10:34:49,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,type III (GSD III),25-30-34-39,0-9-17-25-30,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223707,7/15/2014 10:47:33,,1323501134,7/15/2014 10:47:05,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III) is an inborn,0-9-25-30-34-39-44-47-50-17,0-9-17-25-30-39-44-34,GLYCOGEN STORAGE DISEASE TYPE III (GSD III) is,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223707,7/15/2014 11:00:48,,1323509789,7/15/2014 11:00:10,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III) glycogen metabolism glycogen debranching enzyme,0-9-17-25-34-39-66-75-112-121-133-30,0-9-17-25-30-39-44-66-75-112-121-133,GLYCOGEN STORAGE DISEASE TYPE III III) is glycogen metabolism glycogen debranching enzyme,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223707,7/15/2014 11:01:51,,1323510540,7/15/2014 11:01:04,instagc,1,23149109,USA,NC,Durham,75.189.206.205,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III),0-9-17-25-30-34-39,0-9-17-25-30-34-39,GLYCOGEN STORAGE DISEASE TYPE III (GSD III),Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223707,7/15/2014 11:21:15,,1323524587,7/15/2014 11:20:56,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III III),0-9-17-25-39-30,0-9-17-25-30,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223707,7/15/2014 11:23:10,,1323525625,7/15/2014 11:22:35,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III) glycogen metabolism glycogen enzyme (AGL.,0-9-17-25-30-34-39-66-75-112-133-140,0-9-17-25-30-34-39-44-66-75-112-121-133-140,GLYCOGEN STORAGE DISEASE TYPE III (GSD III) is glycogen metabolism glycogen debranching enzyme (AGL.,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223707,7/15/2014 11:30:10,,1323529566,7/15/2014 11:29:34,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III) glycogen metabolism deficiency glycogen debranching enzyme (AGL.,0-9-17-25-30-39-66-75-98-112-121-133-140-34,0-9-17-25-30-34-39-66-75-98-112-121-133-140,GLYCOGEN STORAGE DISEASE TYPE III (GSD III) glycogen metabolism deficiency glycogen debranching enzyme (AGL.,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223707,7/15/2014 11:37:53,,1323534042,7/15/2014 11:37:29,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,(GSD III),34-39,0-9-17-25-30,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223707,7/15/2014 11:38:27,,1323534423,7/15/2014 11:37:57,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,35,0,,,42,33,GSD III,GLYCOGEN STORAGE DISEASE TYPE III,Glycogen storage disease type III (GSD III),0-9-17-25-34-39-30,0-9-17-25-30-34-39,GLYCOGEN STORAGE DISEASE TYPE III (GSD III),Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL.,39,0 9 17 25 30,35,0,42,33,-1,RO-has_manifestation,906338,Glycogen storage disease type III (GSD III) is an inborn error of glycogen metabolism caused by a deficiency of glycogen debranching enzyme (AGL,GSD III,Glycogen storage disease type III
503223708,7/15/2014 10:24:42,,1323485679,7/15/2014 10:24:31,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,54,HALOTHANE,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223708,7/15/2014 10:28:12,,1323488022,7/15/2014 10:28:00,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,54,HALOTHANE,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223708,7/15/2014 10:33:42,,1323491568,7/15/2014 10:33:25,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,54-64,HALOTHANE challenge,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223708,7/15/2014 10:33:49,,1323491646,7/15/2014 10:33:38,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,54,HALOTHANE,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223708,7/15/2014 10:37:40,,1323494123,7/15/2014 10:37:27,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,54,HALOTHANE,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223708,7/15/2014 10:49:52,,1323502963,7/15/2014 10:49:42,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,54,HALOTHANE,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223708,7/15/2014 11:01:11,,1323510147,7/15/2014 11:01:03,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,54,HALOTHANE,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223708,7/15/2014 11:04:00,,1323511914,7/15/2014 11:03:43,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,54,HALOTHANE,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223708,7/15/2014 11:10:28,,1323517585,7/15/2014 11:10:15,instagc,1,13763729,USA,,,75.182.89.225,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,54,HALOTHANE,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223708,7/15/2014 11:14:54,,1323520617,7/15/2014 11:13:59,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,0,54,,,22,63,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,0-10,0-10-54,Malignant hyperthermia HALOTHANE,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs.,0 10,54,0,54,22,63,1,RO-may_diagnose,906665,Malignant hyperthermia susceptibility was assessed by halothane challenge of pigs,Malignant hyperthermia,halothane
503223709,7/15/2014 10:16:50,,1323480651,7/15/2014 10:16:39,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",69,134,TUBERCULIN,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223709,7/15/2014 10:18:00,,1323481379,7/15/2014 10:17:27,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",69,134,TUBERCULIN,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223709,7/15/2014 10:18:38,,1323481862,7/15/2014 10:18:36,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"low prevalence of TUBERCULOSIS, primary prophylaxis should",51-55-66-69-83-91-103,113-121-131-134-145-154-157,offered primarily to TUBERCULIN positive or anergic,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223709,7/15/2014 10:21:03,,1323483600,7/15/2014 10:20:40,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",69,134,TUBERCULIN,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223709,7/15/2014 10:28:58,,1323488570,7/15/2014 10:28:40,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",69,134,TUBERCULIN,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223709,7/15/2014 10:44:54,,1323499249,7/15/2014 10:44:40,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",69,134,TUBERCULIN,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223709,7/15/2014 11:00:34,,1323509708,7/15/2014 11:00:12,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",69,134,TUBERCULIN,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223709,7/15/2014 11:12:17,,1323518969,7/15/2014 11:12:02,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",69,134,TUBERCULIN,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223709,7/15/2014 11:13:09,,1323519544,7/15/2014 11:12:53,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS,",69,69-134,"tuberculosis, TUBERCULIN","We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223709,7/15/2014 11:14:51,,1323520566,7/15/2014 11:14:16,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,69,134,,,81,144,TUBERCULOSIS,TUBERCULIN,"TUBERCULOSIS, primary prophylaxis",69-83-91,134-145-154-157-165,TUBERCULIN positive or anergic patients,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance.",69,134,69,134,81,144,1,RO-may_diagnose,906813,"We suggest that in a country such as the UK with a low prevalence of tuberculosis, primary prophylaxis should be offered primarily to tuberculin positive or anergic patients from high-incidence groups, including immigrants from high-prevalence countries, intravenous drug users and those with previous tuberculosis, that secondary prophylaxis be withheld from all but very high-risk patients and that four drug regimens which include ethambutol should be used for patients originating from, or who have lived in areas of the world with more than 2% primary isoniazid resistance",tuberculosis,tuberculin
503223710,7/15/2014 10:20:24,,1323483113,7/15/2014 10:20:06,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,CHRONIC LYMPHOCYTIC LEUKEMIA.,86-94-106,62-74,FLUDARABINE therapy,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223710,7/15/2014 10:20:32,,1323483216,7/15/2014 10:20:17,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,CHRONIC LYMPHOCYTIC LEUKEMIA.,86-94-106,62-74,FLUDARABINE therapy,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223710,7/15/2014 10:24:01,,1323485312,7/15/2014 10:23:37,vivatic,1,25451531,GBR,,,83.67.28.193,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,CHRONIC LYMPHOCYTIC LEUKEMIA.,86-94-106,62-74,FLUDARABINE therapy,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223710,7/15/2014 10:34:48,,1323492372,7/15/2014 10:34:39,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,CHRONIC LYMPHOCYTIC LEUKEMIA.,86-94-106,62-74,FLUDARABINE therapy,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223710,7/15/2014 10:38:05,,1323494448,7/15/2014 10:37:54,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,CHRONIC LYMPHOCYTIC LEUKEMIA.,86-94-106,62,FLUDARABINE,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223710,7/15/2014 10:47:01,,1323500854,7/15/2014 10:46:50,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,CHRONIC LYMPHOCYTIC LEUKEMIA.,86-94-106,62,FLUDARABINE,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223710,7/15/2014 11:17:59,,1323522679,7/15/2014 11:17:22,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,Hemolytic anemia after fludarabine therapy for CHRONIC LYMPHOCYTIC LEUKEMIA.,39-49-62-74-82-86-94-106-56,39-49-56-62-74-82-86-94-106,Hemolytic anemia after FLUDARABINE therapy for chronic lymphocytic leukemia.,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223710,7/15/2014 11:46:54,,1323539314,7/15/2014 11:46:34,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,"Weiss RB, Hemolytic anemia fludarabine CHRONIC LYMPHOCYTIC LEUKEMIA.",0-6-39-49-62-86-94-106,0-6-39-49-56-62-94-106,"Weiss RB, Hemolytic anemia after FLUDARABINE lymphocytic leukemia.","Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223710,7/15/2014 12:00:02,,1323546836,7/15/2014 11:59:50,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,CHRONIC LYMPHOCYTIC LEUKEMIA.,86-94-106,62,FLUDARABINE,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223710,7/15/2014 12:04:11,,1323548391,7/15/2014 12:03:58,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,86,62,,,114,73,CHRONIC LYMPHOCYTIC LEUKEMIA,FLUDARABINE,CHRONIC LYMPHOCYTIC LEUKEMIA.,86-94-106,62-74,FLUDARABINE therapy,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia.",86 94 106,62,86,62,114,73,1,RO-may_treat,907492,"Weiss RB, Freiman J, Kweder SL, et al. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia",chronic lymphocytic leukemia,fludarabine
503223711,7/15/2014 10:18:05,,1323481472,7/15/2014 10:17:49,vivatic,1,25451531,GBR,,,83.67.28.193,114,159,,,120,168,JOINTS,ARTHRITIS,knee JOINTS,109-114,150-159,clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223711,7/15/2014 10:26:18,,1323486711,7/15/2014 10:26:04,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,114,159,,,120,168,JOINTS,ARTHRITIS,knee JOINTS,109-114,150-159,clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223711,7/15/2014 10:30:54,,1323489761,7/15/2014 10:30:38,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,114,159,,,120,168,JOINTS,ARTHRITIS,JOINTS,114,150-159,clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223711,7/15/2014 10:33:26,,1323491400,7/15/2014 10:33:14,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,114,159,,,120,168,JOINTS,ARTHRITIS,knee JOINTS,109-114,150-159,clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223711,7/15/2014 10:47:29,,1323501115,7/15/2014 10:46:37,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,114,159,,,120,168,JOINTS,ARTHRITIS,intravenous injection 99mTechnetium pertechnetate knee JOINTS clinical arthritis,14-26-39-53-109-114-150-159,14-39-53-109-114-150-159-26,intravenous injection 99mTechnetium pertechnetate knee joints clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223711,7/15/2014 11:01:24,,1323510286,7/15/2014 11:01:14,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,114,159,,,120,168,JOINTS,ARTHRITIS,knee JOINTS,109-114,150-159,clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223711,7/15/2014 11:09:11,,1323516669,7/15/2014 11:09:01,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,114,159,,,120,168,JOINTS,ARTHRITIS,knee JOINTS,109-114,159-150,clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223711,7/15/2014 11:35:40,,1323532756,7/15/2014 11:35:26,prodege,1,6316959,GBR,,,46.208.145.114,114,159,,,120,168,JOINTS,ARTHRITIS,knee JOINTS,109-114,150-159,clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223711,7/15/2014 11:43:46,,1323537644,7/15/2014 11:43:29,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,114,159,,,120,168,JOINTS,ARTHRITIS,the knee JOINTS,105-109-114,150-159,clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223711,7/15/2014 11:55:27,,1323544550,7/15/2014 11:55:06,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,114,159,,,120,168,JOINTS,ARTHRITIS,knee JOINTS,109-114,150-159,clinical ARTHRITIS,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects.",114,159,114,159,120,168,1,RO-disease_has_primary_anatomic_site,902085,"Shortly after intravenous injection of 99mTechnetium-pertechnetate (99mTcO4-)(200 muCi), the activity of the knee joints was studied in patients with clinical arthritis of one or both knees and compared with that in normal subjects",joints,arthritis
503223712,7/15/2014 10:23:33,,1323485051,7/15/2014 10:22:43,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,44,TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223712,7/15/2014 10:23:38,,1323485129,7/15/2014 10:23:26,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,44,TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223712,7/15/2014 10:25:19,,1323486168,7/15/2014 10:25:10,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,44,TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223712,7/15/2014 10:28:09,,1323488016,7/15/2014 10:28:00,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,44,TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223712,7/15/2014 10:30:22,,1323489387,7/15/2014 10:30:11,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,44,TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223712,7/15/2014 11:00:12,,1323509573,7/15/2014 10:59:49,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,44,TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223712,7/15/2014 11:04:10,,1323512047,7/15/2014 11:04:00,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,44,TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223712,7/15/2014 11:04:59,,1323512806,7/15/2014 11:04:46,clixsense,1,27969116,NLD,,,91.213.37.165,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,22-27-44,kala azar TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223712,7/15/2014 11:06:53,,1323514587,7/15/2014 11:06:41,instagc,1,23149109,USA,NC,Durham,75.189.206.205,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,44,TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223712,7/15/2014 11:16:54,,1323521780,7/15/2014 11:16:32,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,91,44,,,103,54,TUBERCULOSIS,TUBERCULIN,TUBERCULOSIS.,91,22-27-32-39-44,kala azar tested with TUBERCULIN,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis.,91,44,91,44,103,54,1,RO-may_diagnose,906806,2 of 16 patients with kala-azar tested with tuberculin were positive; one was diagnosed as tuberculosis,tuberculosis,tuberculin
503223713,7/15/2014 10:20:32,,1323483228,7/15/2014 10:20:16,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,INTELLECTUAL DISABILITY,26-39,72-77-80-85,PART of WAGR syndrome,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223713,7/15/2014 10:22:46,,1323484695,7/15/2014 10:22:32,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,INTELLECTUAL DISABILITY is,26-39-50,72-77-80-85,PART of WAGR syndrome,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223713,7/15/2014 10:25:16,,1323486123,7/15/2014 10:25:04,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,mild to moderate INTELLECTUAL DISABILITY,9-14-17-26-39,72-77-80-85,PART of WAGR syndrome,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223713,7/15/2014 10:25:40,,1323486305,7/15/2014 10:25:19,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,mild to moderate INTELLECTUAL DISABILITY,9-14-17-26-39,72,PART,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223713,7/15/2014 10:27:05,,1323487200,7/15/2014 10:26:46,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,INTELLECTUAL DISABILITY,26-39,72,PART,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223713,7/15/2014 10:43:55,,1323498584,7/15/2014 10:42:54,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,"INTELLECTUAL DISABILITY WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, metal Retardation, neuropsychological",26-39-80-85-94-102-109-115-125-133-152-158-198,26-39-72-80-85-94-102-109-115-125-152-158-133,"intellectual disability PART WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, metal Retardation,","Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223713,7/15/2014 11:06:20,,1323513947,7/15/2014 11:06:03,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,mild to moderate INTELLECTUAL DISABILITY,9-14-17-26-39,72-77-80-85,PART of WAGR syndrome,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223713,7/15/2014 11:09:46,,1323517138,7/15/2014 11:09:35,instagc,1,23149109,USA,NC,Durham,75.189.206.205,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,mild to moderate INTELLECTUAL DISABILITY,9-14-17-26-39,72-77-80-85,PART of WAGR syndrome,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223713,7/15/2014 11:14:30,,1323520397,7/15/2014 11:14:13,instagc,1,13763729,USA,,,75.182.89.225,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,INTELLECTUAL DISABILITY,26-39,72-77-80-85,PART of WAGR syndrome,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223713,7/15/2014 11:22:09,,1323525033,7/15/2014 11:21:51,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,26,72,,,49,76,INTELLECTUAL DISABILITY,PART,INTELLECTUAL DISABILITY WAGR syndrome,26-39-80-85,72-80-85,PART WAGR syndrome,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature.",26 39,72,26,72,49,76,-1,RO-has_manifestation,906332,"Although mild-to-moderate intellectual disability is usually considered part of WAGR syndrome (Wilms' tumour (WT), Aniridia, Genital abnormalities, and metal Retardation, due to 11p13 deletion) the neuropsychological profile of the syndrome is little reported in the literature",intellectual disability,part
503223714,7/15/2014 10:20:47,,1323483383,7/15/2014 10:20:41,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,32,12,,,36,21,SKIN,PSORIASIS,psoriasis and other SKIN diseases facilitate drug,12-22-26-32-37-46-57,0-3-12-22-26-32,"In general, PSORIASIS and other skin","In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223714,7/15/2014 10:20:49,,1323483425,7/15/2014 10:20:33,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,32,12,,,36,21,SKIN,PSORIASIS,SKIN diseases,32-37,12,PSORIASIS,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223714,7/15/2014 10:26:02,,1323486532,7/15/2014 10:25:32,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,32,12,,,36,21,SKIN,PSORIASIS,SKIN diseases,32-37,12,PSORIASIS,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223714,7/15/2014 10:57:24,,1323507830,7/15/2014 10:57:02,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,32,12,,,36,21,SKIN,PSORIASIS,psoriasis SKIN,12-32,12-32,PSORIASIS skin,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223714,7/15/2014 11:12:02,,1323518785,7/15/2014 11:11:37,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,32,12,,,36,21,SKIN,PSORIASIS,psoriasis SKIN diseases,12-32-37,12-32-37,PSORIASIS skin diseases,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223714,7/15/2014 11:38:20,,1323534344,7/15/2014 11:38:08,prodege,1,23999031,AUS,8,Perth,203.59.238.194,32,12,,,36,21,SKIN,PSORIASIS,psoriasis SKIN,12-32,12,PSORIASIS,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223714,7/15/2014 11:43:28,,1323537446,7/15/2014 11:43:10,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,32,12,,,36,21,SKIN,PSORIASIS,psoriasis and other SKIN diseases,12-22-26-32-37,12-22-26-32-37,PSORIASIS and other skin diseases,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223714,7/15/2014 11:43:34,,1323537506,7/15/2014 11:43:23,prodege,1,6316959,GBR,,,46.208.145.114,32,12,,,36,21,SKIN,PSORIASIS,SKIN diseases,32-37,12,PSORIASIS,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223714,7/15/2014 11:51:37,,1323542197,7/15/2014 11:51:19,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,32,12,,,36,21,SKIN,PSORIASIS,SKIN,32,12,PSORIASIS,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223714,7/15/2014 11:56:18,,1323545003,7/15/2014 11:56:02,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,32,12,,,36,21,SKIN,PSORIASIS,SKIN diseases,32-37,12,PSORIASIS,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin.",32,12,32,12,36,21,1,RO-has_finding_site,905249,"In general, psoriasis and other skin diseases facilitate drug delivery through the skin",skin,psoriasis
503223715,7/15/2014 10:16:26,,1323480265,7/15/2014 10:16:13,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,NEUTROPENIA,52,68-76,FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223715,7/15/2014 10:19:05,,1323482209,7/15/2014 10:18:47,vivatic,1,25451531,GBR,,,83.67.28.193,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,grade 3 4 NEUTROPENIA,42-48-50-52,68-76,FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223715,7/15/2014 10:19:32,,1323482563,7/15/2014 10:19:17,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,NEUTROPENIA,52,68-76,FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223715,7/15/2014 10:26:17,,1323486699,7/15/2014 10:26:00,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,grade 3 4 NEUTROPENIA,42-48-50-52,68-76,FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223715,7/15/2014 10:28:18,,1323488128,7/15/2014 10:27:50,bitcoinget,1,24792414,USA,,,166.181.81.37,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,grade 3 4 NEUTROPENIA,42-48-50-52,68-76,FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223715,7/15/2014 10:29:03,,1323488604,7/15/2014 10:28:51,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,NEUTROPENIA,52,68-76,FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223715,7/15/2014 10:49:04,,1323502409,7/15/2014 10:48:49,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,NEUTROPENIA,52,68-76,FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223715,7/15/2014 10:53:57,,1323505792,7/15/2014 10:53:15,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,toxicities / NEUTROPENIA febrile neutropenia.,26-49-52-68-76,52-68-76-26,toxicities neutropenia FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223715,7/15/2014 11:00:54,,1323509917,7/15/2014 10:59:48,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,NEUTROPENIA,52,68-76,FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223715,7/15/2014 11:03:54,,1323511865,7/15/2014 11:03:38,clixsense,1,27969116,NLD,,,91.213.37.165,52,68,,,63,87,NEUTROPENIA,FEBRILE NEUTROPENIA,NEUTROPENIA febrile neutropenia.,52-68-76,52-68-76,neutropenia FEBRILE NEUTROPENIA.,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia.,52,68 76,52,68,63,87,-1,RO-has_definitional_manifestation,904886,The primary dose-limiting toxicities were grade 3/4 neutropenia and febrile neutropenia,neutropenia,febrile neutropenia
503223716,7/15/2014 10:22:26,,1323484470,7/15/2014 10:22:02,vivatic,1,25451531,GBR,,,83.67.28.193,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"NEUROENDOCRINE DIFFERENTIATION,",66-81,120-126-131-136-143,SMALL CELL LUNG CANCER (SCLC.,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223716,7/15/2014 10:26:45,,1323486967,7/15/2014 10:26:30,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"NEUROENDOCRINE DIFFERENTIATION,",66-81,120-126-131-136-143,SMALL CELL LUNG CANCER (SCLC.,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223716,7/15/2014 10:26:57,,1323487060,7/15/2014 10:26:44,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"NEUROENDOCRINE DIFFERENTIATION,",66-81,120-126-131-136,SMALL CELL LUNG CANCER,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223716,7/15/2014 10:30:59,,1323489845,7/15/2014 10:30:15,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"NEUROENDOCRINE DIFFERENTIATION,",66-81,120-126-131-136-143,SMALL CELL LUNG CANCER (SCLC.,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223716,7/15/2014 10:53:27,,1323505446,7/15/2014 10:53:01,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"NEUROENDOCRINE DIFFERENTIATION,",66-81,120-126-131-136-143,SMALL CELL LUNG CANCER (SCLC.,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223716,7/15/2014 11:00:41,,1323509773,7/15/2014 11:00:17,clixsense,1,27969116,NLD,,,91.213.37.165,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"NEUROENDOCRINE DIFFERENTIATION, small cell lung cancer (SCLC.",66-81-120-126-131-136-143,120-126-131-136-143,SMALL CELL LUNG CANCER (SCLC.,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223716,7/15/2014 11:31:49,,1323530493,7/15/2014 11:31:28,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"NEUROENDOCRINE DIFFERENTIATION,",66-81,120-126-131-136,SMALL CELL LUNG CANCER,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223716,7/15/2014 11:41:18,,1323536001,7/15/2014 11:40:49,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"radioimmunoassay neuron specific enolase (NSE), NEUROENDOCRINE DIFFERENTIATION, small cell lung cancer (SCLC.",2-23-30-39-47-66-81-120-126-131-136-143,2-23-30-39-47-66-81-120-126-131-136-143,"radioimmunoassay neuron specific enolase (NSE), neuroendocrine differentiation, SMALL CELL LUNG CANCER (SCLC.","A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223716,7/15/2014 11:42:44,,1323536939,7/15/2014 11:42:23,prodege,1,6316959,GBR,,,46.208.145.114,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"NEUROENDOCRINE DIFFERENTIATION,",66-81,120-126-131-136-143,SMALL CELL LUNG CANCER (SCLC.,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223716,7/15/2014 12:02:23,,1323547731,7/15/2014 12:02:04,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,66,120,,,96,142,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL LUNG CANCER,"neuron specific enolase a marker of NEUROENDOCRINE DIFFERENTIATION,",23-30-54-56-63-66-81-39,120-126-131-136-143,SMALL CELL LUNG CANCER (SCLC.,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC.",66 81,120 126 131 136,66,120,96,142,-1,RO-disease_has_finding,901631,"A radioimmunoassay for neuron specific enolase (NSE), a marker of neuroendocrine differentiation, has been evaluated in small cell lung cancer (SCLC",neuroendocrine differentiation,small cell lung cancer
503223717,7/15/2014 10:18:35,,1323481843,7/15/2014 10:18:32,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,"intravenous injection of ENDOTOXIN into rats, which",176-188-198-201-211-216-222,125-132-138-141-151-157-161-173,animal model of ENDOTOXIC SHOCK was established by,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223717,7/15/2014 10:27:03,,1323487187,7/15/2014 10:26:42,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,ENDOTOXIN,201,141-151,ENDOTOXIC SHOCK,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223717,7/15/2014 10:27:56,,1323487820,7/15/2014 10:26:59,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,ENDOTOXIN,201,125-132-138-141-151,animal model of ENDOTOXIC SHOCK,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223717,7/15/2014 10:41:53,,1323497029,7/15/2014 10:41:02,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,"endotoxic shock pathological intravenous injection of ENDOTOXIN hepatic stimulating substance, hepatopoietin",54-64-87-176-188-198-201-253-261-273-284,141-151-176-188-198-201-253-261-273-284-87,"pathological ENDOTOXIC SHOCK intravenous injection of endotoxin hepatic stimulating substance, hepatopoietin","In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223717,7/15/2014 11:17:00,,1323521871,7/15/2014 11:16:40,instagc,1,13763729,USA,,,75.182.89.225,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,ENDOTOXIN,201,141-151,ENDOTOXIC SHOCK,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223717,7/15/2014 11:32:00,,1323530638,7/15/2014 11:31:33,prodege,1,23999031,AUS,8,Perth,203.59.238.194,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,endotoxic shock endotoxic shock ENDOTOXIN,54-64-141-201-151,54-141-151-64,endotoxic shock ENDOTOXIC SHOCK,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223717,7/15/2014 11:47:21,,1323539517,7/15/2014 11:47:04,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,intravenous injection of ENDOTOXIN,176-188-198-201,125-132-138-141-151,animal model of ENDOTOXIC SHOCK,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223717,7/15/2014 11:49:26,,1323540576,7/15/2014 11:49:09,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,ENDOTOXIN,201,141-151,ENDOTOXIC SHOCK,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223717,7/15/2014 12:03:19,,1323548078,7/15/2014 12:03:05,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,intravenous injection of ENDOTOXIN,176-188-198-201,141-151-157-161-173-176-188-198-201,ENDOTOXIC SHOCK was established by intravenous injection of endotoxin,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223717,7/15/2014 12:05:25,,1323548824,7/15/2014 12:05:05,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,201,141,,,210,156,ENDOTOXIN,ENDOTOXIC SHOCK,ENDOTOXIN,201,141-151,ENDOTOXIC SHOCK,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN.",201,141 151,201,141,210,156,1,RO-has_causative_agent,903981,"In order to understand the mechanism of prevention of endotoxic shock and evaluate the pathological changes taking place, an animal model of endotoxic shock was established by intravenous injection of endotoxin into rats, which were then treated with a hepatic stimulating substance, hepatopoietin (HPN",endotoxin,endotoxic shock
503223718,7/15/2014 10:17:25,,1323481080,7/15/2014 10:16:57,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,SYPHILIS,41,0,ERYTHROMYCIN,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223718,7/15/2014 10:20:15,,1323483023,7/15/2014 10:20:03,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,SYPHILIS,41,0,ERYTHROMYCIN,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223718,7/15/2014 10:23:01,,1323484765,7/15/2014 10:22:47,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,SYPHILIS,41,0-13,ERYTHROMYCIN failure,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223718,7/15/2014 10:24:22,,1323485490,7/15/2014 10:24:06,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,SYPHILIS,41,0,ERYTHROMYCIN,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223718,7/15/2014 11:01:55,,1323510580,7/15/2014 11:01:34,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,SYPHILIS,41,0,ERYTHROMYCIN,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223718,7/15/2014 11:16:30,,1323521588,7/15/2014 11:16:07,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,SYPHILIS,41,0-13,ERYTHROMYCIN failure,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223718,7/15/2014 11:37:39,,1323533898,7/15/2014 11:37:24,prodege,1,23999031,AUS,8,Perth,203.59.238.194,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,SYPHILIS,41,0-41,ERYTHROMYCIN syphilis,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223718,7/15/2014 11:37:56,,1323534078,7/15/2014 11:37:45,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,the treatment of SYPHILIS,24-28-38-41,0-13,ERYTHROMYCIN failure,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223718,7/15/2014 11:45:13,,1323538326,7/15/2014 11:44:55,prodege,1,6316959,GBR,,,46.208.145.114,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,SYPHILIS,41,0-13,ERYTHROMYCIN failure,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223718,7/15/2014 11:56:25,,1323545068,7/15/2014 11:56:11,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,41,0,,,49,12,SYPHILIS,ERYTHROMYCIN,SYPHILIS,41,0,ERYTHROMYCIN,Erythromycin failure in the treatment of syphilis in a pregnant woman.,41,0,41,0,49,12,1,RO-may_treat,907476,Erythromycin failure in the treatment of syphilis in a pregnant woman,syphilis,Erythromycin
503223719,7/15/2014 10:27:59,,1323487873,7/15/2014 10:27:40,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA,77-86,45-49-59-66,low molecular weight HEPARIN,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223719,7/15/2014 10:32:17,,1323490723,7/15/2014 10:31:42,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA,77-86,66,HEPARIN,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223719,7/15/2014 10:37:26,,1323493946,7/15/2014 10:37:13,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA,77-86,66,HEPARIN,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223719,7/15/2014 10:50:18,,1323503245,7/15/2014 10:50:06,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA,77-86,66,HEPARIN,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223719,7/15/2014 11:00:28,,1323509672,7/15/2014 11:00:12,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA,77-86,66,HEPARIN,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223719,7/15/2014 11:16:20,,1323521454,7/15/2014 11:16:04,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA,77-86,66-77-86,HEPARIN unstable angina,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223719,7/15/2014 11:38:05,,1323534189,7/15/2014 11:37:41,prodege,1,23999031,AUS,8,Perth,203.59.238.194,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA,77-86,66-86,HEPARIN angina,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223719,7/15/2014 11:43:45,,1323537621,7/15/2014 11:42:50,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA,77-86,66,HEPARIN,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223719,7/15/2014 11:44:17,,1323537876,7/15/2014 11:43:57,prodege,1,6316959,GBR,,,46.208.145.114,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA,77-86,45-49-59-66,low molecular weight HEPARIN,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223719,7/15/2014 11:58:56,,1323546324,7/15/2014 11:58:32,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,77,66,,,92,73,UNSTABLE ANGINA,HEPARIN,UNSTABLE ANGINA patients,77-86-93,45-49-59-66,low molecular weight HEPARIN,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency.,77 86,66,77,66,92,73,1,RO-may_treat,908115,The indications and length of treatment with low-molecular-weight heparin in unstable angina patients have to be appropriate and the perioperative management of these patients has to address the bleeding tendency,unstable angina,heparin
503223720,7/15/2014 10:18:55,,1323482043,7/15/2014 10:18:28,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,117,33,,,124,48,FISTULA,CROHN'S DISEASE,FISTULA tract,117-125,33-41,CROHN'S DISEASE,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223720,7/15/2014 10:23:36,,1323485109,7/15/2014 10:23:10,vivatic,1,25451531,GBR,,,83.67.28.193,117,33,,,124,48,FISTULA,CROHN'S DISEASE,FISTULA tract,117-125,26-33-41,severe CROHN'S DISEASE,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223720,7/15/2014 10:28:47,,1323488398,7/15/2014 10:28:34,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,117,33,,,124,48,FISTULA,CROHN'S DISEASE,FISTULA tract,117-125,26-33-41-49-54-57-75,severe CROHN'S DISEASE with an esophagobronchial fistula,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223720,7/15/2014 10:34:37,,1323492171,7/15/2014 10:34:24,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,117,33,,,124,48,FISTULA,CROHN'S DISEASE,FISTULA,117,33-41,CROHN'S DISEASE,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223720,7/15/2014 10:44:06,,1323498661,7/15/2014 10:43:50,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,117,33,,,124,48,FISTULA,CROHN'S DISEASE,FISTULA,117,33-41,CROHN'S DISEASE,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223720,7/15/2014 10:46:24,,1323500405,7/15/2014 10:45:40,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,117,33,,,124,48,FISTULA,CROHN'S DISEASE,esophagobronchial fistula closure of the FISTULA tract with the,57-102-110-113-117-125-131-136-75,18-23-26-33-41-49-54-57-75,case of severe CROHN'S DISEASE with an esophagobronchial fistula,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223720,7/15/2014 10:52:31,,1323504816,7/15/2014 10:51:58,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,117,33,,,124,48,FISTULA,CROHN'S DISEASE,FISTULA tract,117-125,33-41,CROHN'S DISEASE,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223720,7/15/2014 11:01:00,,1323509971,7/15/2014 11:00:42,clixsense,1,27969116,NLD,,,91.213.37.165,117,33,,,124,48,FISTULA,CROHN'S DISEASE,FISTULA tract,117-125,26-33-41,severe CROHN'S DISEASE,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223720,7/15/2014 11:04:13,,1323512072,7/15/2014 11:03:58,instagc,1,23149109,USA,NC,Durham,75.189.206.205,117,33,,,124,48,FISTULA,CROHN'S DISEASE,FISTULA tract,117-125,33-41,CROHN'S DISEASE,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223720,7/15/2014 11:11:35,,1323518449,7/15/2014 11:11:13,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,117,33,,,124,48,FISTULA,CROHN'S DISEASE,FISTULA tract,117-125,23-26-33-41-57-75,of severe CROHN'S DISEASE esophagobronchial fistula,"We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant ""Onyx.",117,33 41,117,33,124,48,-1,RO-has_manifestation,906096,We here present a case of severe Crohn's disease with an esophagobronchial fistula and the successful closure of the fistula tract with the novel liquid polymer sealant &quot;Onyx,fistula,Crohn's disease
503223721,7/15/2014 10:19:32,,1323482571,7/15/2014 10:19:18,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,LYMPH NODE METASTASES.,105-111-116,57-67,MEDULLARY CARCINOMA,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223721,7/15/2014 10:30:36,,1323489549,7/15/2014 10:30:24,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,LYMPH NODE METASTASES.,105-111-116,57-67,MEDULLARY CARCINOMA,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223721,7/15/2014 11:10:14,,1323517468,7/15/2014 11:10:00,instagc,1,13763729,USA,,,75.182.89.225,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,LYMPH NODE METASTASES.,105-111-116,57-67,MEDULLARY CARCINOMA,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223721,7/15/2014 11:12:33,,1323519183,7/15/2014 11:12:04,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,LYMPH NODE METASTASES.,105-111-116,57-67-77-80-84-90,"MEDULLARY CARCINOMA of the right breast,","Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223721,7/15/2014 11:22:28,,1323525175,7/15/2014 11:22:09,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,scirrhous carcinoma medullary carcinoma LYMPH NODE METASTASES.,19-29-57-67-105-111-116,19-29-57-67,scirrhous carcinoma MEDULLARY CARCINOMA,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223721,7/15/2014 11:37:27,,1323533734,7/15/2014 11:37:15,prodege,1,6316959,GBR,,,46.208.145.114,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,LYMPH NODE METASTASES.,105-111-116,57-67,MEDULLARY CARCINOMA,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223721,7/15/2014 11:59:10,,1323546416,7/15/2014 11:58:56,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,LYMPH NODE METASTASES.,105-111-116,57-67,MEDULLARY CARCINOMA,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223721,7/15/2014 11:59:39,,1323546693,7/15/2014 11:59:23,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,but no LYMPH NODE METASTASES.,98-102-105-111-116,57-67-77-80-84-90,"MEDULLARY CARCINOMA of the right breast,","Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223721,7/15/2014 12:01:45,,1323547546,7/15/2014 12:01:27,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,LYMPH NODE METASTASES.,105-111-116,57-67,MEDULLARY CARCINOMA,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223721,7/15/2014 12:07:02,,1323549365,7/15/2014 12:06:42,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,105,57,,,126,76,LYMPH NODE METASTASES,MEDULLARY CARCINOMA,LYMPH NODE METASTASES.,105-111-116,57-67,MEDULLARY CARCINOMA,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases.",105 111 116,57 67,105,57,126,76,-1,RO-disease_may_have_finding,902681,"Histology showed a scirrhous carcinoma of the left and a medullary carcinoma of the right breast, but no lymph node metastases",lymph node metastases,medullary carcinoma
503223722,7/15/2014 10:26:13,,1323486629,7/15/2014 10:25:54,vivatic,1,25451531,GBR,,,83.67.28.193,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,117,71-78-83-86-94-67,the active form of VITAMIN D,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223722,7/15/2014 11:07:07,,1323514812,7/15/2014 11:06:54,instagc,1,23149109,USA,NC,Durham,75.189.206.205,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,117,71-78-83-86-94,active form of VITAMIN D,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223722,7/15/2014 11:12:49,,1323519333,7/15/2014 11:12:41,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,of OSTEOPOROSIS.,114-117,86-94,VITAMIN D,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223722,7/15/2014 11:16:39,,1323521645,7/15/2014 11:16:21,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,117,86-94-117,VITAMIN D osteoporosis.,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223722,7/15/2014 11:36:03,,1323533054,7/15/2014 11:35:41,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,vitamin D OSTEOPOROSIS.,86-94-117,86-94-117,VITAMIN D osteoporosis.,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223722,7/15/2014 11:42:03,,1323536579,7/15/2014 11:41:47,prodege,1,23999031,AUS,8,Perth,203.59.238.194,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,117,86-94-117,VITAMIN D osteoporosis.,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223722,7/15/2014 11:47:30,,1323539631,7/15/2014 11:47:22,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,the treatment of OSTEOPOROSIS.,100-104-114-117,71-78-83-86-94-96-100-104,active form of VITAMIN D for the treatment,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223722,7/15/2014 12:02:26,,1323547746,7/15/2014 12:02:09,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,117,71-78-83-86-94,active form of VITAMIN D,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223722,7/15/2014 12:03:42,,1323548197,7/15/2014 12:03:29,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,the treatment of OSTEOPOROSIS.,100-104-114-117,55-64-67-71-78-83-86-94,efficacy of the active form of VITAMIN D,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223722,7/15/2014 12:06:04,,1323549054,7/15/2014 12:05:50,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,117,86,,,129,95,OSTEOPOROSIS,VITAMIN D,OSTEOPOROSIS.,117,71-78-83-86-94,active form of VITAMIN D,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis.,117,86 94,117,86,129,95,1,RO-may_prevent,907445,Some misunderstandings exist internationally about the efficacy of the active form of vitamin D for the treatment of osteoporosis,osteoporosis,vitamin D
503223723,7/15/2014 10:35:24,,1323492758,7/15/2014 10:35:09,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,93,32,,,102,38,VARICELLA,ZOSTER,VARICELLA,93,22-32-39-45,varicella ZOSTER virus infection,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223723,7/15/2014 10:36:57,,1323493783,7/15/2014 10:36:12,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,93,32,,,102,38,VARICELLA,ZOSTER,VARICELLA zoster virus,93-103-110,22-32-39,varicella ZOSTER virus,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223723,7/15/2014 11:26:46,,1323527587,7/15/2014 11:26:31,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,93,32,,,102,38,VARICELLA,ZOSTER,VARICELLA,93,32,ZOSTER,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223723,7/15/2014 11:40:10,,1323535355,7/15/2014 11:39:36,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,93,32,,,102,38,VARICELLA,ZOSTER,varicella zoster virus infection enzyme immunoassay of VARICELLA zoster virus specific IgG antibody.,22-32-39-45-71-78-90-93-103-110-125-129-116,22-32-39-45-71-78-90-93-103-110-116-129-125,varicella ZOSTER virus infection enzyme immunoassay of varicella zoster virus specific IgG antibody.,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223723,7/15/2014 11:44:48,,1323538058,7/15/2014 11:44:18,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,93,32,,,102,38,VARICELLA,ZOSTER,varicella zoster enzyme immunoassay VARICELLA,32-71-78-93-22,22-32-78-93-129-103,varicella ZOSTER immunoassay varicella zoster antibody.,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223723,7/15/2014 11:47:41,,1323539704,7/15/2014 11:47:13,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,93,32,,,102,38,VARICELLA,ZOSTER,VARICELLA zoster,93-103,22-32,varicella ZOSTER,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223723,7/15/2014 11:56:53,,1323545280,7/15/2014 11:56:19,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,93,32,,,102,38,VARICELLA,ZOSTER,VARICELLA zoster virus specific IgG antibody.,93-103-110-116-125-129,22-32-39-45,varicella ZOSTER virus infection,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223723,7/15/2014 11:59:35,,1323546641,7/15/2014 11:59:11,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,93,32,,,102,38,VARICELLA,ZOSTER,VARICELLA,93,22-32,varicella ZOSTER,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223723,7/15/2014 12:00:40,,1323547130,7/15/2014 12:00:21,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,93,32,,,102,38,VARICELLA,ZOSTER,VARICELLA,93,32,ZOSTER,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223723,7/15/2014 12:06:41,,1323549263,7/15/2014 12:06:22,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,93,32,,,102,38,VARICELLA,ZOSTER,VARICELLA zoster virus,93-103-110,22-32-39,varicella ZOSTER virus,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody.,93,32,93,32,102,38,-1,RO-has_causative_agent,903703,Serologic evidence of varicella-zoster virus infection was measured by enzyme immunoassay of varicella-zoster virus-specific IgG antibody,varicella,zoster
503223724,7/15/2014 10:18:52,,1323482020,7/15/2014 10:18:50,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,haemodialysis with frequent MUSCLE CRAMPS were given 320,29-43-48-57-64-71-76-82,76-82-86-89-97-106-109,given 320 mg QUININE SULPHATE or placebo,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223724,7/15/2014 10:19:52,,1323482806,7/15/2014 10:19:32,vivatic,1,25451531,GBR,,,83.67.28.193,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,MUSCLE CRAMPS,57-64,82-86-89-97,320 mg QUININE SULPHATE,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223724,7/15/2014 10:35:02,,1323492512,7/15/2014 10:34:28,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,MUSCLE CRAMPS,57-64,89-97,QUININE SULPHATE,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223724,7/15/2014 10:49:56,,1323503015,7/15/2014 10:49:31,clixsense,1,6416850,USA,VA,Midlothian,108.4.51.140,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,haemodialysis MUSCLE CRAMPS,29-57-64,89-97,QUININE SULPHATE,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223724,7/15/2014 11:07:16,,1323514955,7/15/2014 11:07:05,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,frequent MUSCLE CRAMPS,48-57-64,89-97,QUININE SULPHATE,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223724,7/15/2014 11:12:26,,1323519107,7/15/2014 11:12:13,instagc,1,13763729,USA,,,75.182.89.225,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,MUSCLE CRAMPS,57-64,89-97,QUININE SULPHATE,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223724,7/15/2014 11:20:30,,1323524222,7/15/2014 11:20:08,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,MUSCLE CRAMPS,57-64,57-64-89-97,muscle cramps QUININE SULPHATE,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223724,7/15/2014 11:26:29,,1323527371,7/15/2014 11:26:14,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,MUSCLE CRAMPS,57-64,89-97,QUININE SULPHATE,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223724,7/15/2014 11:34:42,,1323532203,7/15/2014 11:34:12,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,haemodialysis MUSCLE CRAMPS quinine sulphate placebo identical gelatin capsule) dialysis,29-57-64-97-109-124-134-142-176-89,29-57-64-89-97-109-124-134-142-176,haemodialysis muscle cramps QUININE SULPHATE placebo identical gelatin capsule) dialysis,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223724,7/15/2014 11:40:45,,1323535682,7/15/2014 11:40:22,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,57,89,,,70,105,MUSCLE CRAMPS,QUININE SULPHATE,haemodialysis with frequent MUSCLE CRAMPS,29-43-48-57-64,89-97-106-109,QUININE SULPHATE or placebo,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks.,57 64,89 97,57,89,70,105,1,RO-may_prevent,907060,Nine patients on maintenance haemodialysis with frequent muscle cramps were given 320 mg quinine sulphate or placebo (in an identical gelatin capsule) at the beginning of each dialysis for a period of 12 weeks,muscle cramps,quinine sulphate
503223725,7/15/2014 10:19:15,,1323482352,7/15/2014 10:19:02,clixsense,1,19803139,NLD,6,Veldhoven,212.61.84.196,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,RESPIRATORY TRACT viruses,87-99-105,0-10-12-16-18,"INFLUENZA A and B viruses,","Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223725,7/15/2014 10:19:48,,1323482746,7/15/2014 10:19:45,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,are the primary RESPIRATORY TRACT viruses associated with,71-75-79-87-99-105-113-124,0-10-12-16-18,"INFLUENZA A and B viruses,","Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223725,7/15/2014 10:28:20,,1323488163,7/15/2014 10:28:10,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,primary RESPIRATORY TRACT viruses,79-87-99-105,0-10-12-16-18,"INFLUENZA A and B viruses,","Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223725,7/15/2014 10:29:17,,1323488705,7/15/2014 10:29:05,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,RESPIRATORY TRACT viruses,87-99-105,0-10-18,"INFLUENZA A viruses,","Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223725,7/15/2014 10:51:50,,1323504420,7/15/2014 10:51:27,clixsense,1,6416850,USA,VA,Midlothian,108.4.51.140,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,RESPIRATORY TRACT viruses,87-99-105,0-10-12-16-18-27-43-55-65,"INFLUENZA A and B viruses, adenovirus, respiratory syncytial virus","Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223725,7/15/2014 11:06:19,,1323513946,7/15/2014 11:06:09,instagc,1,23149109,USA,NC,Durham,75.189.206.205,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,RESPIRATORY TRACT viruses,87-99-105,0-10-12-16-18,"INFLUENZA A and B viruses,","Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223725,7/15/2014 11:08:25,,1323515929,7/15/2014 11:08:13,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,primary RESPIRATORY TRACT viruses,79-87-99-105,0-10,INFLUENZA A,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223725,7/15/2014 11:15:29,,1323520938,7/15/2014 11:15:10,instagc,1,13763729,USA,,,75.182.89.225,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,RESPIRATORY TRACT viruses,87-99-105,0-10-16-18-12,"INFLUENZA A and B viruses,","Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223725,7/15/2014 11:38:43,,1323534601,7/15/2014 11:37:49,prodege,1,6316959,GBR,,,46.208.145.114,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,RESPIRATORY TRACT viruses,87-99-105,0-10-16-18-12,"INFLUENZA A and B viruses,","Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223725,7/15/2014 11:42:45,,1323536949,7/15/2014 11:42:23,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,87,0,,,104,11,RESPIRATORY TRACT,INFLUENZA A,"viruses, adenovirus, syncytial virus RESPIRATORY TRACT viruses",18-27-55-87-99-105-65,0-10-16-18-43,"INFLUENZA A B viruses, respiratory","Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease.",87 99,0 10,87,0,104,11,1,RO-has_finding_site,905361,"Influenza A and B viruses, adenovirus, and respiratory syncytial virus are the primary respiratory tract viruses associated with this disease",respiratory tract,Influenza A
503223726,7/15/2014 10:22:11,,1323484319,7/15/2014 10:22:03,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223726,7/15/2014 10:22:31,,1323484534,7/15/2014 10:21:57,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223726,7/15/2014 10:26:31,,1323486835,7/15/2014 10:26:16,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223726,7/15/2014 10:32:39,,1323490945,7/15/2014 10:32:27,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223726,7/15/2014 10:33:04,,1323491200,7/15/2014 10:32:52,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223726,7/15/2014 10:33:24,,1323491383,7/15/2014 10:33:12,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223726,7/15/2014 11:02:33,,1323510933,7/15/2014 11:02:17,clixsense,1,27969116,NLD,,,91.213.37.165,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223726,7/15/2014 11:13:56,,1323520078,7/15/2014 11:13:33,instagc,1,13763729,USA,,,75.182.89.225,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223726,7/15/2014 11:20:14,,1323524078,7/15/2014 11:20:03,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,postmenopausal without POSTMENOPAUSAL BLEEDING,78-93-101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223726,7/15/2014 11:55:25,,1323544520,7/15/2014 11:55:02,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,101,152,,,124,170,POSTMENOPAUSAL BLEEDING,ENDOMETRIAL CANCER,POSTMENOPAUSAL BLEEDING,101-116,152-164,ENDOMETRIAL CANCER.,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer.,101 116,152 164,101,152,124,170,-1,RO-disease_may_have_finding,902927,? Patients who have normal ovulatory cycles without irregular bleeding or are postmenopausal without postmenopausal bleeding are at low risk for having endometrial cancer,postmenopausal bleeding,endometrial cancer
503223727,7/15/2014 10:23:27,,1323485016,7/15/2014 10:23:03,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,88,52,,,94,60,CARIES,FLUORIDE,CARIES,88,52,FLUORIDE,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223727,7/15/2014 10:30:13,,1323489283,7/15/2014 10:29:30,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,88,52,,,94,60,CARIES,FLUORIDE,"CARIES prevention,",88-95,52,FLUORIDE,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223727,7/15/2014 10:51:42,,1323504360,7/15/2014 10:51:03,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,88,52,,,94,60,CARIES,FLUORIDE,fluoride varnish's effectiveness in CARIES,52-61-71-85-88,52-61-71-85-88,FLUORIDE varnish's effectiveness in caries,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223727,7/15/2014 10:54:15,,1323505975,7/15/2014 10:53:52,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,88,52,,,94,60,CARIES,FLUORIDE,CARIES,88,52,FLUORIDE,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223727,7/15/2014 11:14:12,,1323520198,7/15/2014 11:13:57,instagc,1,13763729,USA,,,75.182.89.225,88,52,,,94,60,CARIES,FLUORIDE,"CARIES prevention,",88-95,52,FLUORIDE,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223727,7/15/2014 11:17:45,,1323522503,7/15/2014 11:17:29,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,88,52,,,94,60,CARIES,FLUORIDE,CARIES,88,52-88,FLUORIDE caries,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223727,7/15/2014 11:25:29,,1323526890,7/15/2014 11:24:52,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,88,52,,,94,60,CARIES,FLUORIDE,fluoride varnish's CARIES fluoride treatments,52-61-88-188-197,52-61-88-188-197,FLUORIDE varnish's caries fluoride treatments,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223727,7/15/2014 11:30:42,,1323529853,7/15/2014 11:30:25,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,88,52,,,94,60,CARIES,FLUORIDE,CARIES,88,52,FLUORIDE,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223727,7/15/2014 11:32:36,,1323530907,7/15/2014 11:32:02,prodege,1,23999031,AUS,8,Perth,203.59.238.194,88,52,,,94,60,CARIES,FLUORIDE,CARIES caries,88-243,52-88,FLUORIDE caries,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223727,7/15/2014 11:53:50,,1323543778,7/15/2014 11:53:30,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,88,52,,,94,60,CARIES,FLUORIDE,"CARIES prevention,",88-95,52,FLUORIDE,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods.",88,52,88,52,94,60,1,RO-may_prevent,907105,"This paper reviewed clinical studies and found that fluoride varnish's effectiveness in caries prevention, ease of application, and safety give it an advantage over other types of topical fluoride treatments (such as gels and rinses) or other caries management methods",caries,fluoride
503223728,7/15/2014 10:17:29,,1323481129,7/15/2014 10:17:06,vivatic,1,25451531,GBR,,,83.67.28.193,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,"HEADACHE associated with misuse of analgesics,",134-143-154-159-169-166,111-119-124,"TENSION TYPE HEADACHE,","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223728,7/15/2014 10:17:38,,1323481207,7/15/2014 10:17:22,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,HEADACHE,134,111-119-124,"TENSION TYPE HEADACHE,","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223728,7/15/2014 10:20:40,,1323483291,7/15/2014 10:20:29,prodege,1,6490968,USA,VA,Manassas,68.32.171.188,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,"tension type headache, HEADACHE associated with misuse",111-119-124-134-143-154-159,94-102-105-111-119-124-134-143-154,"without an aura, TENSION TYPE HEADACHE, headache associated with","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223728,7/15/2014 10:35:08,,1323492580,7/15/2014 10:34:54,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,HEADACHE,134,111-119-124,"TENSION TYPE HEADACHE,","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223728,7/15/2014 10:46:32,,1323500507,7/15/2014 10:46:15,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,HEADACHE,134,111-119-124,"TENSION TYPE HEADACHE,","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223728,7/15/2014 10:53:00,,1323505105,7/15/2014 10:52:33,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,HEADACHE,134,111-119-124,"TENSION TYPE HEADACHE,","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223728,7/15/2014 10:56:40,,1323507438,7/15/2014 10:55:44,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,"headache syndromes migraine tension type headache, HEADACHE analgesics, cluster headache,",49-58-76-111-119-134-169-181-189-124,49-58-76-111-119-124-134-181-189-169,"headache syndromes migraine TENSION TYPE HEADACHE, headache analgesics, cluster headache,","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223728,7/15/2014 11:01:03,,1323510021,7/15/2014 11:00:39,instagc,1,23149109,USA,NC,Durham,75.189.206.205,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,"HEADACHE associated with misuse of analgesics,",134-143-154-159-166-169,111-119-124,"TENSION TYPE HEADACHE,","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223728,7/15/2014 11:15:09,,1323520729,7/15/2014 11:14:50,instagc,1,13763729,USA,,,75.182.89.225,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,HEADACHE,134,111-119-124,"TENSION TYPE HEADACHE,","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223728,7/15/2014 11:22:07,,1323525028,7/15/2014 11:21:48,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,134,111,,,142,132,HEADACHE,TENSION TYPE HEADACHE,HEADACHE,134,111-119-124,"TENSION TYPE HEADACHE,","In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion.",134,111 119 124,134,111,142,132,-1,RO-has_definitional_manifestation,904891,"In the international classification, the primary headache syndromes include migraine with and without an aura, tension type headache, headache associated with misuse of analgesics, cluster headache, and a number of rare forms of headache with no structural lesion",headache,tension type headache
503223729,7/15/2014 10:21:56,,1323484127,7/15/2014 10:21:43,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,SCHIZOPHRENIA.,129,44,"CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223729,7/15/2014 10:23:49,,1323485226,7/15/2014 10:23:39,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,SCHIZOPHRENIA.,129,44,"CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223729,7/15/2014 10:31:30,,1323490205,7/15/2014 10:31:19,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,SCHIZOPHRENIA.,129,44,"CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223729,7/15/2014 10:32:44,,1323491001,7/15/2014 10:32:30,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,SCHIZOPHRENIA.,129,44,"CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223729,7/15/2014 10:34:36,,1323492157,7/15/2014 10:34:25,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,SCHIZOPHRENIA.,129,44,"CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223729,7/15/2014 11:00:10,,1323509570,7/15/2014 10:59:26,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,SCHIZOPHRENIA.,129,44,"CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223729,7/15/2014 11:00:38,,1323509742,7/15/2014 11:00:16,instagc,1,23149109,USA,NC,Durham,75.189.206.205,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,cognition in SCHIZOPHRENIA.,126-129-116,41-44,"as CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223729,7/15/2014 11:03:37,,1323511646,7/15/2014 11:03:22,clixsense,1,27969116,NLD,,,91.213.37.165,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,SCHIZOPHRENIA.,129,0-9-23-29-36-41-44,"Atypical antipsychotic drugs (APDs) such as CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223729,7/15/2014 11:16:13,,1323521398,7/15/2014 11:15:58,instagc,1,13763729,USA,,,75.182.89.225,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,SCHIZOPHRENIA.,129,44,"CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223729,7/15/2014 11:33:31,,1323531450,7/15/2014 11:33:18,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,129,44,,,142,53,SCHIZOPHRENIA,CLOZAPINE,SCHIZOPHRENIA.,129,44,"CLOZAPINE,","Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia.",129,44,129,44,142,53,1,RO-may_treat,908255,"Atypical antipsychotic drugs (APDs) such as clozapine, but not the typical APD haloperidol, improve some aspects of cognition in schizophrenia",schizophrenia,clozapine
503223730,7/15/2014 10:57:58,,1323508201,7/15/2014 10:57:37,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"severe HYPERTENSION,",196-203,221-234,HYPERTENSIVE ENCEPHALOPATHY.,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223730,7/15/2014 10:59:57,,1323509410,7/15/2014 10:59:41,clixsense,1,27969116,NLD,,,91.213.37.165,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"severe HYPERTENSION, and hypertensive encephalopathy.",196-203-221-234-217,196-203-221-234,"severe hypertension, HYPERTENSIVE ENCEPHALOPATHY.","Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223730,7/15/2014 11:18:32,,1323523010,7/15/2014 11:16:04,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"adrenal adenoma, severe HYPERTENSION, hypertensive encephalopathy.",179-187-196-203-221-234,179-187-196-203-221-234,"adrenal adenoma, severe hypertension, HYPERTENSIVE ENCEPHALOPATHY.","Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223730,7/15/2014 11:27:57,,1323528313,7/15/2014 11:27:44,gifthulk,1,22552178,AUS,5,Adelaide,118.210.152.60,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"HYPERTENSION,",203,221-234,HYPERTENSIVE ENCEPHALOPATHY.,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223730,7/15/2014 11:46:00,,1323538746,7/15/2014 11:45:40,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"hypertension adenoma; adrenal adenoma, HYPERTENSION, encephalopathy.",82-179-187-203-234-141,203-221-234-141,"adenoma; hypertension, HYPERTENSIVE ENCEPHALOPATHY.","Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223730,7/15/2014 11:59:01,,1323546377,7/15/2014 11:58:49,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"HYPERTENSION,",203,221-234,HYPERTENSIVE ENCEPHALOPATHY.,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223730,7/15/2014 11:59:13,,1323546445,7/15/2014 11:58:57,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"severe HYPERTENSION,",196-203,221-234,HYPERTENSIVE ENCEPHALOPATHY.,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223730,7/15/2014 12:00:07,,1323546888,7/15/2014 11:59:57,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"severe HYPERTENSION,",196-203,221-234,HYPERTENSIVE ENCEPHALOPATHY.,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223730,7/15/2014 12:04:06,,1323548353,7/15/2014 12:03:52,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"severe HYPERTENSION,",196-203,221-234,HYPERTENSIVE ENCEPHALOPATHY.,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223730,7/15/2014 12:07:21,,1323549460,7/15/2014 12:07:01,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,203,221,,,215,248,HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY,"severe HYPERTENSION,",196-203,221-234,HYPERTENSIVE ENCEPHALOPATHY.,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy.",203,221 234,203,221,215,248,-1,RO-disease_has_finding,901904,"Two cases are reported as follows: 1) 1 female patient with accelerated-malignant hypertension secondary to an aldosterone-producing adrenal adenoma; and 2) 1 female patient with adrenal adenoma, severe hypertension, and hypertensive encephalopathy",hypertension,hypertensive encephalopathy
503223731,7/15/2014 10:14:56,,1323479358,7/15/2014 10:14:46,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"PALPITATION,",467,438,PHEOCHROMOCYTOMA,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223731,7/15/2014 10:22:22,,1323484434,7/15/2014 10:21:52,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"postpartum Hypertension secondary to pheochromocytoma Headaches, PALPITATION, anxiety attacks, unusual sweating, hyperglycemia, and weight loss",412-425-435-438-456-467-480-488-497-505-515-530-534-541-401,412-425-435-438-456-480,"Hypertension secondary to PHEOCHROMOCYTOMA Headaches, anxiety","Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223731,7/15/2014 10:31:17,,1323490055,7/15/2014 10:30:55,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"PALPITATION,",467,438-456,"PHEOCHROMOCYTOMA Headaches,","Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223731,7/15/2014 10:56:48,,1323507507,7/15/2014 10:56:25,clixsense,1,27969116,NLD,,,91.213.37.165,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"pheochromocytoma Headaches, PALPITATION, anxiety attacks,",438-456-467-480-488,438-456,"PHEOCHROMOCYTOMA Headaches,","Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223731,7/15/2014 11:11:57,,1323518753,7/15/2014 11:11:39,instagc,1,13763729,USA,,,75.182.89.225,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"PALPITATION,",467,438,PHEOCHROMOCYTOMA,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223731,7/15/2014 11:14:02,,1323520156,7/15/2014 11:12:08,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"Hypertension hyperaldosteronism Muscle weakness, hypokalemia postpartum pheochromocytoma Headaches, PALPITATION, anxiety attacks, catecholamines; perinatal morbidity",0-26-46-53-63-438-456-467-480-488-604-643-653-401,26-46-53-401-412-438-456-467-480-488-638-643-653-63,"hyperaldosteronism Muscle weakness, hypokalemia postpartum Hypertension PHEOCHROMOCYTOMA Headaches, palpitation, anxiety attacks, high perinatal morbidity","Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223731,7/15/2014 11:44:58,,1323538140,7/15/2014 11:43:19,prodege,1,23999031,AUS,8,Perth,203.59.238.194,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"Hypertension hyperaldosteronism Muscle weakness, hypokalemia hyperaldosteronism Hypertension pheochromocytoma Headaches, PALPITATION, hyperglycemia,",0-26-46-53-63-279-412-438-456-467-515,0-26-46-53-63-279-412-438-456-467-515,"Hypertension hyperaldosteronism Muscle weakness, hypokalemia hyperaldosteronism Hypertension PHEOCHROMOCYTOMA Headaches, palpitation, hyperglycemia,","Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223731,7/15/2014 11:56:01,,1323544838,7/15/2014 11:55:28,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"PALPITATION,",467,438-456,"PHEOCHROMOCYTOMA Headaches,","Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223731,7/15/2014 12:00:34,,1323547072,7/15/2014 12:00:21,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"PALPITATION,",467,438,PHEOCHROMOCYTOMA,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223731,7/15/2014 12:02:11,,1323547685,7/15/2014 12:01:35,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,467,438,,,478,454,PALPITATION,PHEOCHROMOCYTOMA,"PALPITATION,",467,412-425-435-438,Hypertension secondary to PHEOCHROMOCYTOMA,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and.",467,438,467,438,478,454,1,RO-disease_may_have_finding,902819,"Hypertension secondary to hyperaldosteronism  Muscle weakness, hypokalemia in the setting of low renin levels  Diagnosis confirmed by renin levels that do not increase with volume depletion and aldosterone levels that do not decrease appropriately in response to volume loading; hyperaldosteronism can be partly masked in pregnancy by the effects of high progesterone levels, but manifestations recur postpartum Hypertension secondary to pheochromocytoma  Headaches, palpitation, anxiety attacks, unusual sweating, hyperglycemia, and weight loss  Diagnosis confirmed by a serum or 24-hour urine test for catecholamines; associated with a high perinatal morbidity and",palpitation,pheochromocytoma
503223732,7/15/2014 10:20:16,,1323483031,7/15/2014 10:20:01,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,75,52,,,82,60,ASCITES,HEPATOMA,"ASCITES,",75,52,HEPATOMA,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223732,7/15/2014 10:21:39,,1323484014,7/15/2014 10:21:29,clixsense,1,15189335,GBR,E4,Colchester,5.67.141.89,75,52,,,82,60,ASCITES,HEPATOMA,"ASCITES,",75,52,HEPATOMA,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223732,7/15/2014 10:23:07,,1323484797,7/15/2014 10:22:40,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,75,52,,,82,60,ASCITES,HEPATOMA,"ASCITES,",75,52,HEPATOMA,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223732,7/15/2014 10:23:54,,1323485277,7/15/2014 10:23:33,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,75,52,,,82,60,ASCITES,HEPATOMA,"ASCITES,",75,52,HEPATOMA,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223732,7/15/2014 10:27:47,,1323487727,7/15/2014 10:27:27,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,75,52,,,82,60,ASCITES,HEPATOMA,"ASCITES,",75,52,HEPATOMA,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223732,7/15/2014 10:49:39,,1323502882,7/15/2014 10:48:40,clixsense,1,8888883,USA,FL,Orlando,76.26.232.146,75,52,,,82,60,ASCITES,HEPATOMA,"ASCITES, elemental diet containing maltose amino acids",75-84-94-99-110-122-128,52-75,"HEPATOMA ascites,","In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223732,7/15/2014 10:53:51,,1323505707,7/15/2014 10:53:28,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,75,52,,,82,60,ASCITES,HEPATOMA,"ASCITES,",75,52,HEPATOMA,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223732,7/15/2014 10:56:24,,1323507279,7/15/2014 10:55:49,clixsense,1,27969116,NLD,,,91.213.37.165,75,52,,,82,60,ASCITES,HEPATOMA,"hepatoma patients with ASCITES,",52-61-70-75,39-46-52,sepsis and HEPATOMA,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223732,7/15/2014 11:04:45,,1323512636,7/15/2014 11:03:14,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,75,52,,,82,60,ASCITES,HEPATOMA,"fulminant hepatitis sepsis hepatoma ASCITES, maltose amino acids",14-24-39-52-75-110-122-128,14-39-52-75-110-122-128-24,"fulminant hepatitis sepsis HEPATOMA ascites, maltose amino acids","In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223732,7/15/2014 11:28:13,,1323528542,7/15/2014 11:27:38,prodege,1,9525153,CAN,ON,Toronto,65.95.187.40,75,52,,,82,60,ASCITES,HEPATOMA,"fulminant hepatitis with sepsis hepatoma ASCITES, elemental diet maltose amino acids",14-24-34-39-52-75-84-94-110-122-128,14-24-39-52-75-84-94-110-122-128,"fulminant hepatitis sepsis HEPATOMA ascites, elemental diet maltose amino acids","In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water.",75,52,75,52,82,60,-1,RO-disease_may_have_finding,902970,"In 2 cases of fulminant hepatitis with sepsis and 3 hepatoma patients with ascites, elemental diet containing maltose and amino acids was used to supply sufficient amounts of nutrients in a minimum volume of water",ascites,hepatoma
503223733,7/15/2014 10:20:39,,1323483288,7/15/2014 10:20:25,clixsense,1,26649250,GBR,N7,Epsom,193.117.31.2,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"congenital LACTIC ACIDOSIS,",145-156-163,195-205-211,infantile LEIGH SYNDROME.,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223733,7/15/2014 10:25:06,,1323485973,7/15/2014 10:24:53,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"congenital LACTIC ACIDOSIS, recurrent ataxia,",145-156-163-173-183,195-205-211,infantile LEIGH SYNDROME.,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223733,7/15/2014 10:28:50,,1323488436,7/15/2014 10:28:38,eup_slw,1,21338859,GBR,K6,Portsmouth,86.6.113.168,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"congenital LACTIC ACIDOSIS,",145-156-163,195-205-211,infantile LEIGH SYNDROME.,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223733,7/15/2014 10:32:00,,1323490504,7/15/2014 10:31:48,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"congenital LACTIC ACIDOSIS,",145-156-163,195-205-211,infantile LEIGH SYNDROME.,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223733,7/15/2014 10:34:43,,1323492255,7/15/2014 10:33:58,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"Pyruvate dehydrogenase deficiency encephalopathy lactic acidosis congenital LACTIC ACIDOSIS, ataxia, infantile Leigh syndrome.",0-9-23-70-108-145-156-163-183-195-205-211-101,0-9-23-70-108-145-156-163-183-195-205-211-101,"Pyruvate dehydrogenase deficiency encephalopathy lactic acidosis congenital lactic acidosis, ataxia, infantile LEIGH SYNDROME.","Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223733,7/15/2014 11:19:29,,1323523596,7/15/2014 11:18:57,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"congenital LACTIC ACIDOSIS, recurrent ataxia, and infantile Leigh syndrome.",145-156-163-173-183-191-195-205-211,145-156-163-183-191-195-205-211-173,"congenital lactic acidosis, recurrent ataxia, and infantile LEIGH SYNDROME.","Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223733,7/15/2014 11:36:18,,1323533106,7/15/2014 11:36:02,prodege,1,6316959,GBR,,,46.208.145.114,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"congenital LACTIC ACIDOSIS,",145-156-163,195-205-211,infantile LEIGH SYNDROME.,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223733,7/15/2014 11:36:49,,1323533418,7/15/2014 11:36:32,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"dehydrogenase congenital LACTIC ACIDOSIS, recurrent ataxia, and Leigh syndrome.",145-156-163-173-183-191-205-211-9,183-191-195-205-211-9,"dehydrogenase ataxia, and infantile LEIGH SYNDROME.","Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223733,7/15/2014 11:58:06,,1323545938,7/15/2014 11:57:44,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"common causes of encephalopathy account for congenital LACTIC ACIDOSIS,",53-60-67-70-133-141-145-156-163,195-205-211,infantile LEIGH SYNDROME.,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223733,7/15/2014 11:58:08,,1323545951,7/15/2014 11:57:48,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,156,205,,,171,219,LACTIC ACIDOSIS,LEIGH SYNDROME,"congenital LACTIC ACIDOSIS,",145-156-163,195-205-211,infantile LEIGH SYNDROME.,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome.",156 163,205 211,156,205,171,219,-1,RO-has_manifestation,906187,"Pyruvate dehydrogenase deficiency is one of the most common causes of encephalopathy associated with lactic acidosis and is known to account for congenital lactic acidosis, recurrent ataxia, and infantile Leigh syndrome",lactic acidosis,Leigh syndrome
503223734,7/15/2014 10:14:51,,1323479338,7/15/2014 10:14:25,vivatic,1,25451531,GBR,,,83.67.28.193,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,nonrenal forms of HYPERTENSION,15-24-30-33,66,"PHEOCHROMOCYTOMA,","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223734,7/15/2014 10:24:03,,1323485338,7/15/2014 10:23:50,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,33,66,"PHEOCHROMOCYTOMA,","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223734,7/15/2014 10:32:32,,1323490870,7/15/2014 10:32:16,bitcoinget,1,24792414,USA,WI,Juneau,166.181.83.37,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,33,66,"PHEOCHROMOCYTOMA,","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223734,7/15/2014 10:33:45,,1323491621,7/15/2014 10:32:50,clixsense,1,8769423,AUS,6,Launceston,147.69.131.74,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,33,66,"PHEOCHROMOCYTOMA,","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223734,7/15/2014 11:04:20,,1323512145,7/15/2014 11:04:01,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,33,66,"PHEOCHROMOCYTOMA,","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223734,7/15/2014 11:15:33,,1323520997,7/15/2014 11:14:55,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,33,33-66,"hypertension PHEOCHROMOCYTOMA,","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223734,7/15/2014 11:20:21,,1323524115,7/15/2014 11:19:54,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,"HYPERTENSION pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension",33-66-84-104-122-133,33-66-84-104-122-133,"hypertension PHEOCHROMOCYTOMA, hyperaldosteronism, hypercortisolism, iatrogenic hypertension","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223734,7/15/2014 11:35:26,,1323532642,7/15/2014 11:35:11,prodege,1,6316959,GBR,,,46.208.145.114,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,33,66,"PHEOCHROMOCYTOMA,","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223734,7/15/2014 11:41:56,,1323536503,7/15/2014 11:41:32,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,"HYPERTENSION pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension",33-66-84-104-133-122,66-84-104-122-133,"PHEOCHROMOCYTOMA, hyperaldosteronism, hypercortisolism, iatrogenic hypertension","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223734,7/15/2014 11:59:49,,1323546809,7/15/2014 11:59:36,instagc,1,21551272,GBR,Q3,Wolverhampton,2.103.57.104,33,66,,,45,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,33,66,"PHEOCHROMOCYTOMA,","The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence.",33,66,33,66,45,82,1,RO-disease_may_have_finding,902705,"The secondary, nonrenal forms of hypertension principally include pheochromocytoma, hyperaldosteronism, hypercortisolism, iatrogenic hypertension following medication, and hypertension related to overindulgence",hypertension,pheochromocytoma
503223735,7/15/2014 10:15:45,,1323479963,7/15/2014 10:15:31,vivatic,1,25451531,GBR,,,83.67.28.193,42,118,,,52,128,DEPRESSION,PAROXETINE,major DEPRESSION,36-42,118,PAROXETINE,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223735,7/15/2014 10:24:21,,1323485484,7/15/2014 10:24:09,gifthulk,1,22144176,GBR,U8,Edinburgh,129.215.149.99,42,118,,,52,128,DEPRESSION,PAROXETINE,DEPRESSION,42,118,PAROXETINE,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223735,7/15/2014 11:03:37,,1323511653,7/15/2014 11:03:26,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,42,118,,,52,128,DEPRESSION,PAROXETINE,major DEPRESSION,36-42,118,PAROXETINE,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223735,7/15/2014 11:05:59,,1323513664,7/15/2014 11:05:32,clixsense,1,27969116,NLD,,,91.213.37.165,42,118,,,52,128,DEPRESSION,PAROXETINE,DEPRESSION,42,118-139-150-153,PAROXETINE recurrence of depression.,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223735,7/15/2014 11:08:59,,1323516506,7/15/2014 11:08:48,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,42,118,,,52,128,DEPRESSION,PAROXETINE,major DEPRESSION,36-42,118,PAROXETINE,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223735,7/15/2014 11:09:59,,1323517316,7/15/2014 11:09:42,instagc,1,13763729,USA,,,75.182.89.225,42,118,,,52,128,DEPRESSION,PAROXETINE,DEPRESSION,42,118,PAROXETINE,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223735,7/15/2014 11:10:46,,1323517862,7/15/2014 11:10:09,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,42,118,,,52,128,DEPRESSION,PAROXETINE,major DEPRESSION,36-42,118-153,PAROXETINE depression.,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223735,7/15/2014 11:38:19,,1323534325,7/15/2014 11:37:54,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,42,118,,,52,128,DEPRESSION,PAROXETINE,DEPRESSION paroxetine,42-118,118-42,depression PAROXETINE,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223735,7/15/2014 11:41:05,,1323535914,7/15/2014 11:40:46,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,42,118,,,52,128,DEPRESSION,PAROXETINE,major DEPRESSION,42-36,91-103-113-118-129-139-150-153,maintenance treatment with PAROXETINE prevented recurrence of depression.,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223735,7/15/2014 11:43:17,,1323537281,7/15/2014 11:42:55,prodege,1,23999031,AUS,8,Perth,203.59.238.194,42,118,,,52,128,DEPRESSION,PAROXETINE,DEPRESSION depression.,42-153,36-42-118-153,major depression PAROXETINE depression.,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression.",42,118,42,118,52,128,1,RO-may_treat,907618,"CONCLUSIONS  In older patients with major depression who responded to treatment, long-term maintenance treatment with paroxetine prevented recurrence of depression",depression,paroxetine
503223736,7/15/2014 10:50:04,,1323503082,7/15/2014 10:49:54,clixsense,1,27793793,GBR,C5,Chester,151.230.27.155,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,BLOOD PRESSURE ELEVATION,92-98-107,76,HYPERTENSION,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223736,7/15/2014 10:55:41,,1323506860,7/15/2014 10:55:18,prodege,1,27934334,GBR,B9,High Wycombe,86.166.72.139,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,BLOOD PRESSURE ELEVATION,92-98-107,76,HYPERTENSION,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223736,7/15/2014 10:57:06,,1323507644,7/15/2014 10:56:47,clixsense,1,6344001,AUS,2,Strathfield,60.241.129.81,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,BLOOD PRESSURE ELEVATION,92-98-107,76,HYPERTENSION,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223736,7/15/2014 11:04:45,,1323512647,7/15/2014 11:04:28,clixsense,1,27969116,NLD,,,91.213.37.165,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,hypertension or BLOOD PRESSURE ELEVATION,76-89-92-98-107,76-89-92-98,HYPERTENSION or blood pressure,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223736,7/15/2014 11:32:07,,1323530656,7/15/2014 11:31:50,elite,1,28397222,GBR,Y4,Usk,31.50.223.75,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,BLOOD PRESSURE ELEVATION,92-98-107,76,HYPERTENSION,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223736,7/15/2014 11:37:17,,1323533659,7/15/2014 11:36:51,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,hypertension BLOOD PRESSURE ELEVATION dyspnea.,76-92-98-107-229,76-92-98-163-229,HYPERTENSION blood pressure BNP dyspnea.,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223736,7/15/2014 11:38:44,,1323534606,7/15/2014 11:38:28,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,hypertension or BLOOD PRESSURE ELEVATION,76-89-92-98-107,63-65-73-76-89-92-98-107,a history of HYPERTENSION or blood pressure elevation,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223736,7/15/2014 11:55:56,,1323544774,7/15/2014 11:55:26,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,BLOOD PRESSURE ELEVATION,92-98-107,76,HYPERTENSION,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223736,7/15/2014 11:59:34,,1323546637,7/15/2014 11:59:00,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,BLOOD PRESSURE ELEVATION,92-98-107,63-65-73-76,a history of HYPERTENSION,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223736,7/15/2014 12:03:32,,1323548144,7/15/2014 12:02:10,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,92,76,,,116,88,BLOOD PRESSURE ELEVATION,HYPERTENSION,hypertension or BLOOD PRESSURE ELEVATION,76-89-92-98-107,76-89-92-98-107,HYPERTENSION or blood pressure elevation,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea.,92 98 107,76,92,76,116,88,-1,RO-has_definitional_manifestation,904546,The objective of the present study was to assess the impact of a history of hypertension or blood pressure elevation on admission on the diagnostic performance of BNP in the diagnosis of heart failure (HF) in patients with acute dyspnea,blood pressure elevation,hypertension
503223737,7/15/2014 10:31:27,,1323490169,7/15/2014 10:31:14,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN,36,54,ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
503223737,7/15/2014 10:54:28,,1323506119,7/15/2014 10:54:02,rewardsspot,1,24482174,GBR,H9,London,46.23.68.180,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN endometriosis.,36-54,54-36,pain ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
503223737,7/15/2014 11:16:05,,1323521304,7/15/2014 11:15:43,neodev,1,15848372,AUS,2,Jannali,27.96.208.89,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN is caused by endometriosis.,36-41-44-51-54,41-44-51-54-36,pain is caused by ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
503223737,7/15/2014 11:21:47,,1323524871,7/15/2014 11:21:31,rewardsspot,1,17763704,USA,VA,Manassas,198.7.62.204,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN endometriosis.,36-54,54-36,pain ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
503223737,7/15/2014 11:41:10,,1323535948,7/15/2014 11:40:53,neodev,1,24578640,USA,IL,Chicago,65.60.20.66,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN endometriosis.,36-54,54-36,pain ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
503223737,7/15/2014 11:46:23,,1323538947,7/15/2014 11:46:13,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN is caused by,36-41-44-51,44-51-54,caused by ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
503223737,7/15/2014 11:49:39,,1323540709,7/15/2014 11:49:27,prodege,1,24403612,CAN,ON,Ajax,99.242.234.239,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN,36,54,ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
503223737,7/15/2014 11:57:07,,1323545448,7/15/2014 11:56:54,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN,36,54,ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
503223737,7/15/2014 12:04:03,,1323548319,7/15/2014 12:03:45,neodev,1,27608448,USA,SC,Graniteville,24.145.86.46,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN endometriosis.,36-54,54,ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
503223737,7/15/2014 12:07:42,,1323549542,7/15/2014 12:07:22,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,36,54,,,40,67,PAIN,ENDOMETRIOSIS,PAIN,36,54,ENDOMETRIOSIS.,The problem is determining when the pain is caused by endometriosis.,36,54,36,54,40,67,-1,RO-has_definitional_manifestation,904760,The problem is determining when the pain is caused by endometriosis,pain,endometriosis
